WO2008124787A2 - Ethmoidotomy system and implantable spacer devices having therapeutic substance delivery capability for treatment of paranasal sinusitis - Google Patents
Ethmoidotomy system and implantable spacer devices having therapeutic substance delivery capability for treatment of paranasal sinusitis Download PDFInfo
- Publication number
- WO2008124787A2 WO2008124787A2 PCT/US2008/059786 US2008059786W WO2008124787A2 WO 2008124787 A2 WO2008124787 A2 WO 2008124787A2 US 2008059786 W US2008059786 W US 2008059786W WO 2008124787 A2 WO2008124787 A2 WO 2008124787A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- penetrator
- reservoir
- sinus
- sheath
- substance
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/24—Surgical instruments, devices or methods, e.g. tourniquets for use in the oral cavity, larynx, bronchial passages or nose; Tongue scrapers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/34—Trocars; Puncturing needles
- A61B17/3417—Details of tips or shafts, e.g. grooves, expandable, bendable; Multiple coaxial sliding cannulas, e.g. for dilating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/34—Trocars; Puncturing needles
- A61B17/3417—Details of tips or shafts, e.g. grooves, expandable, bendable; Multiple coaxial sliding cannulas, e.g. for dilating
- A61B17/3421—Cannulas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F11/00—Methods or devices for treatment of the ears or hearing sense; Non-electric hearing aids; Methods or devices for enabling ear patients to achieve auditory perception through physiological senses other than hearing sense; Protective devices for the ears, carried on the body or in the hand
- A61F11/20—Ear surgery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/34—Trocars; Puncturing needles
- A61B17/3415—Trocars; Puncturing needles for introducing tubes or catheters, e.g. gastrostomy tubes, drain catheters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
- A61B90/06—Measuring instruments not otherwise provided for
- A61B2090/062—Measuring instruments not otherwise provided for penetration depth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/01—Introducing, guiding, advancing, emplacing or holding catheters
- A61M25/06—Body-piercing guide needles or the like
- A61M25/0662—Guide tubes
- A61M2025/0681—Systems with catheter and outer tubing, e.g. sheath, sleeve or guide tube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/105—Balloon catheters with special features or adapted for special applications having a balloon suitable for drug delivery, e.g. by using holes for delivery, drug coating or membranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0067—Catheters; Hollow probes characterised by the distal end, e.g. tips
- A61M25/0074—Dynamic characteristics of the catheter tip, e.g. openable, closable, expandable or deformable
- A61M25/0075—Valve means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0067—Catheters; Hollow probes characterised by the distal end, e.g. tips
- A61M25/0082—Catheter tip comprising a tool
- A61M25/0084—Catheter tip comprising a tool being one or more injection needles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/01—Introducing, guiding, advancing, emplacing or holding catheters
- A61M25/02—Holding devices, e.g. on the body
- A61M25/04—Holding devices, e.g. on the body in the body, e.g. expansible
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M29/00—Dilators with or without means for introducing media, e.g. remedies
- A61M29/02—Dilators made of swellable material
Definitions
- the present invention relates generally to medical devices and methods and more particularly to substance delivering implants and methods for treating a broad range of disorders including but not limited to sinusitis and other ear, nose and throat disorders.
- the paranasal sinuses require adequate ventilation to prevent microbial chronic infection within the sinus cavities.
- ventilation is provided through the small natural openings, known as ostia, through which the sinus cavities open into the nose.
- the natural ostia serve as drainage channels as ciliated cells lining the interior of the sinus cavity continually direct a flow of mucus toward the ostia.
- ostia When the natural ostia become narrowed or blocked, ventilation and drainage from the sinus cavity is impaired.
- the resultant hypoxia, pH changes and mucus stasis within the sinus cavity gives rise to an environment in which some types of microbial growth can flourish.
- Such microbial infection can, in itself, result in further mucosal inflammation and even further constriction or blockage of the natural sinus ostium.
- Functional endoscopic sinus surgery is a common type of surgery wherein an endoscope is inserted into the nose and, under visualization through the endoscope, the surgeon may remove diseased or hypertrophic tissue or bone and may surgically enlarge the ostia of the sinuses to restore normal ventilation and drainage of the sinuses.
- a balloon catheter may be advanced into the constricted sinus ostium and used to dilate the ostium, thereby eliminating the need for cutting or removing tissue surrounding the ostium (Balloon SinuplastyTM technology, Acclarent, Inc., Menlo Park, California).
- Balloon SinuplastyTM technology Acclarent, Inc., Menlo Park, California.
- Examples of such balloon dilation procedures are described in United States Patent Application Publications No. 2006/0004286, 2006/0063973, 2006/0210605, 2007/0129751 , 2007/0135789, 2007/0167682, 2007/0208252, 2007/0208301 and 2007/0293727, the entire disclosure of each such patent application being expressly incorporated herein by reference.
- One example of a commercially available frontal sinus stent is the FreemanTM Frontal Sinus Stent (InHealth Technologies, Inc., Carpinteria, California.
- the FreemanTM stent comprises a silicon tube that has flanges on either end to retain the stent within the frontal outflow tract for a desired period of time following surgery.
- Other commercially available frontal sinus stents include the Jasin Frontal Sinus Stent (Medtronic Xomed, Inc., Jacksonville, FIa.), and the Salman FES Stent (Boston Medical Products, Westborough, Mass.).
- a sphenoid sinus stent is described in United States Patent No. 7,235,099 (Duncavage, et al.).
- This stent comprises a soft compressible plastic tube having a generally hemispherical hollow dome on one end. The diameter of the dome is greater than the predetermined diameter of the plastic tube.
- the stent further includes an annular flange located a predetermined distance from the hemispherical dome.
- the device is designed to be fitted through a surgically enlarged ostium of the sphenoid sinus such that the dome resides within the sinus cavity and the flange abuts the bony wall surrounding the ostium.
- This stent serves maintain patency of the surgically altered ostium during the postoperative period and allows irrigation/suction ing through the lumen of the stent.
- This sphenoid sinus stent is also commerciaily available as the SP-82020 Sphenoid Sinus Stent (Micromedics, Inc., St. Paul, Minnesota).
- the above-described frontal and sphenoid sinus stents do not deliver therapeutic substances. Thus, they are frequently used concurrently with orally administered drugs (e.g., corticosteroids) and/or topical nasal sprays.
- drugs e.g., corticosteroids
- topical nasal sprays e.g., topical nasal sprays.
- surgeons may place gel-like materials within the surgically altered ostium or outflow tract to prevent ingrowth of scar tissue during the post-surgical period.
- One example of such material is the MeroPackTM Bioresorbable Nasal Dressing and Sinus Stent available from Medtronic ENT, Inc., Jacksonville, Florida.
- the MeroPackTM material consists of 80 percent esterified hyaluronic acid and 20 percent collagen. This material is inserted while in its dry state and, upon hydration, swells to 1.0cm diameter in about six seconds. When in its hydrated state, this material is a biocompatible, muco-adhesive gel.
- biodegradable implants for treating sinusitis, such implants having a size, shape, density, viscosity, and/or mucoadhesiveness that prevents them from being substantially cleared by the mucociliary lining of the sinuses during the intended treatment period.
- These biodegradable implants deliver therapeutic agents such as antibiotics, steroids or both.
- These biodegradable implants may be in various forms such as rods, pellets, beads, strips, or microparticles, and may be delivered into a sinus in various pharmaceutically acceptable carriers.
- United States Patent Application Publication No. 20070005094 (Eaton et al.) describes implantable devices useable for the treatment of paranasal sinus conditions.
- the devices include cavity members that have a first collapsed configuration that permits the device to pass through a sinus ostium and a second expanded configuration after placement into the sinus * cavity.
- the devices may include a nasal portion and an ostial member that is configured to reside within the sinus ostium.
- the cavity member is attached to the distal end of the ostial member.
- the nasal portion is attached to the proximal end of the ostial member and lies within the nasal passage.
- the active agent may be incorporated into all portions of the device or only included in the expandable cavity member, the ostial member, or nasal portion.
- the sheath After surgery to create a fenestration in a frontal sinus as been performed, the sheath (which has been preloaded with the active substance) is inserted into the surgically created fenestration where it a) deters closure of the surgically created fenestration, b) serves as a conduit to facilitate drainage from the sinus and c) delivers the active substance.
- the sheath is formed of multiple layers of polymeric material, one or more of which is/are loaded with the active substance and one or more of which is/are free of the active substance.
- the sheath has a "hollow body" which forms a reservoir system wherein the active substance is contained and a membrane which controls the release of the active substance from the reservoir.
- the sheath may be anchored by causing the end of the sheath that extends into the sinus to swell or otherwise enlarge.
- United States Patent Application Publication No. 2005/0245906 (Makower et al.) describes a biodegradable polymeric device that comprises a spacer positionable within a sinus ostium. The spacer has a plurality of substance-eluting struts. The device may be implanted such that the struts are substantially parallel to the cilial flow of mucus along the sinus cavity walls so that normal mucociliary transport is not interrupted.
- implantable drug delivery devices have been proposed for use in the nose and/or paranasal sinuses.
- United States Patent No. 3,948,254 (Zaffaroni) describes implantable drug delivery reservoirs having microporous walls.
- the reservoir may be formed of a solid drug carrier that is permeable to passage of the drug and the rate of passage of the drug through the microporous wall may be slower than the rate at which the drug passes through the solid drug carrier that forms the reservoir.
- Zaffaroni also describes a number of applications for the implantable drug delivery devices including placement in a nasal passage.
- Zaffaroni claims a nasal delivery device for dispensing a drug within a nasal passage at a controlled rate
- the nasal device is comprised of (a) a wall defining the device dimensioned for insertion and placement within a nasal passage, with the wall formed of a nasal acceptable microporous material, (b) a reservoir surrounded by the wall and comprised of a solid carrier permeable to drug and containing drug in an amount sufficient for the device to meter it at a continuous and controlled rate for a prolonged period of time from the device, (c) a liquid medium permeable to the passage of drug by diffusion charged in the micropores, and (d) wherein the device releases drug when in a nasal environment by passage of drug from the carrier and through the liquid to the exterior of the device to produce a useful result.
- the entire disclosure of United States Patent No. 3,948,254 (Zaffaroni) is expressly incorporated herein by reference.
- gelatin In this clinical series a water soluble gelatin was used as carrier and was mixed with the drug prior to application and introduced as a mass into the sinus. Since the substance had little mechanical integrity and dissolved in a relatively short timeframe, to achieve a therapeutic effect, the author suggested that it must be instilled every 2 to 3 days.
- An alternative to gelatin could be a sponge loaded with the therapeutic substance as suggested in United States Patent No. 6,398,758 (Jacobsen, et al.). In this patent directed at delivering a sustained release device against the wall of a blood vessel, a hollow cylindrical sponge is loaded with drug and pressed against the wall. This allows the drug to contact the wall while sustaining blood flow within the center of the lumen.
- a skin is provided to direct the drug into the walls of the blood vessel and prevent drug from flowing into the lumen. While sponges loaded with drug at the time of their application do permit some degree of sustained release, the time required to load them also correlates closely the time over which they will elute substance. Thus, if delivery is required for a longer period of time additional mechanisms must be employed to regulate their release.
- implantable drug delivery devices include those described in United States Patent Nos. 3,993,073; 4,217,898; 5,304,123; 6,042,561 ; 6,183,461 ; 6,780,168 and 6,783,522, the entire disclosure of each such patent being expressly incorporated herein by reference.
- the distal tip of this device is capable of penetrating through tissue (e.g., through the ethmoid bulla) to a desired position (e.g., within the ethmoid air cells). Openings are formed in a distal portion of the intubation device so that medication (e.g., a typical steroid) injected through the flexible tube will flow out of the tube into contact with the adjacent area (e.g., the diseased ethmoid air cells).
- a cannula-trocar may be initially inserted and the nasal intubation device may then be advanced through that cannula-trocar.
- EP0624349 describes a balloon-tipped catheter having an anatomically shaped balloon which may be inserted through a surgically created opening into a body cavity (e.g., frontal sinus or ethmoid cell) and inflated to create a tamponade by being shaped to suit the anatomical shape of the cavity.
- a body cavity e.g., frontal sinus or ethmoid cell
- the present invention provides substance delivering spacer devices and methods including expandable reservoirs that are implantable in paranasal sinuses and other cavities, openings and passageways of the body to maintain patency and/or to provide sustained local delivery of a therapeutic or diagnostic substance. Also provided are sinus penetrator devices, systems and methods for creating ethmoidotomy openings or other openings in the walls of paranasal sinuses or other anatomical structures.
- One embodiment of a device and method for treating ethmoid sinusitis involves a penetrator device that has a distal tip and a stopping mark or member located a spaced distance proximal to its distal tip. The distance between the stopping mark or member and the distal tip is less than the distance between the ethmoid bulla and the ipsalateral sphenoid sinus.
- An ethmoidotomy channel is formed by advancing the penetrator through the ethmoid bulla in a direction that is non-perpendicular to the skull base and generally directed toward the ipsalateral sphenoid sinus. Advancement of the penetrator is stopped when the stopping mark or member is approximately flush with the ethmoid bulla.
- a stent, spacer or substance delivering spacer device may then be placed in the ethmoidotomy channel for a period of time to maintain patency of the channel and/or to effect local delivery of a therapeutic substance.
- a sinus penetrator device and method may be used to form an ethmoidotomy channel or other opening in a paranasal sinus wall or other body structure.
- Such device comprises an elongate penetrator member and a handle coupled with the penetrator member at or near its proximal end.
- a sighting member is disposed along the handle or the elongate member at a location to make it visible from an extracorporeal vantage point when the distal end of the elongate member is inserted into the patient.
- Such sighting member is useable by a user of the device to generally aim the distal end of the penetrator in a desired direction within the patient's body.
- the sighting member may comprise a fin.
- the sighting member may extend in a plane that is substantially parallel to a plane in which the elongate the penetrator extends from the handle and, optionally may include another member (e.g., a cross member) that is substantially normal to the plane in which the elongate penetrator extends from the handle.
- the elongate penetrator may have a curve formed therein and at least a portion of the sighting member may be parallel to the portion of the elongate penetrator that is distal to the curve, thereby providing an indication of the direction or trajectory on which the distal portion of the elongate penetrator is being advanced.
- the substance delivering spacer device comprises a shaft and an expandable reservoir located on the shaft.
- the reservoir may be introduced into a body cavity or opening (e.g., a paranasal sinus, ethmoidotomy channel, frontal sinus outflow tract, or other body cavity, opening, passageway) while in a collapsed configuration.
- a therapeutic substance may be loaded into the reservoir, causing the reservoir to expand in situ.
- the shaft may be severed or cut at a desired location and the proximal portion of the shaft may be removed after the reservoir has been loaded.
- the reservoir is designed such that the substance will elute from the reservoir over a period of time.
- the reservoir may have a side wall and tapered ends, with openings being formed in the sidewall and tapered ends such that a therapeutic substance loaded into the reservoir will elute through the openings and out of the reservoir.
- the device may be equipped with apparatus for holding the reservoir in a desired position within the body (e.g., retention wings, projections, suture loops, etc.) for holding the reservoir in a desired position within the body.
- a substance delivering spacer device of the above-described character is used in combination with a sinus penetrator (e.g., the ethmoidotomy device described above or any other penetrator) and a sheath.
- a sinus penetrator e.g., the ethmoidotomy device described above or any other penetrator
- the sheath is initially disposed over the sinus penetrator and the penetrator/sheath combination is advanced through a wall of a paranasal sinus or air cell.
- the penetrator is then removed, leaving the sheath in place.
- the substance delivering spacer device is advanced into the sheath.
- the sheath is then removed, leaving the substance delivering spacer device in place within the sinus or air cell.
- a diagnostic or therapeutic substance is then loaded into the reservoir such that the substance will thereafter elute from the reservoir into the paranasal sinus or air cell.
- an implantable device having a substance eluting reservoir is positioned within a paranasal sinus or within the ostium or outflow tract of a paranasal sinus. Thereafter, a steroid is introduced into the substance eluting reservoir so that the steroid elutes from the reservoir in an amount that is effective to treat the sinusitis.
- Figure 1 shows a spacer device of the present invention being used in conjunction with an endoscope to treat a human subject.
- Figure 2 is a side view of one embodiment of a spacer device of the present invention.
- Figure 2A is an enlarged longitudinal sectional view of a distal portion of the device of Figure A.
- Figure 2B is an enlarged longitudinal sectional view of a distal portion of the device of Figure A during infusion of a substance into the reservoir portion of the device.
- Figure 2C is a longitudinal sectional view through the proximal hub of the device of Figure 2.
- Figure 2D is a side view of the device of Figure 2 with a constraining sheath in a retracted position.
- Figure 2E is a side view of the device of Figure 2 with a constraining sheath in an advanced position.
- Figure 2F is a diagram of the expandable reservoir of the device of Figure 2.
- Figure 2G is an enlarged view of region 2G of Figure 2F.
- Figure 2 H is a proximal end view of the expandable reservoir of Figure 2F.
- Figure 3 is a side view of a distal portion of another embodiment of a spacer device of the present invention incorporating an alternative retention system.
- Figure 4 is a side view of one embodiment of a sheath that is useable in conjunction with an ethmoidotomy needle of the present invention.
- Figure 5 is a side view of one embodiment of an ethmoidotomy needle device of the present invention.
- Figure 5A is a longitudinal sectional view through a distal portion of the handpiece of the ethmoidotomy needle device of Figure 5.
- Figure 5B is a distal end view of the ethmoidotomy needle device of Figure 5.
- Figure 5C is a side view of the distal tip of the ethmoidotomy needle device of Figure 5.
- Figure 5D is a side view of another embodiment of an ethmoidotomy device of the present invention incorporating a rotating burr tip.
- Figure 5E is an enlarged side view of the rotating burr tip of the ethmoidotomy device of Figure 5D.
- Figure 6 is a side view of the ethmoidotomy needle device of Figure 5 with the sheath of Figure 4 positioned thereon.
- Figures 7A through 7K show steps in a method for performing an ethmoidotomy and implanting a substance delivering spacer device in accordance with the ethmoidotomy channel in accordance with the present invention.
- Figures 8A-8G show steps in a method for using a guide catheter for implantation of the substance delivering spacer device of Figure 2 within the outflow tract of the frontal sinus of a human subject in accordance with the present invention.
- Figures 9A-9D show steps in a method fir using the sheath of Figure 4 and an optional dilator for implantation of the substance delivering spacer device of Figure 2 within the outflow tract of the frontal sinus of a human subject in accordance with the present invention.
- Figure 10 is a graph showing Lund McKay Scores for 14 human subjects referred to below.
- Figure 11 is a bar graph showing the average SNOT 20 scores at various time points for human subjects referred to below.
- Figure 12 is a perspective view of a substance delivering/bone penetrating screw device of the present invention.
- Figure 12A is a diagram showing the substance delivering/bone penetrating screw device of Figure 12 implanted in a bony intranasal structure covered with mucosal tissue.
- Figure 13 is a partial left/right sagittal section of a human head showing an ethmoidotomy needle having a depth controlling stop member inserted through the subject's nostril and advanced into the ethmoid sinuses until the stop member has abutted against the subject's nose, thereby preventing further advancement of the needle.
- Figure 14 is a partial, cut-away side view of another embodiment of a substance delivering spacer device of the present invention incorporating a multi-layer expandable reservoir.
- Figure 14A is a cross sectional view through line 14A-14A of figure 14 showing three separate fill lumens which extend into three separate regions of the reservoir balloon.
- Figure 14 B is an enlarged view of a portion of the outer layer of the reservoir balloon of the device of Figure 14.
- Figure 14 C is an enlarged view of a portion of the middle layer of the reservoir balloon of the device of Figure 14.
- Figure 14 D is an enlarged view of a portion of the inner layer of the reservoir balloon of the device of Figure 14.
- FIGs 1 through 2G show one embodiment of an implantable substance delivery device and/or spacer 10 of the present invention.
- This device 10 comprises an elongate flexible catheter shaft 12 having a proximal portion 12a and a distal portion 12b which may be severed from one another at separation marker 15.
- the proximal shaft portion 12a and distal shaft portion 12b may be formed of the same or different materials and may have the same or different dimensions (e.g., diameter, wall thickness, etc.).
- the proximal shaft portion 12a may be made of a suitable biocompatible material of sufficient column strength (e.g., pushability) to enable a user to push the substance delivery device 10 into the paranasal anatomy.
- a suitable biocompatible material e.g., pushability
- the distal shaft portion 12b may be made of a more flexible biocompatible material such as nylon or polyethylene teraphthalate (PET).
- PET polyethylene teraphthalate
- a lumen 13 extends continuously through the shaft 12.
- the distal shaft portion 12a may be tapered or necked down to a smaller diameter than the proximal shaft portion to facilitate insertion of the device, as described below.
- a plug 23 is mounted in the distal end of lumen 13.
- the plug 23 may comprise any suitable closure member such as a wall of closed end on the tube, an end cap, a mass within the end of the lumen 13 or any other suitable flow blocking member.
- the plug 23 comprises a biocompatible polymeric adhesive disposed within the distal end of lumen 13.
- the plug 23 may include a soft, atraumatic (e.g., bulbous or blunt) tip member that protrudes beyond the distal end of the distal shaft portion 12b.
- An expandable reservoir 14 is mounted in a collapsed configuration on the distal shaft portion 12b near its distal end and expands to an expanded configuration as it is filled. Details of one embodiment of such reservoir 14 are seen in Figures 2A and 2B as well as 2F, 2G and 2H.
- the reservoir 14 comprises a balloon that has a cylindrical side wall wherein openings 31 are formed.
- the reservoir 14 may be formed of any suitable biocompatible material and, in some embodiments, may comprise a balloon formed of non-compliant or semi-compliant material such as Nylon 12.
- the material and wall thickness of the reservoir be such that the reservoir is flexible enough to a) allow the device to be extracted and removed from the body without causing significant trauma, b) not force all of the contents of the reservoir to come out at once and c) maintain substantially consistent size of the openings 31 as the reservoir expands.
- the number of reservoir(s) 14 (such as two or more), the size of the reservoir(s) and the number and size of the openings 31 may vary on the basis of the intended implantation location and/or the potency, viscosity, particle size (for suspensions) and/or other properties of the substance being delivered.
- the reservoir 14 may have a length of from about 0.5 cm to about 3.5 cm and typically approximately 2cm, a diameter when fully expanded of about 0.1 cm to about 0.5 cm and typically approximately 0.3 cm. Also, depending on the substance and the intended elution rate, there may be any suitable number of openings 31. Typically there will be between about 50 and about 5000 openings 31 sized in the range of from about 5 microns in diameter to about 80 microns in diameter.
- this embodiment of the reservoir 14 may be inserted, in a collapsed configuration, into a body opening, passageway or cavity (such as, for example, a frontal sinus outflow tract, paranasal sinus ostium, antrostomy, ethmoidotomy opening, or other location within the ear, nose or throat of a subject) and, thereafter, the reservoir may be loaded with the desired substance, causing the reservoir to transition to an expanded state.
- a body opening, passageway or cavity such as, for example, a frontal sinus outflow tract, paranasal sinus ostium, antrostomy, ethmoidotomy opening, or other location within the ear, nose or throat of a subject
- the reservoir 14 may be loaded with approximately 0.10 ml of an aqueous suspension containing 40 mg/ml of Triamcinolone Acetonide Injectable Suspension, USP (Kenalog®-40, Bristol- Myers Squibb, Somerville, New Jersey). This will cause approximately 100 ⁇ g of Triamcinolone Acetonide to elute from the reservoir per day over a period of 14 days.
- this reservoir 14 may also be used to deliver an antifungal agent such as liposomal or non-liposomal Amphotericin B of 0.3 to 1.5 mg/kg available from Pfizer as Amphocin® anti-fungal.
- an antifungal agent such as liposomal or non-liposomal Amphotericin B of 0.3 to 1.5 mg/kg available from Pfizer as Amphocin® anti-fungal.
- Systemically administered Amphotericin typically has limited distribution from the bloodstream across the mucus membranes and vice versa. With this substance delivery device 10, Amphotericin may be released locally into the mucus membrane where the offending fungal organisms are present and therapeutic concentrations of the drug may remain in the mucus as it is distributed through the sinuses by ciliary action.
- this reservoir 14 may be capable of delivering solutions as well as suspensions to the surrounding anatomy. This is especially useful for delivery of steroids since most steroids are available as suspensions.
- the reservoir 14 need not be used to deliver a therapeutic substance in all applications. It may, in fact, be used as a space occupying device (e.g., instead of a sinus stent). In such applications, the reservoir 14 may be loaded in situ with saline solution of other inert liquid causing the reservoir 14 to expand and frictionally engage or contact adjacent anatomical structure(s), thereby providing a degree of retention at the desired implantation location. This aspect of the reservoir 14 may be further facilitated by the provision of surface projections on the reservoir, in cases where it is intended for the reservoir 14 to function
- the reservoir 14 may be relatively small in diameter when in its collapsed configuration, thus allowing it to be introduced or removed easily.
- the reservoir 14 will not undergo substantial elastic deformation in the filling process and thus will not exert pressure on its contents in order to expel the desired substance through openings 31. Rather, the substance in the reservoir 14 will be carried out through the openings 31 by gravity or by being in contact with the mucus or blood that is continually moved along by the ciliary action in the sinuses. This non- pressurized delivery allows for the slow release of the desired substance over several days.
- the reservoir 14 may be formed of compliant or elastic material with small openings 31 such that the material of which the balloon 14 is formed will contract as substance passes out of the openings 31 , thereby maintaining pressure within the balloon.
- the reservoir 14 may have approximately 2200 laser cut openings 31 approximately 20 to 40 microns in diameter formed in the sidewall of the reservoir 14.
- the openings 31 may be aligned in longitudinal rows and the positioning of the individual openings 31 may be staggered one row to the next.
- the longitudinal distance D1 between individual openings is 0.30 +/- 0.03 mm and the distance D2 between rows is 0.68 +/- 0.1 mm.
- the reservoir has a cylindrical side wall 14a which defines the working length of the reservoir, a distal taper 14b which transitions from the cylindrical side wall 14a to the distal shaft 12b (distal to the reservoir) and a proximal taper 14c that transitions from the cylindrical side wall 14a to the distal shaft 12b (proximal to the reservoir) and the openings 31 extend onto the proximal and distal tapers 14b, 14c, as shown.
- the reservoir 14 has an overall length of about 16 mm and a working length (i.e., the length of the cylindrical side wall 14c) of about 13 mm and is expandable to a fully expanded diameter of 3.0 to 3.5 mm.
- each laser cut opening 31 is formed in the side wall 14a of the reservoir 14.
- the diameter of each laser cut opening 31 is 40 microns.
- This particular reservoir design when loaded with 0.31 to 0.35 ml of 40 mg/ml Triamcinolone Acetonide Injectable Suspension, USP (Kenalog®-40, Bristol-Myers Squibb, Somerville, New Jersey) will deliver a dose of approximately 100 ⁇ g Triamcinolone Acetonide per day for a period of 28 days.
- the distal shaft portion 12b may be made of Nylon 12 and may have an outer diameter of 0.028 inches, an inner diameter of 0.020 inches and length of 17mm.
- An aperture 28 as seen in Figures 1 B-1C is formed in the catheter shaft 12 to facilitate filling of the reservoir 14.
- a valve 26 allows the substance (or component(s) of the substance) to flow from the lumen 13 of the catheter shaft 12 into the reservoir 14 (see Figure 1 C) but does not allow substantial backflow from the reservoir 14 into the lumen 13 (see Figure 1 B).
- the valve 26 may comprise any suitable type of one way valve.
- the valve 28 comprises an elastomeric sleeve valve made of a segment of C-f!ex ® thermoplastic elastomer tubing (Consolidated Polymer Technologies, Inc., Clearwater, Florida).
- a distal radiopaque marker 24 and proximal radiopaque marker 22 may be provided to facilitate the desired positioning of the reservoir 14 within a subject's body.
- Each of these markers 22, 24 may be made of a ring of radiopaque material and may be mounted on the shaft 12 in alignment with each end of the reservoir's cylindrical sidewall 14a.
- each marker 22, 24 comprises a band of Platinum-lridium alloy having outer diameter 0.034 inches and inner diameter 0.030 inches. These markers are visible under various imaging techniques including fluoroscopy and CT scanning.
- the proximal shaft portion 12a may be made of polyimide tubing of outer diameter 0.0618 inches and inner diameter 0.052 inches and length 20cm.
- a hub 16 comprising a female Luer connector made of dear polycarbonate (Part No. 41519, Qosina, Edgewood, NY) is attached to the proximal end of shaft 12. As seen in Figure 2C, this hub 16 has a proximal bore 100 that gradually narrows to a distal bore 102, thereby facilitating infusion of suspensions and viscous liquids.
- the distal bore 102 is approximately the same diameter as, and is continuous with, the shaft lumen 13.
- the device incorporates two types of position retaining apparatus, namely a suture loop 20 as well as a pair of projections in the nature of retention wings 18.
- the retention wings 18 are located at diametrically opposed locations on the shaft 12, proximal to the reservoir 14 to help retain the reservoir 14 at a desired position within the body, as will be explained in substantial detail below.
- each retention wing 18 comprises a preformed loop of nickel-titanium (nitinol) wire of diameter 0.0086 inches.
- Each retention wing 18 may be flexed or compressed to a collapsed position where it lies substantially flat against the outer surface of the shaft 12.
- each retention wing 18 is biased to a preformed configuration such that, when unconstrained, each retention wing 18 will resiliently spring outwardly to an extended position wherein it extends at an angle of from about 65 to 90 degrees relative to the longitudinal axis of the shaft 12.
- Such pre-forming of these wings 18 may be accomplished by heat treating the nitinol wire loop at 520°c for 20 minutes to produce an austenite finish temperature (A f ) of 20 0 C.
- a f austenite finish temperature
- Figure 3 shows an alternative retaining member 88 comprising proximal and distal resilient elastomeric flanges 90, 92 which are at spaced apart locations so as to rest against and engage opposite sides of an anatomical wall or structure.
- the anatomical wall or structure comprises a bulla or sinus wall formed of bone B covered by mucosal tissue M.
- the distal flange 88 is sufficiently resilient and flexible to collapse while passing through the small opening in the anatomical wall and to thereafter resume its expanded shape as seen in Figure 3.
- the suture loop 20 (e.g., an eyelet or ring) may be formed of supple, flexible, resilient, elastic or superelastic material such as suture thread or nickel-titanium alloy (Nitinol) wire.
- the suture loop is formed of black monofilament Nylon non-absorbable surgical suture material having a diameter of 0.0075 inches.
- the suture loop 20 may be collapsed against the outer surface of shaft 12.
- the suture loop 20 may be affixed to the outer surface of shaft 12 by winding the wire or other material around the shaft and securing the wire to the shaft using a suitable adhesive such as cyanoacrylate, epoxy or LJV curable adhesive and/or by mounting a polymeric sleeve or heat shrinkable member about the portions of wire that are wound around the shaft 12.
- the suture loop may be colored so as to be visually distinguishable from blood and the red-pink color of the intra-nasal mucosa.
- the suture loop 20 may be black, bright blue or green in color so as to be easily locatable by the surgeon. This suture loop 20 may be sutured to the adjacent tissue to anchor the distal portion of the device 10 in place.
- a tubular constraining sheath 30 may be positioned over the shaft 12.
- this constraining sheath 30 comprises a 10cm length of plastic tubing having an outer diameter of .084 inches and an inner diameter of .075 inches.
- This constraining sheath 30 is moveable back and forth between a retracted position (seen in Figure 2D) and an extended position (seen in Figure 2E). When in the extended position, the constraining sheath extends over the retention wings 18, suture loop 20 and the collapsed reservoir 14, thereby holding the retention wings 18 in their collapsed positions and forming a smooth protective covering over the retention wings 18, suture loop 20 and collapsed reservoir 14.
- the constraining sheath 30 when in the extended position, the constraining sheath 30 will add column strength to the over all device and will deter kinking of the shaft 12 as it is pushed through relatively narrow and/or tortuous anatomical passages.
- the constraining sheath 12 may be withdrawn to its retracted position, thereby allowing the suture loop 20 to be accessible, the retention wings 18 to spring outwardly to their extended positions and the reservoir 14 to undergo expansion when it is subsequently loaded with the desired substance.
- the spacer device 10 described above include a reservoir 14 formed of a single layer balloon
- the reservoir may comprise a balloon having multiple layers with different sized openings in each layer.
- the substance may then be selectively introduced between the particular layers that will facilitate the desired delivery of that particular substance at the desired rate.
- Figures 14 through 14D show another embodiment of a substance delivering spacer device 610 having a shaft 612 and a multi- layered reservoir balloon 614.
- the shaft 612 may be constructed and equipped in the same manner as the shaft 12 of the device 10 described above.
- three lumens 616, 618 and 620 extend through the shaft 612 and the reservoir 614 comprises a balloon having three layers 614a, 614b and 614c.
- the outermost layer 614a has openings 631a of a first size.
- the middle layer 614b has openings 631b of a second size that is smaller than the size of the openings 631a formed in the outer layer 614a.
- the inner-most layer 614c has openings 631c of a third size that is smaller than the size of the openings 631 b formed in the middle layer 614b.
- First lumen 616 opens into the space within the innermost layer 614c.
- Second lumen 618 opens into the space between the inner-most layer 614c and the middle layer 614b.
- Third lumen 620 opens into the space between the middle layer 614b and the outer-most layer 614a.
- the operator may select the particular space into which a particular substance is to be infused so that the substance will be required to pass through either: a) only the openings 631a in the outer-most layer 614a; b) the openings 631b in the middle layer 614b as well as the openings 631a in the outer layer 614a; or c) all of the openings 631a, 631b, 631c in all three layers 614a, 614b and 614c. In this manner, the rate of elution of the substance may be optimized.
- the substance delivering spacer device 10, 610 may be implanted in any suitable part or location of the body of a human or animal subject to perform a spacing function (e.g., to prevent tissue ingrowth, scarring, fibrosis, adhesion formation, etc.) and/or to deliver any desired therapeutic substance.
- a spacing function e.g., to prevent tissue ingrowth, scarring, fibrosis, adhesion formation, etc.
- the device 10, 610 may be implanted in a natural ostium or man-made opening formed in any paranasal sinus or air cell or in any other natural, surgically modified or surgically created opening or passageway, such as the outflow tract of a frontal sinus, the inferior, superior or medial meatus, etc.
- FIGs 4-5E show an example of an ethmoidotomy system that may be used separately or in conjunction with a substance delivering spacer device 10, 610 of the type described above.
- This ethmoidotomy system comprises a sheath 40 seen in Figure 5 and a sinus needle 60 seen in Figure 6.
- the sheath 40 and sinus needle 60 may be used separately or in combination.
- the combination of the sheath 40 and sinus needle 60 is shown in Figure 6.
- the sheath 40 may be formed of a biocompatible polymer such as PEBAX and comprises a proximal sheath body 42 of a first diameter, a distal sheath body 44 of a second diameter (smaller than the first diameter) and a tapered step-down segment 54 between the proximal sheath body 42 and the distal sheath body 44.
- a flared region 46 is located at the proximal end PE of the sheath 40.
- a visual marker band 50 is optionally provided on the proximal sheath body 42 near its proximal end PE.
- a second visual marker band 48 is optionally located on the distal shaft portion 44 approximately 17 mm from the distal end DE.
- radiopaque markers 52, 56 may be provided at spaced apart locations on the distal sheath body 44.
- the distal radiopaque marker 56 is located approximately 1.5 mm from the distal end and the proximal radiopaque marker 52 is located approximately 17 mm from the distal end DE and beneath the distal edge of visual marker 48.
- optional wing members 53 may extend laterally from the distal sheath body 44 in the region of visual marker 48. These optional wing members 53 may be constructed in substantially the same manner as the retention wings18 of the substance delivering spacer device 10 described above and, when extended, each wing member 53 may have a length of about 2 cm.
- This sheath 40 may be used to facilitate insertion of the above-described substance delivering spacer device 10 or this sheath 40 may be used alone to facilitate suctioning of matter or for delivery of therapeutic or diagnostic substances.
- the sinus needle 60 comprises an elongate, curved needle body 62 having a sharp trocar tip 63.
- the proximal end of the needle body 62 is firmly, non-rotatebly anchored to handpiece 64. As seen in Figure 5A, this may be accomplished by forming a 90 degree bend in the proximal end of the needle body 62 and molding it in place within the handpeice 64 thereby providing a strong connection and preventing the needle body 62 from rotating relative to the handpiece 64.
- the needle body 48 is formed of solid stainless steel wire having an outer diameter of approximately 0.07 inches.
- a curve 65 is formed in the needle body 62.
- the needle body 62 is about 102 mm in length and the center of the curve 65 is located about 31 mm from the distal tip 63 of the needle body 62.
- the curve 65 forms an angle A2 of approximately 33 degrees.
- This particular embodiment of the sinus needle 60 is particularly suited for a needle ethmoidotomy as described below and the curve 52 allows the distal portion of the needle body 62 to be advanced through the ethmoid bulla and into the ethmoid air cells with decreased potential for inadvertent penetration through the adjacent skull base which protects the subject's brain.
- the trocar tip 63 has three beveled edges arranged symmetrically around the central axis of needle shaft with each beveled edge being disposed at an angle B of about 20 degrees relative to the longitudinal axis of the needle body 62.
- This design enables sinus needle device 60 to be used for penetration through soft tissue (e.g., mucosa) as well as thin bone (e.g., the ethmoid bulla and other bones separating individual ethmoid air cells.
- the handpiece 64 comprises a sighting member such as a fin 66, a top elongate member 70 and a bottom elongate member 68 that is attached to and substantially parallel to the top elongate member.
- the handpiece may also comprise a a distal grip portion 72,. All or part of the handpiece 64 may be coated with an elastomeric material and/or may be provided with grooves, ridges or surface configurations that facilitate firm grasping of the handpiece 64 by the operator.
- the sighting fin 66 extends from the handpiece in a plane that is parallel to the plane of the needle curve 65, thereby providing to the operator a visual indication of the lateral direction in which the distal portion of the needle body 62 is advancing even when the distal end of the needle body 62 is within the subject's body and out of direct sight of the operator. Additionally, the top edge 67 of the vertical sighting fin 66 is parallel to and in substantial alignment with the distal portion of the needle body 62, thereby providing to the operator a visual indication of the vertical tilt or trajectory on which the needle tip 63 is advancing even when the distal end of the needle body 62 is within the subject's body and out of direct sight of the operator.
- Figure 6 shows the needle sheath 40 positioned on the sinus needle body 62.
- the length of the needle sheath 40 is such that when the sheath 40 is fully advanced onto the needle body 62, the flared region 46 located at the proximal end PE of the sheath 40 will abut against the distal surface of the handpiece 64 and the distal tip 63 of the needle body 62 will protrude out of and beyond the distal end DE of the sheath 40.
- the sheath 40 is flexible enough to conform to the curve 65 of sinus needle body 62, as shown.
- an optical or electrical image guidance component 74 may be attached to the upper elongate member 70 of the handpiece 64, as seen in Figure 6, thereby allowing an optical or electromagnetic image guidance system to be used, in accordance with techniques well known in the art of ear, nose and throat surgery, to determine and/or guide the positioning of the needle tip 63 within the body of human or animal subject.
- United States Patents Nos. 5,314,417 entitled “Safety Trocar” and 5,267,965 entitled “Safety Trocar” disclose safety mechanisms that may optionally be used in combination with the sinus needle device 60 and sheath 40.
- the sinus needle may comprise any other suitable tissue penetrating apparatus capable of forming the desired penetration through the intended tissue (e.g., for ethmoid applications, through mucosal tissue and bone).
- suitable tissue penetrating apparatus include but are not limited to rotating drills, burs, bipolar or monopolar radiofrequency or electrocautery probes, laser probes, etc.
- FIGs 5D and 5E show one example of an alternative sinus penetrator 60a which is similar in construction to the sinus needle 60 described above except that the bottom elongate member 68 of the handpeice is replaced by a housing 68a having an electric motor (not shown) positioned therewithin and an on-off button.
- the needle body 62 is replaced by a rotating bur assembly which comprises an elongate curved tube 62a having a flexible rotating drive shaft 84 extending therethrough and a rotating burr tip 82 attached to the distal end of the drive shaft 84, as shown in Figure 5E. Because the drive shaft 84 is flexible, it is capable of rotating even though it extends through the curve 65a of the tubular body 62a.
- the rotating burr tip may be a 0.6 mm, 0.7mm or 0.8mm diamond bur tip and the motor, drive shaft 84 and bur tip 82 may be substantially the same as used in the UltraburTM Fixed Tip Drill (Invotec International, Inc., Jacksonville, Florida).
- a fiber optic laser waveguide may extend through the probe and a suitable type of laser light may be delivered through the wave guide and out of the distal end of the probe to penetrate through the desired anatomical structure.
- a suitable type of laser is a holmiun ⁇ YAG laser. See, Metson, Ralph; Holmium ⁇ AG Laser Endoscopic Sinus Surgery: A Randomized, Controlled Study; Laryngoscope; 106(1) Supplement 77:1-18 (January 1996).
- Figures 7A-7K show one example of a method by which the above- described sinus needle device 60, sheath 40 and substance delivery device 10 may be used to perform a needle ethmoidotomy, to effectively "stent" the ethmoidotomy channel and to deliver a therapeutic substance (e.g., a corticosteroid) into the diseased ethmoid sinuses for a period of time postoperatively.
- a therapeutic substance e.g., a corticosteroid
- the needle sheath 40 is placed on the needle body 62 as shown in Figure 6.
- the inner diameter of the proximal sheath portion 42 is large enough to allow the constraining sheath 30 of the substance delivery device (shown in Figures 1D and 1E) to pass therethrough, whereas the internal diameter of the distal sheath portion 44 is the same or smaller than the outer diameter of the moveable sheath 30 but still sufficiently large in diameter to allow the collapsed reservoir 14 and non-deployed retention wings 18 to pass thereinto.
- the subject is anesthetized or appropriate analgesia/sedation is administered.
- the needle body 62 having the sheath 40 mounted thereon is inserted through the subject's nostril along with an endoscope 400 such as a Storz HopkinsTM II, 0 degree, autoclavable 4mm X 18mm telescope with a Storz Xenon 300TM or Xenon NovaTM light source (Karl Storz GmbH & Co., Tuttlingen, Germany).
- an endoscope 400 such as a Storz HopkinsTM II, 0 degree, autoclavable 4mm X 18mm telescope with a Storz Xenon 300TM or Xenon NovaTM light source (Karl Storz GmbH & Co., Tuttlingen, Germany).
- a C-arm fluoroscope system may optionally be used to provide fluoroscopic images during portions of the procedure.
- C arm fluoroscope system One example of a commercially available C arm fluoroscope system that is suitable for this purpose is the OEC 9800 PlusTM Digital Mobile Imaging System (G. E. OEC Medical Systems, Inc., Salt Lake City, Utah).
- the operator may verify that the distal portion of the needle body 62 is in the proper vertical tilt and lateral direction by viewing the sighting fin 66 and its leading edge 67. Under endoscopic guidance, the needle tip 50 is pushed through the ethmoid bulla EB and into one or more ethmoid air cells EAC.
- the approximately thirty-three degree angle 65 formed in this embodiment of the sinus needle body 62 allows the distal tip 63 to be advanced on a trajectory that is substantially parallel to (or in some cases even divergent from) the adjacent skull base SB.
- the curve 65 of the ethmoidotomy needle body 62 may have a radius of about 0.75 inch and may form an angle A of about 33 degrees.
- the distal portion of the needle body 62 i.e., the portion extending from the curve 62 to its distal tip 63
- the ethmoidotomy needle body 62 is formed of a .073" diameter 304 stainless steel wire having a measured tensile strength (ASTM A313-03) in the range of about 253852 to 258665 psi.
- ASTM A313-03 measured tensile strength
- the operator may additionally use known techniques and apparatus for optical or electromagnetic image guidance of the advancement of the sinus needle body 62 relative to the skull base SB and other critical anatomical structures. Also, the depth of penetration must be carefully controlled so as not to penetrate all the way though the sphenoid wall and into the sphenoid sinus SS.
- the surgeon may choose a sheath 40 wherein the distance from the distal end DE of the sheath 40 to the proximal edge of visual marker 48 is less than the distance from the anterior surface of the ethmoid bulla EB to the wall of the sphenoid sinus SS.
- the distal visual marker 48 on the sheath 40 may then be visualized via the endoscope to gage the depth of penetration into the ethmoid air cells.
- the advancement may be stopped when the proximal end of visual marker 48 is seen to be flush with the ethmoid bulla EB, thereby ensuring that the sphenoid wall has not been breached.
- an optional external stop member 600 may be attached by any suitable means, such as a clip 602, grasper, adhesive, frictional engagement or any other means, to the sheath 40 at a location which will cause the stop member 600 to abut against the subjects nose, thereby preventing the needle 62 and sheath 40 from being advanced beyond a safe distance into the ethmoids.
- the distance between the proximal and distal radiographic markers 52, 56 is substantially the same as the length of the reservoir 14 and such markers 44 may be viewed by fluoroscopy. The surgeon can use such fluoroscopic image to position the markers 52, 56 such that they demarcate the locations where the proximal and distal ends of the reservoir 14 are intended to reside.
- the physician may optionally retract the constraining sheath 30 to expose suture loop 20, and a length of 2-0 or 3-0 suture material 17 having a straight or curved needle 19 may be passed through suture loop and doubled over.
- the constraining sheath 30 may then be moved to its advanced position, and the opposite ends of the doubled over suture 17 will be caused to protrude out of the proximal end of the constraining sheath 30 as shown in Figure 7C.
- the substance delivery device 10 with its reservoir in a collapsed state and the constraining sheath 30 in its advanced position is then inserted into the proximal end of the needle sheath 40 as seen in Figure 7C.
- the substance delivery device 10 with the constraining sheath 30 in its advanced position is advanced through the sheath 40 to a position where slight resistance to further advancement is felt due to abutment of the distal end of the constraining sheath 30 with the narrowed wall of the internal surface of the tapered segment 54.
- the surgeon will apply sufficient force to overcome the resistance to advancement, causing the constraining sheath 30 to move proximally to its retracted position (shown in Figure 2D) as the distal portion of the substance delivering spacer device 10, including the collapsed reservoir 14, advances into the distal sheath portion 42.
- the positioning of the reservoir 14 within the distal sheath portion 42 may then be verified fluoroscopically by viewing the positions of the radiographic marker 24 on the device 10 relative to the positions of the radiographic markers 44 on the distal sheath portion 42. Also, using these markers, the actual positioning of the reservoir 14 relative to the surrounding anatomy may be checked.
- the sheath 40 with the constraining sheath 30 contained therein may be withdrawn proximally.
- the deployment and engagement of the retention wings 18 may be verified fluoroscopically.
- a syringe containing 0.31 cc to 0.35cc of Triamcinolone Acetonide injectable suspension (Kenalog ® 40, Brystol-Myers Squibb Company, Princeton, New Jersey) is attached to the proximal Luer connector 16 of the substance delivering spacer device 10 and the Triamcinolone Acetonide injectable suspension is injected, thereby causing the reservoir 14 to expand.
- the shaft 12 of the substance delivering spacer device 10 may be transparent so that the delivery of the substance through lumen 13 may be viewed through the endoscope 400.
- the shaft 12 adjacent to proximal Luer connector 16 is cut thereby removing the Luer hub 16.
- the sheath 40 can be provided with a longitudinal perforation or weakened region which will allow the sheath to be peeled away and removed.
- this procedure results in an ethmoidotomy channel or opening extending into one or more ethmoid air cell(s) EAC with the substance eluting reservoir 14 and distal shaft 12b remaining in place for a period of time (e.g., between 1 hour to 90 days, preferably between 7 to 29 days, most preferably about 14 days and in some cases about 7 days) following the performance of the needle ethmoidotomy procedure. Additionally, a small amount of the substance will remain in the distal shaft 12b distal to the location at which it is cut. This remaining substance may slowly leak out of the cut end of the distal shaft 12b thereby providing medication to adjacent turbinate or other nearby anatomical structures within the nasal antrum.
- a period of time e.g., between 1 hour to 90 days, preferably between 7 to 29 days, most preferably about 14 days and in some cases about 7 days
- the sinus needle sheath 40 has a distal shaft portion 44 made of Nylon having an outer diameter of .087 inches and inner diameter of .075 inches and length of 25mm.
- Intermediate tapered region 54 is about 5 mm in length and is tapered from an outer diameter of .104 inches and an inner diameter of .088 inches at its proximal end, to an outer diameter of .092 inches and an inner diameter of .075 inches at its distal end.
- Proximal shaft portion 42 is made of Nylon 12 and has an outer diameter of .102 inches and inner diameter of .088 inches and length of 3.5 inches.
- Distal and proximal sheath markers 44 are made of rings of a Pt-Ir alloy with an outer diameter of 0.087 inches and an inner diameter of 0.085 inches.
- the distal shaft marker 44 is located 1mm from the distal end DE of needle sheath 134.
- Proximal shaft marker 148 is located 18mm from the distal end of needle sheath 40.
- the total length of needle sheath 40 is 115mm.
- Figures 7A-7K is specific to treatment of ethmoid disease
- the system of devices shown in the example of Figures 3A- 3L may also be used to form penetration tracts or openings (e.g., antrostomy openings, etc.) in various paranasal sinuses and other anatomical structures and to position the substance delivering spacer device 10 within such penetration tracts or openings.
- the substance delivering spacer device 10 may be used separately from the sinus needle device 60 in various ostia, openings, incisions and passageways of the body to act simply as a spacer and/or to deliver a desired diagnostic or therapeutic substance.
- steroids such as Kenalog®-40 (Triamcinolone Acetonide injectable Suspension, USP) are delivered to a paranasal region such as the ethmoid sinuses with device 10.
- the implantable device 10 can be used to preferably deliver fluids or suspensions with a low surface tension. Fluids with low surface tension easily spread across a surface. This is especially useful to deliver substances over a large surface area, especially in anatomical regions such as ethmoid sinuses that have complicated 3-D geometries.
- the low surface tension fluid comprises a surfactant.
- a low surface tension irrigating fluid containing one or more substances is delivered to the ethmoid sinuses.
- a substantially inert fluid such as saline solution may be delivered to moisten the surrounding tissues and the device may perform a spacing and/or drainage/ventilation function.
- an active substance such as a therapeutic or diagnostic substance may be delivered in addition to the spacing and/or drainage/ventilation function of the implanted device 10.
- the substance delivering spacer device 10 may be implanted within openings (e.g., natural ostia, surgically altered ostia, other man-made openings) of paranasal sinuses to facilitate the treatment of a disease or disorder affecting the paranasal sinus.
- the opening of the paranasal sinus may be enlarged (e.g., dilated) before or after placement of a device 10, 104 of the present invention within such opening.
- One such procedure is balloon dilation of sinus cavity ostia.
- a guide catheter having a substantially fixed shape is inserted through the nose and advanced to a position where the distal end of the guide catheter is adjacent to the ostium of a paranasal sinus.
- a guidewire is then advanced through the guide catheter (e.g., RelievaTM Guide Catheter, Acclarent, Inc., Menlo Park, California) and into the paranasal sinus.
- a balloon catheter ⁇ e.g., RelievaTM Balloon Catheter, Acclarent, Inc., Menlo Park, California
- Figures 8A through 8G show an example of one method by which the substance delivering spacer device 10 may be placed in the frontal sinus outflow tract FSO to perform a stenting and substance delivery function following balloon dilation of the frontal sinus outflow tract FSO.
- the endoscope 400 is inserted and, optionally, a C- arm fluoroscope (not shown) may also be positioned to provide fluoroscopic images of the procedure when desired.
- a C- arm fluoroscope (not shown) may also be positioned to provide fluoroscopic images of the procedure when desired.
- the endoscope 400 is shown only in Figures 8A and 8B 1 such endoscope 400 may remain in place throughout all or any part of this procedure and may be used for real time visualization of the movement and operation of the devices, as described in this example.
- a frontal sinus guide catheter 500 e.g., the Relieva ® 70 Degree Sinus Guide Catheter; Acclarent, Inc., Menlo Park, California
- a frontal sinus guide catheter 500 is inserted through the nostril and advanced to a position where its distal end is within or aligned with the frontal sinus ostium FSO.
- Such positioning of the guide catheter 500 may be verified by endoscopic visualization and/or fluoroscopy.
- a guidewire GW (Relieva ® Sinus Guidewire; Acclarent, Inc., Menlo park, California) is advanced through the guide catheter 500 and into the frontal sinus FS, as shown in Figure 8A.
- the fluoroscope 404 may be used to verify that the guidewire GW has become coiled within the frontal sinus FS.
- a dilation catheter 502 (e.g., the Relieva® or Retieva XL Sinus Balloon Catheter, Acclarent, Inc., Menlo Park, California) is advanced over the guidewire GW and through the guide catheter 500 to a position where its dilator balloon 504 is positioned within the frontal sinus ostium FSO.
- the fluoroscope 400 may be used to verify that the guidewire GW has become coiled within the frontal sinus FS. With the dilator 504 so positioned, the dilator balloon 504 is expanded to cause dilation of the frontal sinus ostium FSO or other frontal sinus outflow tract.
- the substance delivering spacer device 10 is prepared and advanced through the guide catheter 500 and into the frontal sinus FS.
- the constraining tube 42 may be removed and the retention wings 18 may be manually folded forward (i.e., in the distal direction) using finger pressure as the spacer device 10 is inserted into the proximal end of the guide catheter 500.
- the retention wings 18 will spring outwardly and will engage the frontal sinus ostium FSO as shown in Figure 8C. Positioning of the reservoir 14 within the frontal sinus and successful deployment of the retention wings 18 may be verified fluoroscopically.
- a syringe containing 0.31 cc to 0.35cc of Triamcinolone Acetonide injectable suspension (Kenalog ® 40, Brystol-Myers Squibb Company, Princeton, New Jersey) is attached to the proximal Luer connector of the sinus spacer device 10 and the Triamcinolone Acetonide injectable suspension is injected, thereby causing the reservoir 14 to expand. Successful expansion of the reservoir 14a may be verified by CT.
- the proximal end of the sinus spacer device 10 is cut off and the guide catheter is retracted proximally and removed.
- the operator may grasp the shaft 12 of the spacer device distal to the distal end of the guide catheter 500 as the guide catheter is removed to stabilize the spacer device 10 and to prevent it from being inadvertently dislodged from the frontal sinus FS during removal of the guide catheter 500.
- a proximal portion of the shaft 12 of spacer device 10 may be cut away, leaving a short length of the shaft 12 hanging within the nose.
- the suture 17 with straight needle 19 is used to suture the suture tab 20 of the spacer device 10 to tissue within the nose, thereby helping to retain the implanted portion of the spacer device 10 in its desired position for a desired time period following the procedure.
- Some of the substance will remain in the remaining segment of shaft 12 distal to the cut and may leak into the nasal cavity subsequent to the procedure, thereby providing medication to other structures within the nasal cavity as well.
- Figures 9A-9D show steps in another method in which frontal sinusitis is treated in an adult human subject.
- the frontal sinus ostium FSO may or may not have been previously surgically altered or dilated as described above.
- a frontal sinus guide catheter 500 e.g., the Relieva ® 70 Degree Sinus Guide Catheter; Acclarent, Inc., Menlo Park, California
- Such positioning of the guide catheter 500 may be verified by endoscopic visualization and/or fluoroscopy.
- a guidewire GW (Relieva ® Sinus Guidewire; Acclarent, Inc., Menlo park, California) is advanced through the guide catheter 500 and into the frontal sinus FS, as shown in Figure 9A.
- the fluoroscope 404 may be used to verify that the guidewire GW has become coiled within the frontal sinus FS.
- the frontal sinus guide catheter 500 is removed, leaving the guidewire GW in place.
- a 5 French vascular dilator 420 e.g., 5 F vessel dilator (inner diameter of 0.038 in.), Merritt Medical Systems, Inc., South Jordan, UT).
- the sheath/dilator combination is then advanced over the guidewire GW.
- the C-arm fluoroscope and/or the endoscope 400 may be used to observe the advancement of the sheath/dilator combination to a position where the proximal radiographic marker 52 of the sheath 40 is distal to the frontal recess (i.e., within the cavity of the frontal sinus). Once the sinus sheath 40 has been advanced to such location while within the lumen of the dilator, the 5F dilator 420 and the guidewire GW are removed leaving the sheath 40 in place, as shown in Figure 9C.
- the substance spacer device 10 is prepared as described above and the constraining tube 30 is placed in its advanced position so as to constrain and cover the suture loop 20, retention wings 18 and reservoir 14 in their collapsed positions.
- the device 10 is advanced into the previously inserted sheath 40 in substantially the same manner as described above and shown in Figures 8C-8E.
- the sheath 40 and constraining tube 30 are retracted and a syringe containing 0.31 cc to 0.35cc of Triamcinolone Acetonide injectable suspension (Kenalog ® 40, Brystol-Myers Squibb Company, Princeton, New Jersey) is attached to the proximal Luer connector of the sinus spacer device 10 and the Triamcinolone Acetonide injectable suspension is injected, thereby causing the reservoir 14 to expand within the frontal sinus FS, as previously described above. Successful expansion of the reservoir 14a may be verified by CT scan if desired.
- a proximal portion of the shaft 12 of spacer device 10 may be cut away, leaving a short length of the shaft 12 hanging within the nose.
- the suture 17 with straight needle 19 is used to suture the suture tab 20 of the spacer device 10 to tissue within the nose, thereby helping to retain the implanted portion of the spacer device 10 in its desired position for a desired time period following the procedure as seen in Figure 9D.
- Triamcinolone Acetonide suspension that remains in the short segment of shaft 12 distal to the cut may subsequently leak into the nasal cavity NC, providing some additional therapeutic benefit to tissues in that area.
- the operator may use a technique that is essentially the same as that described above and shown in figures 9A-9D except that, instead of the frontal sinus guide 500, the operator will insert a maxillary sinus guide catheter 500 (e.g., the Relieva ® 110 Degree Sinus Guide Catheter; Acclarent, Inc., Menlo park, California) through the nostril and will advance that guide catheter to a position where its distal end is within or aligned with the maxillary sinus ostium.
- a maxillary sinus guide catheter 500 e.g., the Relieva ® 110 Degree Sinus Guide Catheter; Acclarent, Inc., Menlo park, California
- the operator may use a technique that is essentially the same as that described above and shown in figures 9A-9D except that, instead of the frontal sinus guide 500, the operator will insert a sphenoid sinus guide catheter 500 (e.g., the Relieva ® 30 Degree Sinus Guide Catheter; Acclarent, Inc., Menlo park, California) through the nostril and will advance that guide catheter to a position where its distal end is within or aligned with the sphenoid sinus ostium.
- a sphenoid sinus guide catheter 500 e.g., the Relieva ® 30 Degree Sinus Guide Catheter; Acclarent, Inc., Menlo park, California
- Triamcinolone Acetonide injectable suspension (Kenalog ® 40, Brystol-Myers Squibb Company, Princeton, New Jersey), when loaded into the reservoir 14 of the substance delivering spacer device 10, remains intact and capable of pharmacologic activity for at least 30 days following implantation of the device.
- the reservoir 14 of one device 10 was loaded by injecting 0.31cc of the Triamcinolone Acetonide injectable suspension as described above ⁇ hereinafter referred to as "Triamcinolone Acetonide loaded reservoir").
- the reservoir 14 of a second device 10 was loaded with saline (hereinafter referred to as “placebo loaded reservoir”) and the reservoir of a third device remained empty (hereinafter referred to as "blank reservoir”) All three devices were maintained under ICH stability conditions (40°C + 2°C/ 75% RH ⁇ 5% RH) in Caron Model 6030 Environmental Stability Chamber. High Performance Liquid Chromatography (HPLC) was performed on aliquots of the contents of each reservoir at day 0 and day 30. The results of this study are summarized in Table 1 below:
- Total impurities (Total peak area of imp/Total peak area of K-40 sinus spacer) x
- Triamcinolone Acetonide is a second generation synthetic corticosteroid of which there are currently six compounds approved for intranasal use. All six corticosteroids appear to be relatively equal with regard to potency and effectiveness.
- TA was chosen for use in the Ethmoid Sinus Spacer as the compound with the longest safety record and for its availability in a concentrated solution suitable for use in this device.
- Kenalog-40 was used as it is one of the approved and marketed formulations of Triamcinolone Acetonide.
- the volume of vehicle in the substance delivering spacer device 10 used in this study has a reservoir 14 that will hold 0.1 ml. when loaded to maximum capacity. If loaded to maximum capacity with the Kenalog-40, the reservoir will contain 4mg of TA. This amount of TA is roughly equivalent in potency to the 35-40 mg of Cortisol produced daily by normal human adrenal glands. Thus, a total 4 mg TA, even if released all at once, would not be expected to adversely affect adrenal corticoid activity.
- the openings 31 in the reservoir 14 of the substance delivering spacer device 10 may be designed to limit diffusion of TA from the reservoir so that only a small daily dose of drug is delivered over the course of two weeks. In this manner, the dose delivered locally into the ethmoids or other paranasal sinuses may be less than the recommended dose of TA delivered with commercially available nasal inhalers (e.g., Nasacort ® Inhaler, Sanofi-Aventis, Bridgewater, New Jersey).
- nasal inhalers e.g., Nasacort ® Inhaler, Sanofi-Aventis, Bridgewater, New Jersey.
- Blood levels of TA were determined in subjects 1-10 prior to the administration of anesthesia and at 1 , 2 and 4 hours following implantation and loading of the substance delivering spacer device 10. If the particular subject stayed overnight at the treatment facility, a blood sample was taken at 23 hours or just prior to discharge. Additional blood samples were collected in subjects 1-10 at 3, 7, 10 and 14 days after the procedure and immediately prior to explant and removal of the substance delivering spacer device 10.
- a final CT scan of the ethmoid sinuses was taken at eight weeks to assess the condition of the ethmoid sinuses and when compared to baseline, the degree of improvement.
- Subjects Nos. 11 through 13 received the same post-operative care and blood sample collection as Subject Nos. 1-10, with the following exceptions:
- Subject No. 14 was the one who was treated for frontal sinusitis rather than ethmoid disease. Subject No. 14 received post-operative follow-up and data collection (e.g., blood samples and SNOT-20 questionaires) in substantially the same manner as Subject Nos. 1-10.
- post-operative follow-up and data collection e.g., blood samples and SNOT-20 questionaires
- Figure 11 shows the average improvement from baseline in the SNOT- 20 scores as measured at 1 , 2, 4, and 6 weeks (Note: One patient deviated from protocol and completed the 6 week follow-up visit at four weeks.) A score of 1.07 or below was deemed to be indicative of a clinically significant reduction of sinusitis symptoms (i.e., a reduction of at least 0.8 from the baseline SNOT 20 score). These data indicate that clinically significant reductions in the average SNOT 20 scores were observed at 2, 4 and 6 weeks after the procedure.
- CT scans were performed at baseline and 42 days following the procedure to derive the LMK score.
- the null and alternative hypotheses evaluated based on this endpoint are as follows:
- the primary efficacy endpoint was examined using inferential statistics. Based on the performance success of the 14 patients enrolled (100%), the lower 95% exact binomial confidence interval was 76.84%.
- substance as used herein is to be broadly construed to include any feasible drugs, prodrugs, proteins, gene therapy preparations, cells, diagnostic agents, contrast or imaging agents, biologicals, etc. Such substances may be in bound or free form, liquid or solid, colloid or other suspension, solution or may be in the form of a gas or other fluid or non-fluid.
- the substance delivered may comprise a pharmaceutically acceptable salt or dosage form of an antimicrobial agent (e.g., antibiotic, antiviral, antiparasitic, antifungal, etc.), a corticosteroid or other antiinflammatory (e.g., an NSAID), a decongestant (e.g., vasoconstrictor), a mucous thinning agent (e.g., an expectorant or mucolytic), an agent that prevents of modifies an allergic response (e.g., an antihistamine, cytokine inhibitor, leucotriene inhibitor, IgE inhibitor, immunomodulator), an anesthetic agent with or without a vasoconstriction agents (e.g.
- an antimicrobial agent e.g., antibiotic, antiviral, antiparasitic, antifungal, etc.
- a corticosteroid or other antiinflammatory e.g., an NSAID
- a decongestant e.g., vasoconstrictor
- Xylocaine with or without Epinephrine an analgesic agent
- an allergen or another substance that causes secretion of mucous by tissues hemostatic agents to stop bleeding
- antiproliferative agents cytotoxic agents e.g. alcohol
- biological agents such as protein molecules, stem cells, genes or gene therapy preparations
- viral vectors carrying proteins or nucleic acids such as DNA or mRNA coding for important therapeutic functions or substances
- cauterizing agents e.g. silver nitrate, etc.
- antimicrobial agents include acyclovir, amantadine, rimantadine, oseltamivir, zanamivir, aminoglycosides (e.g., amikacin, gentamicin and tobramycin), amoxicillin, amoxicillin/clavulanate, amphotericin B, ampicillin, ampicillin/sulbactam, atovaquone, azithromycin, cefazolin, cefepime, cefotaxime, cefotetan, cefpodoxime, ceftazidime, ceftizoxime, ceftriaxone, cefuroxime, cefuroxime axetil, cephalexin, chloramphenicol, clotrimazole, ciprofloxacin, clarithromycin, clindamycin, dapsone, dicloxacillin, doxycycline, erythromycin, flucon
- the substances delivered in this invention may include various steroids or other anti-inflammatory agents (e.g., nonsteroidal anti-inflammatory agents or NSAIDs), analgesic agents or antipyretic agents.
- steroids or other anti-inflammatory agents e.g., nonsteroidal anti-inflammatory agents or NSAIDs
- analgesic agents e.g., analgesic agents or antipyretic agents.
- corticosteroids that have previously administered by intranasal administration may be used, such as beclomethasone (Vancenase® or Beconase®), flunisolide (Nasalide®), fluticasone proprionate (Flonase®), triamcinolone acetonide (Nasacort®), budesonide (Rhinocort Aqua®), loterednol etabonate (Locort) and mometasone (Nasonex®).
- beclomethasone Vancenase® or Beconase®
- flunisolide Nasalide®
- Fluticasone proprionate Flonase®
- triamcinolone acetonide Nasacort®
- budesonide Rost Aqua®
- loterednol etabonate Locort
- mometasone Nasonex®
- Other salt forms of the aforementioned corticosteroids
- steroids include but are not limited to aclometasone, desonide, hydrocortisone, betamethasone, clocortolone, desoximetasone, fluocinolone, fiurandrenolide, mometasone, prednicarbate; amcinonide, desoximetasone, diflorasone, fluocinolone, fluocinonide, halcinonide, clobetasol, augmented betamethasone, diflorasone, haiobetasol, prednisone, dexamethasone and methylprednisolone.
- COX inhibitors e.g., salicylic acid derivatives, aspirin, sodium salicylate, choline magnesium thsalicylate, salsalate, diflunisal, sulfasalazine and olsalazine; para-aminophenol derivatives such as acetaminophen; indole and indene acetic acids such as indomethacin and sulindac; heteroaryl acetic acids such as tolmetin, dicofenac and ketorolac; arylpropionic acids such as ibuprofen, naproxen, flurbiprofen, ketoprofen, fenoprofen and oxaprozin; anthranilic acids (fenamates) such as mefenamic acid and meloxicam; enolic acids such as the oxicams (piroxicam, meloxicam
- the substances delivered in this invention may include a) various cytokine inhibitors such as humanized anti-cytokine antibodies, anti-cytokine receptor antibodies, recombinant (new cell resulting from genetic recombination) antagonists, or soluble receptors; b) various leucothene modifiers such as zafirlukast, montelukast and zileuton; c) immunoglobulin E (IgE) inhibitors such as Omalizumab (an anti-lgE monoclonal antibody formerly called rhu Mab-E25) and secretory leukocyte protease inhibitor).
- various cytokine inhibitors such as humanized anti-cytokine antibodies, anti-cytokine receptor antibodies, recombinant (new cell resulting from genetic recombination) antagonists, or soluble receptors
- leucothene modifiers such as zafirlukast, montelukast and zileuton
- IgE immunoglobulin E
- the substances delivered in this invention may include various vasoconstrictors for decongestant and or hemostatic purposes including but not limited to pseudoephedrine, xylometazoline, oxymetazoline, phenylephrine, epinephrine, etc.
- the substances delivered in this invention may include various mucolytics or other agents that modify the viscosity or consistency of mucous or mucoid secretions, including but not limited to acetylcysteine (MucomystTM, MucosilTM) and guaifenesin.
- various mucolytics or other agents that modify the viscosity or consistency of mucous or mucoid secretions including but not limited to acetylcysteine (MucomystTM, MucosilTM) and guaifenesin.
- the substances delivered in this invention may include various mast cell stabilizers or drugs which prevent the release of histamine such as cromolyn (e.g., Nasal Chrom®) and nedocromil.
- cromolyn e.g., Nasal Chrom®
- nedocromil e.g., nedocromil
- the substances delivered in this invention may include various antihistamines such as azelastine (e.g., Astylin®), diphenhydramine, loratidine, etc.
- azelastine e.g., Astylin®
- diphenhydramine e.g., diphenhydramine, loratidine, etc.
- the substances delivered in this invention may include substances that weaken or modify bone and/or cartilage to facilitate other procedures of this invention wherein bone or cartilage is remodeled, reshaped, broken or removed.
- an agent such as a calcium chelator such as EDTA that could be injected or delivered in a substance delivery implant next to a region of bone that is to be remodeled or modified.
- Another example would be a preparation consisting of or containing bone degrading cells such as osteoclasts.
- the substances delivered in this invention may include other classes of substances that are used to treat rhinitis, nasal polyps, nasal inflammation, and other disorders of the ear, nose and throat including but not limited to anti-cholinergic agents that tend to dry up nasal secretions such as ipratropium (Atrovent Nasal®), as well as other agents not listed here.
- CGN collagenase
- trypsin trypsin/EDTA
- hyaluronidase hyaluronidase
- TLCM tosyllysylchloromethane
- the substances delivered in this invention may include other classes of substances that are used to treat rhinitis, nasal polyps, nasal inflammation, and other disorders of the ear, nose and throat including but not limited to anti-cholinergic agents that tend to dry up nasal secretions such as ipratropium (Atrovent Nasal®), as well as other agents not listed here.
- the substances delivered in this invention may include locally or topically acting diuretics such as furosemide and/or hyperosmolar agents such as sodium chloride gel or other salt preparations that draw water from tissue or substances that directly or indirectly change the osmolar content of the mucous to cause more water to exit the tissue to shrink the polyps directly at their site.
- diuretics such as furosemide
- hyperosmolar agents such as sodium chloride gel or other salt preparations that draw water from tissue or substances that directly or indirectly change the osmolar content of the mucous to cause more water to exit the tissue to shrink the polyps directly at their site.
- the substances delivered in this invention may include antitumor agents (e.g., cancer chemotherapeutic agents, biological response modifiers, vascularization inhibitors, hormone receptor blockers, cryotherapeutic agents or other agents that destroy or inhibit neoplasia or tumorigenesis) such as; alkylating agents or other agents which directly kill cancer cells by attacking their DNA (e.g., cyclophosphamide, isophosphamide), nitrosoureas or other agents which kill cancer cells by inhibiting changes necessary for cellular DNA repair (e.g., carmustine (BCNLJ) and lomustine (CCNU)), antimetabolites and other agents that block cancer cell growth by interfering with certain cell functions, usually DNA synthesis (e.g., 6 mercaptopurine and 5-fluorouracil (5FU), antitumor antibiotics and other compounds that act by binding or intercalating DNA and
- antitumor agents e.g., cancer chemotherapeutic agents, biological response modifiers, vascularization inhibitors
- biological response modifiers e.g., interferon, bacillus calmette- guerin (BCG), monoclonal antibodies, interluken 2, granulocyte colony stimulating factor (GCSF), etc.
- BCG Bacillus calmette- guerin
- GCSF granulocyte colony stimulating factor
- PGDF receptor antagonists herceptin, asparaginase, busuiphan, carboplatin, cisplatin, carmustine, cchlorambucil, cytarabine, dacarbazine, etoposide, flucarbazine, flurouracil, gemcitabine, hydroxyurea, ifosphamide, irinotecan, lomustine, melphalan, mercaptopurine, methotrexate, thioguanine, thiotepa, tomudex, topotecan, treosulfan, vinblastine, vincristine, mitoazitrone, oxa
- the substances delivered in this invention may include cells (mucosal cells, fibroblasts, stem cells or genetically engineered cells) as well as genes and gene delivery vehicles like plasmids, adenoviral vectors or naked DNA, mRNA, etc. injected with genes that code for anti-inflammatory substances, etc., and, as mentioned above, osteoclasts that modify or soften bone when so desired.
- any of the devices and methods described herein may also be used to deliver substances to the brain or alter the functioning of the olfactory system.
- Such examples include, the delivery of energy or the deposition of devices and/or substances and/or substance delivering implant(s) to occlude or alter olfactory perception, to suppress appetite or otherwise treat obesity, epilepsy (e.g., barbiturates such as phenobarbital or mephoobarbital; iminostilbenes such as carbamazepine and oxcarbazepine; succinimides such as ethyisuximide; valproic acid; benzodiazepines such as clonazepam, clorazepate, diazepam and lorazepam, gabapentin, lamotrigine, acetazolamide, felbamate, levetiraceam, tiagabine, topiramate, zonisamide, etc.), personality or mental disorders (e.g., antidepressants
- the devices and methods disclosed herein may be used to deliver several combinations of two or more substances disclosed herein to a suitable target anatomical region.
- the devices and methods disclosed herein are used to deliver a combination of an antiinflammatory agent (e.g. a steroid or an NSAID) and a mucolytic agent.
- an antiinflammatory agent e.g. a steroid or an NSAID
- a mucolytic agent e.g. a steroid or an NSAID
- the devices and methods disclosed herein may be used to deliver gels or viscous liquids comprising one or more substances to anatomical regions such as paranasal sinuses. Such gels or viscous liquids may coat and adhere to a mucous membrane and thus provide sustained delivery of one or more substances to the mucous membrane.
- a plasticized hydrocarbon gel comprising gelatin, pectin and sodium carboxymethylcellulose and a suitable substance may be delivered to a mucous membrane such as the mucous membrane of a paranasal sinus.
- Such gels can be used for sustained delivery of the suitable substance to the mucous membrane.
- One or more of the substance reservoirs disclosed herein may comprise multiple compartments such that each compartment stores a particular substance formulation.
- the multiple compartments prevent mixing of multiple substance formulations before substance formulations are delivered to the anatomy.
- One or more of the substance reservoirs comprising holes or pores may be filled with a suitable substance at a sufficiently high pressure to cause a portion of the substance to squirt out of the holes or pores. This process may be used to deliver an initial bolus of the substance to the surrounding anatomy.
- One or more of the substance reservoirs disclosed herein may be filled with a suitable substance after the substance reservoir is introduced in an anatomical region.
- one or more of the substance reservoirs disclosed herein may be filled with a suitable substance before the substance reservoir is introduced in an anatomical region.
- one or more of the substance reservoirs disclosed herein may be pre-filled with a solid, lyophilized or concentrated substance. The solid, lyophilized or concentrated substance is converted to an active form by introducing a solvent into the substance reservoir. This may be done just before or after the substance reservoir is introduced in an anatomical region.
- one or more of the substance reservoirs disclosed herein may be pre-filled with an inactive form of a substance. The inactive form of the substance is converted to an active form by introducing an activating agent into the substance reservoir. This may be done just before or after the substance reservoir is introduced in an anatomical region.
- the implantable portion of a substance delivering spacer device 10 may include a through lumen that may function as a vent and/or drain when such implantable portion device is in a paranasal sinus, air cell, Eustachian tube, opening formed in the tympanum or any other location within the body.
- the devices and methods disclosed herein may be used to mark an anatomical region with a suitable imageable marker.
- the devices and methods disclosed herein may be used to deliver a radio opaque marker such as a radio opaque contrast agent to an ostium of a paranasal sinus. This enables a user to image the ostium of the paranasal sinus using X-rays or fluoroscopy.
- One or more of the substance delivery devices disclosed herein may comprise a curved, bent or angled region to enable the drug delivery devices to navigate through the anatomy.
- the distal-most regions of one or more substance delivery devices disclosed herein may comprise an atraumatic tip.
- the atraumatic tip is used to prevent or reduce damage to the anatomy by the distal-most regions of the one or more substance delivery devices.
- the outer surface of one of more substance delivery devices disclosed herein may comprise a coating that reduces or eliminates the risk of encrusting of the outer surface by a biological material.
- the coating comprises a material that absorbs water to form a gel. Examples of such materials include, but are not limited to hyaluronic acid, etc.
- One or more of the substance delivery devices disclosed herein may be designed to be easily removable from the anatomy after completion of a treatment.
- One or more of the substance delivery devices disclosed herein may be refilled after a significant volume of substance filled in a substance reservoir has been delivered to the anatomy.
- One or more of the substance delivery devices disclosed herein may comprise one or more markers to enable a user to locate and/or navigate the substance delivery devices through the anatomy.
- the substance delivery devices may comprise visual markers to enable the user to determine the depth of insertion of the substance delivery devices into the anatomy.
- the substance delivery devices may comprise imaging markers to enable the user to locate and/or navigate the substance delivery devices using imaging modalities such as X-rays, MRI, etc.
- opening of a paranasal sinus shall include any opening in a paranasal sinus or air cell such as natural ostia, surgically altered natural ostia, surgically created openings, antrostomy openings, ostiotomy openings, burr holes, drilled holes, ethmoidotomy openings, ethmoidectomy openings, natural or man made passageways, etc.
- the term "implantable” shall include any device that is maintained in the body of a human or animal for a period ranging from 30 minutes to 60 days.
- an endoscope 400 is shown as being inserted separately form the other devices.
- an endoscope may be attached to or integrated with one or more of the other devices used during the procedure as described in parent application Serial No. .
- Examples 2 and 3 above describe techniques which may be used for introducing the spacer device 10 into frontal sinuses which may or may not have been previously altered by surgery or prior balloon dilations.
- the operator may simply deliver the spacer device 10 through the constraining tube 42 (or sinus sheath 40, 40a) and into the frontal sinus, with or without the use of forceps or other operative instruments, thereby eliminating the need for the use of a guide catheter, guidewire, dilator or other devices for guiding or facilitating advancement of the spacer device 10 into the frontal sinus as described in Examples 2 and 3.
- Triamcinolone Acetonide injectable suspension (Kenalog ® 40, Brystol-Myers Squibb Company, Princeton, New Jersey) as the therapeutic agent that is loaded into and elutes from the reservoir
- various other therapeutic agents may be used in addition to, or as an alternative to, this Triamcinolone Acetonide injectable suspension.
- the steroid may be prepared as a solution rather than a suspension. In such cases, the steroid will be dissolved in a suitable, biologically compatible solvent.
- Cyclodextrins have been described as suitable solvents for dissolution of at least some steroids.
- Khomutov, S. M., Dovbnya, D.V. and Donova, M. V. Dissolution of a Mixture of Steroids in Cyclodextrin Solutions: a Model Description; Pharmaceutical Chemistry Journal; Vol. 35, No. 1 i, pp.627-629 (November, 2001 ).
- the devices of the present invention may be used to deliver steroids or other substances in formulations that are commercially available as, or otherwise suitable for, intra-nasal delivery to the nasal mucosa as nasal drops or sprays (i.e., nasal solutions).
- nasal solutions are prepared so that they are similar to nasal secretions and, thus, do not interfere with normal ciliary action.
- Such nasal solutions usually are isotonic and slightly buffered to a pH of 5.5 to 6.5.
- antimicrobial preservatives similar to those used in ophthalmic preparations, and appropriate drug stabilizers, if required, may be included in the formulation.
- Various commercial nasal preparations are known and include, for example, antibiotics, steroids, antihistamines, decongestants and ipitropium bromide.
- any of the substances delivered by devices of the present invention may be in the form of liposomes or nanoparticles (e.g., nanocapsules).
- liposomes are formed from phospholipids dispersed in an aqueous medium such that they spontaneously form multilamellar concentric biiayer vesicles sometimes referred to as multilamellar vesicles (MLVs).
- MLVs are typically from 25 nm to 4 ⁇ m in diameter.
- MLVs When sonicated, MLVs form small unilamellar vesicles (SUVs) of about 200 to 500 angstroms in diameters having cores which contain the aqueous solution.
- SUVs small unilamellar vesicles
- phospholipids when dispersed in an aqueous medium, can form various structures other than liposomes, depending on the molar ratio of lipid to water. At low molar lipd to water ratios, liposomes will form. The physical characteristics of liposomes depend on pH, tonicity and the presence or non-presence of divalent cations.
- Liposomes can interact with cells by different mechanisms, including 1) endocytosis (e.g., phagocytosis of the liposome by cells such as macrophages and neutrophils), adsorption to the cell surface, 2) interaction with cell-surface components, 3) fusion with the plasma cell membrane by insertion of the lipid bilayer of the liposome into the plasma membrane or 4) transfer of liposomal lipids to cellular or subcellular membranes, or vice versa. Varying the liposome formulation can alter which mechanism(s) by which the lyposomes will interact with cells in the paranasal sinus, nasal mucosa, etc.
- a nanocapsule is any nanoparticle that consists of a shell and a space, in which desired substances may be placed.
- Techniques for forming nanocapsules are known in the art.
- Polymeric nanocapsules can be made in specific sizes and shapes. They can be produced as monodisperse particles which have precisely defined physical and chemical properties and, thus, can be tailored to facilitate release of the therapeutic or diagnostic substance in response to particular bimolecular triggering mechanisms, such as pH, mucous flow or other conditions present within the paranasal sinus or other area in the ear, nose or throat where the device is implanted.
- Nanocapsules can be used in the present invention as "smart drugs" which have specific chemical receptors or binding sites that will bind to specific target cells (e.g., cancer cells associated with sinus or nasal tumors or cells associated with inflammatory conditions.
Abstract
Substance delivering spacer devices may comprise expandable reservoirs that are implantable in paranasal sinuses and other cavities, openings and passageways of the body to maintain patency and to provide sustained local delivery of a therapeutic or diagnostic substance. Also provided are sinus penetrator devices and systems for performing ethmoidotomy procedures or for creating other openings in the walls of paranasal sinuses or other anatomical structures.
Description
ETHMOIDOTOMY SYSTEM AND IMPLANTABLE SPACER DEVICES
HAVING THERAPEUTIC SUBSTANCE DELIVERY CAPABILITY FOR
TREATMENT OF PARANASAL SINUSITIS
RELATED APPLICATIONS
[0001] This patent application claims priority to United States Provisional Patent Application No. 60/922,730 entitled "Ethmoidotomy System And Implantable Spacer Having Therapeutic Substance Delivery Capability For Treatment Of Paranasal Sinusitis" filed April 9, 2007, the entire disclosure of which is expressly incorporated herein by reference.
[0002] Additionally, this patent application is a continuation-in-part of copending United States Patent Application 11/544,009 entitled "Implantable Devices and Methods for Treating Sinusitis and Other Disorders" filed on October 4, 2006, which is a continuation in part of 11/234,395 entitled "Devices and Methods for Delivering Therapeutic Substances for the Treatment of Sinusitis and Other Disorders" filed on September 23, 2005, which is a continuation in part of Serial No. 10/829,917 entitled Devices, Systems and Methods for Diagnosing and Treating Sinusitis and Other Disorders of the Ears, Nose and/or Throat filed on April 21 , 2004, 10/912,578 entitled Implantable Device and Methods for Delivering Drugs and Other Substances to Treat Sinusitis and Other Disorders filed on August 4, 2004 and 11/037,548 entitled Devices, Systems and Methods for Treating Disorders of the Ear, Nose and Throat, filed on January 17, 2005, the entire disclosure of each such application being expressly incorporated herein by reference.
FIELD OF THE INVENTION
[0003] The present invention relates generally to medical devices and methods and more particularly to substance delivering implants and methods for treating a broad range of disorders including but not limited to sinusitis and other ear, nose and throat disorders.
BACKGROUND
[0004] The paranasal sinuses require adequate ventilation to prevent microbial chronic infection within the sinus cavities. Normally, ventilation is provided through the small natural openings, known as ostia, through which the sinus cavities open into the nose. In addition to ventilation, the natural ostia serve as drainage channels as ciliated cells lining the interior of the sinus cavity continually direct a flow of mucus toward the ostia. Thus, when the natural ostia become narrowed or blocked, ventilation and drainage from the sinus cavity is impaired. The resultant hypoxia, pH changes and mucus stasis within the sinus cavity gives rise to an environment in which some types of microbial growth can flourish. Such microbial infection can, in itself, result in further mucosal inflammation and even further constriction or blockage of the natural sinus ostium.
Techniques For Improving Ventilation and Drainage of Paranasal Sinuses
[0005] Functional endoscopic sinus surgery (FESS) is a common type of surgery wherein an endoscope is inserted into the nose and, under visualization through the endoscope, the surgeon may remove diseased or hypertrophic tissue or bone and may surgically enlarge the ostia of the sinuses to restore normal ventilation and drainage of the sinuses.
[0006] As an alternative to incisional surgery, in some patients, a balloon catheter may be advanced into the constricted sinus ostium and used to dilate the ostium, thereby eliminating the need for cutting or removing tissue surrounding the ostium (Balloon Sinuplasty™ technology, Acclarent, Inc., Menlo Park, California). Examples of such balloon dilation procedures are described in United States Patent Application Publications No. 2006/0004286, 2006/0063973, 2006/0210605, 2007/0129751 , 2007/0135789, 2007/0167682, 2007/0208252, 2007/0208301 and 2007/0293727, the entire disclosure of each such patent application being expressly incorporated herein by reference.
Implantation of Stents and Space Occupying Materials to Deter Re- Occlusion Following Surgery
[0007] In cases where tissue adjacent to the ostium has been surgically removed or incised, post-operative scar tissue, fibrosis, polyposis or tissue ingrowth can result in re-occlusion of the sinus ostium. To deter such re- occlusion of frontal and sphenoid sinuses following surgery, small tubular stents have been placed in the surgically altered sinus ostium or outflow tract for a limited time period following surgery.
[0008] One example of a commercially available frontal sinus stent is the Freeman™ Frontal Sinus Stent (InHealth Technologies, Inc., Carpinteria, California. The Freeman™ stent comprises a silicon tube that has flanges on either end to retain the stent within the frontal outflow tract for a desired period of time following surgery. Other commercially available frontal sinus stents include the Jasin Frontal Sinus Stent (Medtronic Xomed, Inc., Jacksonville, FIa.), and the Salman FES Stent (Boston Medical Products, Westborough, Mass.).
[0009] A sphenoid sinus stent is described in United States Patent No. 7,235,099 (Duncavage, et al.). This stent comprises a soft compressible plastic tube having a generally hemispherical hollow dome on one end. The diameter of the dome is greater than the predetermined diameter of the plastic tube. The stent further includes an annular flange located a predetermined distance from the hemispherical dome. The device is designed to be fitted through a surgically enlarged ostium of the sphenoid sinus such that the dome resides within the sinus cavity and the flange abuts the bony wall surrounding the ostium. This stent serves maintain patency of the surgically altered ostium during the postoperative period and allows irrigation/suction ing through the lumen of the stent. This sphenoid sinus stent is also commerciaily available as the SP-82020 Sphenoid Sinus Stent (Micromedics, Inc., St. Paul, Minnesota).
[0010] The above-described frontal and sphenoid sinus stents do not deliver therapeutic substances. Thus, they are frequently used concurrently with orally administered drugs (e.g., corticosteroids) and/or topical nasal sprays.
[0011] in some cases, in lieu of a stent, surgeons may place gel-like materials within the surgically altered ostium or outflow tract to prevent ingrowth of scar tissue during the post-surgical period. One example of such material is the MeroPack™ Bioresorbable Nasal Dressing and Sinus Stent available from Medtronic ENT, Inc., Jacksonville, Florida. The MeroPack™ material consists of 80 percent esterified hyaluronic acid and 20 percent collagen. This material is inserted while in its dry state and, upon hydration, swells to 1.0cm diameter in about six seconds. When in its hydrated state, this material is a biocompatible, muco-adhesive gel.
Local Drug Delivery In the Treatment of Sinus Disease
[0012] Various drug delivery implants have been proposed for use in or around the paranasal sinuses to treat sinusitis and/or to deter re-occlusion of surgically altered outflow tracts or ostia following surgery.
[0013] For example, United States Patent Application Publication No. 20050043706 (Eaton et al.) describes biodegradable implants for treating sinusitis, such implants having a size, shape, density, viscosity, and/or mucoadhesiveness that prevents them from being substantially cleared by the mucociliary lining of the sinuses during the intended treatment period. These biodegradable implants deliver therapeutic agents such as antibiotics, steroids or both. These biodegradable implants may be in various forms such as rods, pellets, beads, strips, or microparticles, and may be delivered into a sinus in various pharmaceutically acceptable carriers.
[0014] Also, United States Patent Application Publication No. 20070005094 (Eaton et al.) describes implantable devices useable for the treatment of paranasal sinus conditions. The devices include cavity members that have a first collapsed configuration that permits the device to pass through a sinus ostium and a second expanded configuration after placement into the sinus * cavity. In addition to a cavity member, the devices may include a nasal portion and an ostial member that is configured to reside within the sinus ostium. The cavity member is attached to the distal end of the ostial member. The nasal portion is attached to the proximal end of the ostial member and lies within the nasal passage. The active agent may be incorporated into all
portions of the device or only included in the expandable cavity member, the ostial member, or nasal portion.
[0015] Some investigators have proposed adding drug delivery capability to frontal sinus stents to deliver controlled amounts of drug to the surgically altered outflow tract following frontal sinus surgery. For example, United States Patent Application Publication 2004/0116958A1 (Gopferich et ai.) describes a tubular sheath or "spacer" formed of biodegradable or nonbiodegradable polymer that, prior to insertion in the frontal outflow tract, is loaded with a controlled amount of an active substance, such as a corticosteroid or anti-proliferative agent. After surgery to create a fenestration in a frontal sinus as been performed, the sheath (which has been preloaded with the active substance) is inserted into the surgically created fenestration where it a) deters closure of the surgically created fenestration, b) serves as a conduit to facilitate drainage from the sinus and c) delivers the active substance. In some embodiments, the sheath is formed of multiple layers of polymeric material, one or more of which is/are loaded with the active substance and one or more of which is/are free of the active substance. In other embodiments, the sheath has a "hollow body" which forms a reservoir system wherein the active substance is contained and a membrane which controls the release of the active substance from the reservoir. In some embodiments, the sheath may be anchored by causing the end of the sheath that extends into the sinus to swell or otherwise enlarge. Also, United States Patent Application Publication No. 2005/0245906 (Makower et al.) describes a biodegradable polymeric device that comprises a spacer positionable within a sinus ostium. The spacer has a plurality of substance-eluting struts. The device may be implanted such that the struts are substantially parallel to the cilial flow of mucus along the sinus cavity walls so that normal mucociliary transport is not interrupted.
[0016] Additionally, various other types of implantable drug delivery devices have been proposed for use in the nose and/or paranasal sinuses. For example, United States Patent No. 3,948,254 (Zaffaroni) describes implantable drug delivery reservoirs having microporous walls. The reservoir may be formed of a solid drug carrier that is permeable to passage of the drug
and the rate of passage of the drug through the microporous wall may be slower than the rate at which the drug passes through the solid drug carrier that forms the reservoir. Zaffaroni also describes a number of applications for the implantable drug delivery devices including placement in a nasal passage. Specifically, Zaffaroni claims a nasal delivery device for dispensing a drug within a nasal passage at a controlled rate wherein the nasal device is comprised of (a) a wall defining the device dimensioned for insertion and placement within a nasal passage, with the wall formed of a nasal acceptable microporous material, (b) a reservoir surrounded by the wall and comprised of a solid carrier permeable to drug and containing drug in an amount sufficient for the device to meter it at a continuous and controlled rate for a prolonged period of time from the device, (c) a liquid medium permeable to the passage of drug by diffusion charged in the micropores, and (d) wherein the device releases drug when in a nasal environment by passage of drug from the carrier and through the liquid to the exterior of the device to produce a useful result. The entire disclosure of United States Patent No. 3,948,254 (Zaffaroni) is expressly incorporated herein by reference.
[0017] Other publications have also reported that introduction of drugs directly into the paranasal sinuses is effective in the treatment of sinusitis. See.Tarasov, D. I., et al., Application of Drugs Based on Polymers in the Treatment of Acute and Chronic Maxillary Sinusitis, Vestn Otorinolaringol. Vol. 6, Pages 45-7 (1978). Also, R. Deutschmann, et al., A Contribution to the Topical Treatment of [Maxillary] Sinusitis Preliminary Communication, Stomat. DDR 26 (1976), 585-592 describes the placement of a resorbable drug delivery depot within the maxillary sinus for the purposes of eluting drugs, specifically Chloramphenicol. In this clinical series a water soluble gelatin was used as carrier and was mixed with the drug prior to application and introduced as a mass into the sinus. Since the substance had little mechanical integrity and dissolved in a relatively short timeframe, to achieve a therapeutic effect, the author suggested that it must be instilled every 2 to 3 days. An alternative to gelatin could be a sponge loaded with the therapeutic substance as suggested in United States Patent No. 6,398,758 (Jacobsen, et al.). In this patent directed at delivering a sustained release device against the wall of a blood vessel, a hollow cylindrical sponge is loaded with drug and
pressed against the wall. This allows the drug to contact the wall while sustaining blood flow within the center of the lumen. Further, a skin is provided to direct the drug into the walls of the blood vessel and prevent drug from flowing into the lumen. While sponges loaded with drug at the time of their application do permit some degree of sustained release, the time required to load them also correlates closely the time over which they will elute substance. Thus, if delivery is required for a longer period of time additional mechanisms must be employed to regulate their release.
[0018] There are also several examples in the patent literature where various sustained release mechanisms have generally been proposed using systems with drugs pre-incorporated into matrices or polymers. These include 3,948,254 (Zaffaroni), US 2003/0185872A2 (Kochinke), WO 92/15286 (Shikani), and 5,512,055 (Domb, et al.). In general, these references discuss various materials and structures that may be used to construct sustained drug delivery vehicles and provide a good overview of the state of sustained drug delivery art. While helpful in laying out certain materials and schemes for creating sustained release systems for drugs, these references do not, however, describe specific methods, means or structures which would permit them to be easily adapted for intended uses that are targeted in the present application.
[0019] Other examples of implantable drug delivery devices include those described in United States Patent Nos. 3,993,073; 4,217,898; 5,304,123; 6,042,561 ; 6,183,461 ; 6,780,168 and 6,783,522, the entire disclosure of each such patent being expressly incorporated herein by reference.
Techniques for Treatment of Ethmoid Disease
[0020] To date, the use of stents and spacers in relation to nose and sinus surgery has been largely limited to placement in the frontal outflow tract or sphenoid sinus ostium following surgery wherein tissue and bone have been cut away or removed. However, as new devices and methods become available for the treatment of other types of nasal and sinus disorders, there will likely be a need for intranasal or sinus spacers and stents (with or without
drug eluting capabilities) suitable for placement at various locations lot limited to the frontal outflow tract.
[0021] In the prior art, diseased ethmoid air cells have sometimes been treated by a procedure known as an ethmoidectomy wherein a man made passageway is formed between the interiors of the ethmoid air cells and the nasal cavity. Stenting and/or delivery of drugs or other therapeutic substances into these manmade ethmoidectomy passageways has been, in at least some cases, desirable. To accomplish this, strips of gauze soaked with medication may be pushed into the manmade opening and later extracted. Also, in this regard, United States Patent No. 6,543,452 (Lavigne) describes a nasal intubation device that comprises a flexible tube having a flanged distal tip whereon the flanges generally from an arrow shape. The distal tip of this device is capable of penetrating through tissue (e.g., through the ethmoid bulla) to a desired position (e.g., within the ethmoid air cells). Openings are formed in a distal portion of the intubation device so that medication (e.g., a typical steroid) injected through the flexible tube will flow out of the tube into contact with the adjacent area (e.g., the diseased ethmoid air cells). In some cases, a cannula-trocar may be initially inserted and the nasal intubation device may then be advanced through that cannula-trocar. Also, European Patent Publication EP0624349 (Milewski) describes a balloon-tipped catheter having an anatomically shaped balloon which may be inserted through a surgically created opening into a body cavity (e.g., frontal sinus or ethmoid cell) and inflated to create a tamponade by being shaped to suit the anatomical shape of the cavity.
[0022] There remains a need in the art for the development of new devices and methods for delivering drugs and other therapeutic or diagnostic substances over a sustained period of time into paranasal sinuses, Eustachian tubes, middle ear and/or other locations within the body for the treatment of sinusitis, otitis or other diseases and disorders.
SUMMARY OF THE INVENTION
[0023] The present invention provides substance delivering spacer devices and methods including expandable reservoirs that are implantable in
paranasal sinuses and other cavities, openings and passageways of the body to maintain patency and/or to provide sustained local delivery of a therapeutic or diagnostic substance. Also provided are sinus penetrator devices, systems and methods for creating ethmoidotomy openings or other openings in the walls of paranasal sinuses or other anatomical structures.
[0024] One embodiment of a device and method for treating ethmoid sinusitis involves a penetrator device that has a distal tip and a stopping mark or member located a spaced distance proximal to its distal tip. The distance between the stopping mark or member and the distal tip is less than the distance between the ethmoid bulla and the ipsalateral sphenoid sinus. An ethmoidotomy channel is formed by advancing the penetrator through the ethmoid bulla in a direction that is non-perpendicular to the skull base and generally directed toward the ipsalateral sphenoid sinus. Advancement of the penetrator is stopped when the stopping mark or member is approximately flush with the ethmoid bulla. Thereafter, the penetrator is removed. Optionally, a stent, spacer or substance delivering spacer device may then be placed in the ethmoidotomy channel for a period of time to maintain patency of the channel and/or to effect local delivery of a therapeutic substance.
[0025] According to one embodiment, a sinus penetrator device and method may be used to form an ethmoidotomy channel or other opening in a paranasal sinus wall or other body structure. Such device comprises an elongate penetrator member and a handle coupled with the penetrator member at or near its proximal end. A sighting member is disposed along the handle or the elongate member at a location to make it visible from an extracorporeal vantage point when the distal end of the elongate member is inserted into the patient. Such sighting member is useable by a user of the device to generally aim the distal end of the penetrator in a desired direction within the patient's body. In some embodiments, the sighting member may comprise a fin. The sighting member may extend in a plane that is substantially parallel to a plane in which the elongate the penetrator extends from the handle and, optionally may include another member (e.g., a cross member) that is substantially normal to the plane in which the elongate penetrator extends from the handle. In some embodiments, the elongate
penetrator may have a curve formed therein and at least a portion of the sighting member may be parallel to the portion of the elongate penetrator that is distal to the curve, thereby providing an indication of the direction or trajectory on which the distal portion of the elongate penetrator is being advanced.
[0026] Still further in accordance with the invention, there is provided a substance delivering spacer device and method. In one embodiment, the substance delivering spacer device comprises a shaft and an expandable reservoir located on the shaft. The reservoir may be introduced into a body cavity or opening (e.g., a paranasal sinus, ethmoidotomy channel, frontal sinus outflow tract, or other body cavity, opening, passageway) while in a collapsed configuration. Thereafter, a therapeutic substance may be loaded into the reservoir, causing the reservoir to expand in situ. The shaft may be severed or cut at a desired location and the proximal portion of the shaft may be removed after the reservoir has been loaded. The reservoir is designed such that the substance will elute from the reservoir over a period of time. The reservoir may have a side wall and tapered ends, with openings being formed in the sidewall and tapered ends such that a therapeutic substance loaded into the reservoir will elute through the openings and out of the reservoir. In some embodiments, the device may be equipped with apparatus for holding the reservoir in a desired position within the body (e.g., retention wings, projections, suture loops, etc.) for holding the reservoir in a desired position within the body.
[0027] Still further in accordance with the invention, there is provided a method and system wherein a substance delivering spacer device of the above-described character is used in combination with a sinus penetrator (e.g., the ethmoidotomy device described above or any other penetrator) and a sheath. The sheath is initially disposed over the sinus penetrator and the penetrator/sheath combination is advanced through a wall of a paranasal sinus or air cell. The penetrator is then removed, leaving the sheath in place. The substance delivering spacer device is advanced into the sheath. The sheath is then removed, leaving the substance delivering spacer device in place within the sinus or air cell. A diagnostic or therapeutic substance is then
loaded into the reservoir such that the substance will thereafter elute from the reservoir into the paranasal sinus or air cell.
[0028] Still further in accordance with the invention, there is provided an embodiment of a method for treating sinusitis where an implantable device having a substance eluting reservoir is positioned within a paranasal sinus or within the ostium or outflow tract of a paranasal sinus. Thereafter, a steroid is introduced into the substance eluting reservoir so that the steroid elutes from the reservoir in an amount that is effective to treat the sinusitis.
[0029] Still further aspects and details of the present invention will be understood upon reading of the detailed description and examples set forth below.
BRIEF DESCRIPTION OF THE DRAWINGS
[0030] Figure 1 shows a spacer device of the present invention being used in conjunction with an endoscope to treat a human subject.
[0031] Figure 2 is a side view of one embodiment of a spacer device of the present invention.
[0032] Figure 2A is an enlarged longitudinal sectional view of a distal portion of the device of Figure A.
[0033] Figure 2B is an enlarged longitudinal sectional view of a distal portion of the device of Figure A during infusion of a substance into the reservoir portion of the device.
[0034] Figure 2C is a longitudinal sectional view through the proximal hub of the device of Figure 2.
[0035] Figure 2D is a side view of the device of Figure 2 with a constraining sheath in a retracted position.
[0036] Figure 2E is a side view of the device of Figure 2 with a constraining sheath in an advanced position.
[0037] Figure 2F is a diagram of the expandable reservoir of the device of Figure 2.
[0038] Figure 2G is an enlarged view of region 2G of Figure 2F.
[0039] Figure 2 H is a proximal end view of the expandable reservoir of Figure 2F.
[0040] Figure 3 is a side view of a distal portion of another embodiment of a spacer device of the present invention incorporating an alternative retention system.
[0041] Figure 4 is a side view of one embodiment of a sheath that is useable in conjunction with an ethmoidotomy needle of the present invention.
[0042] Figure 5 is a side view of one embodiment of an ethmoidotomy needle device of the present invention.
[0043] Figure 5A is a longitudinal sectional view through a distal portion of the handpiece of the ethmoidotomy needle device of Figure 5.
[0044] Figure 5B is a distal end view of the ethmoidotomy needle device of Figure 5.
[0045] Figure 5C is a side view of the distal tip of the ethmoidotomy needle device of Figure 5.
[0046] Figure 5D is a side view of another embodiment of an ethmoidotomy device of the present invention incorporating a rotating burr tip.
[0047] Figure 5E is an enlarged side view of the rotating burr tip of the ethmoidotomy device of Figure 5D.
[0048] Figure 6 is a side view of the ethmoidotomy needle device of Figure 5 with the sheath of Figure 4 positioned thereon.
[0049] Figures 7A through 7K show steps in a method for performing an ethmoidotomy and implanting a substance delivering spacer device in
accordance with the ethmoidotomy channel in accordance with the present invention.
[0050] Figures 8A-8G show steps in a method for using a guide catheter for implantation of the substance delivering spacer device of Figure 2 within the outflow tract of the frontal sinus of a human subject in accordance with the present invention.
[0051] Figures 9A-9D show steps in a method fir using the sheath of Figure 4 and an optional dilator for implantation of the substance delivering spacer device of Figure 2 within the outflow tract of the frontal sinus of a human subject in accordance with the present invention.
[0052] Figure 10 is a graph showing Lund McKay Scores for 14 human subjects referred to below.
[0053] Figure 11 is a bar graph showing the average SNOT 20 scores at various time points for human subjects referred to below.
[0054] Figure 12 is a perspective view of a substance delivering/bone penetrating screw device of the present invention.
[0055] Figure 12A is a diagram showing the substance delivering/bone penetrating screw device of Figure 12 implanted in a bony intranasal structure covered with mucosal tissue.
[0056] Figure 13 is a partial left/right sagittal section of a human head showing an ethmoidotomy needle having a depth controlling stop member inserted through the subject's nostril and advanced into the ethmoid sinuses until the stop member has abutted against the subject's nose, thereby preventing further advancement of the needle.
[0057] Figure 14 is a partial, cut-away side view of another embodiment of a substance delivering spacer device of the present invention incorporating a multi-layer expandable reservoir.
[0058] Figure 14A is a cross sectional view through line 14A-14A of figure 14 showing three separate fill lumens which extend into three separate regions of the reservoir balloon.
[0059] Figure 14 B is an enlarged view of a portion of the outer layer of the reservoir balloon of the device of Figure 14.
[0060] Figure 14 C is an enlarged view of a portion of the middle layer of the reservoir balloon of the device of Figure 14.
[0061] Figure 14 D is an enlarged view of a portion of the inner layer of the reservoir balloon of the device of Figure 14.
DETAILED DESCRIPTION
[0062] The following detailed description and the accompanying drawings are intended to describe some, but not necessarily all, examples or embodiments of the invention. The contents of this detailed description do not limit the scope of the invention in any way.
[0063] Figures 1 through 2G show one embodiment of an implantable substance delivery device and/or spacer 10 of the present invention. This device 10 comprises an elongate flexible catheter shaft 12 having a proximal portion 12a and a distal portion 12b which may be severed from one another at separation marker 15. The proximal shaft portion 12a and distal shaft portion 12b may be formed of the same or different materials and may have the same or different dimensions (e.g., diameter, wall thickness, etc.). For example, in some embodiments intended for implantation in paranasal sinuses or other ear, nose or throat locations, the proximal shaft portion 12a may be made of a suitable biocompatible material of sufficient column strength (e.g., pushability) to enable a user to push the substance delivery device 10 into the paranasal anatomy. One such material is polyamide. In some embodiments, the distal shaft portion 12b may be made of a more flexible biocompatible material such as nylon or polyethylene teraphthalate (PET). A lumen 13 extends continuously through the shaft 12. The distal shaft portion 12a may be tapered or necked down to a smaller diameter than
the proximal shaft portion to facilitate insertion of the device, as described below. A plug 23 is mounted in the distal end of lumen 13. The plug 23 may comprise any suitable closure member such as a wall of closed end on the tube, an end cap, a mass within the end of the lumen 13 or any other suitable flow blocking member. In the particular example shown in the drawings, the plug 23 comprises a biocompatible polymeric adhesive disposed within the distal end of lumen 13. In some embodiments the plug 23 may include a soft, atraumatic (e.g., bulbous or blunt) tip member that protrudes beyond the distal end of the distal shaft portion 12b.
[0064] An expandable reservoir 14 is mounted in a collapsed configuration on the distal shaft portion 12b near its distal end and expands to an expanded configuration as it is filled. Details of one embodiment of such reservoir 14 are seen in Figures 2A and 2B as well as 2F, 2G and 2H. In this embodiment, the reservoir 14 comprises a balloon that has a cylindrical side wall wherein openings 31 are formed. The reservoir 14 may be formed of any suitable biocompatible material and, in some embodiments, may comprise a balloon formed of non-compliant or semi-compliant material such as Nylon 12. In at least some embodiments, it is preferable that the material and wall thickness of the reservoir be such that the reservoir is flexible enough to a) allow the device to be extracted and removed from the body without causing significant trauma, b) not force all of the contents of the reservoir to come out at once and c) maintain substantially consistent size of the openings 31 as the reservoir expands. The number of reservoir(s) 14 (such as two or more), the size of the reservoir(s) and the number and size of the openings 31 may vary on the basis of the intended implantation location and/or the potency, viscosity, particle size (for suspensions) and/or other properties of the substance being delivered. For example, in an embodiment of the device 10 intended to be passed through an ethmoidotomy channel and positioned within an ethmoid air cell to treat ethmoid sinusitis, the reservoir 14 may have a length of from about 0.5 cm to about 3.5 cm and typically approximately 2cm, a diameter when fully expanded of about 0.1 cm to about 0.5 cm and typically approximately 0.3 cm. Also, depending on the substance and the intended elution rate, there may be any suitable number of openings 31. Typically there will be between about 50 and about 5000 openings 31 sized in
the range of from about 5 microns in diameter to about 80 microns in diameter.
[0065] As described in further below, this embodiment of the reservoir 14 may be inserted, in a collapsed configuration, into a body opening, passageway or cavity (such as, for example, a frontal sinus outflow tract, paranasal sinus ostium, antrostomy, ethmoidotomy opening, or other location within the ear, nose or throat of a subject) and, thereafter, the reservoir may be loaded with the desired substance, causing the reservoir to transition to an expanded state. For example, for applications intended to treat inflammation of a paranasal sinus using the particular reservoir 14 described above with the opening size/pattern seen in Figures 2F-2H, the reservoir 14 may be loaded with approximately 0.10 ml of an aqueous suspension containing 40 mg/ml of Triamcinolone Acetonide Injectable Suspension, USP (Kenalog®-40, Bristol- Myers Squibb, Somerville, New Jersey). This will cause approximately 100 μg of Triamcinolone Acetonide to elute from the reservoir per day over a period of 14 days. When used for the treatment of fungal sinusitis or other fungal infections, this reservoir 14 may also be used to deliver an antifungal agent such as liposomal or non-liposomal Amphotericin B of 0.3 to 1.5 mg/kg available from Pfizer as Amphocin® anti-fungal. Systemically administered Amphotericin typically has limited distribution from the bloodstream across the mucus membranes and vice versa. With this substance delivery device 10, Amphotericin may be released locally into the mucus membrane where the offending fungal organisms are present and therapeutic concentrations of the drug may remain in the mucus as it is distributed through the sinuses by ciliary action. However, substantial amounts of the Amphotericin will not be substantially absorbed through the sinus mucosa, thereby avoiding the potential for untoward systemic effects of the Amphotericin such as renal toxicity. Also, this reservoir 14 may be capable of delivering solutions as well as suspensions to the surrounding anatomy. This is especially useful for delivery of steroids since most steroids are available as suspensions.
[0066] Also, the reservoir 14 need not be used to deliver a therapeutic substance in all applications. It may, in fact, be used as a space occupying device (e.g., instead of a sinus stent). In such applications, the reservoir 14
may be loaded in situ with saline solution of other inert liquid causing the reservoir 14 to expand and frictionally engage or contact adjacent anatomical structure(s), thereby providing a degree of retention at the desired implantation location. This aspect of the reservoir 14 may be further facilitated by the provision of surface projections on the reservoir, in cases where it is intended for the reservoir 14 to function
[0067] The reservoir 14 may be relatively small in diameter when in its collapsed configuration, thus allowing it to be introduced or removed easily. In embodiments where the reservoir 14 is formed of non-compliant or semi- compliant material, the reservoir 14 will not undergo substantial elastic deformation in the filling process and thus will not exert pressure on its contents in order to expel the desired substance through openings 31. Rather, the substance in the reservoir 14 will be carried out through the openings 31 by gravity or by being in contact with the mucus or blood that is continually moved along by the ciliary action in the sinuses. This non- pressurized delivery allows for the slow release of the desired substance over several days. In some other embodiments, the reservoir 14 may be formed of compliant or elastic material with small openings 31 such that the material of which the balloon 14 is formed will contract as substance passes out of the openings 31 , thereby maintaining pressure within the balloon. In cases where the reservoir 14 is intended to be inserted into a sinus ostium, outflow tract, antrostomy opening or ethmoidectomy/ethmoidotomy opening and used to deliver an aqueous suspension containing 40 mg/ml of Triamcinolone Acetonide Injectable Suspension, USP (Kenalog®-40, Bristol-Myers Squibb, Somerville, New Jersey) or another substance of similar consistency, the reservoir 14 may have approximately 2200 laser cut openings 31 approximately 20 to 40 microns in diameter formed in the sidewall of the reservoir 14. As seen in Figures 2F-2H, the openings 31 may be aligned in longitudinal rows and the positioning of the individual openings 31 may be staggered one row to the next. In this particular example, the longitudinal distance D1 between individual openings is 0.30 +/- 0.03 mm and the distance D2 between rows is 0.68 +/- 0.1 mm. Also, in this example, the reservoir has a cylindrical side wall 14a which defines the working length of the reservoir, a distal taper 14b which transitions from the cylindrical side wall 14a to the distal
shaft 12b (distal to the reservoir) and a proximal taper 14c that transitions from the cylindrical side wall 14a to the distal shaft 12b (proximal to the reservoir) and the openings 31 extend onto the proximal and distal tapers 14b, 14c, as shown. Also in this example, the reservoir 14 has an overall length of about 16 mm and a working length (i.e., the length of the cylindrical side wall 14c) of about 13 mm and is expandable to a fully expanded diameter of 3.0 to 3.5 mm. Approximately 768 laser cut openings 31 are formed in the side wall 14a of the reservoir 14. The diameter of each laser cut opening 31 is 40 microns. This particular reservoir design, when loaded with 0.31 to 0.35 ml of 40 mg/ml Triamcinolone Acetonide Injectable Suspension, USP (Kenalog®-40, Bristol-Myers Squibb, Somerville, New Jersey) will deliver a dose of approximately 100μg Triamcinolone Acetonide per day for a period of 28 days.
[0068] In the particular example shown, the distal shaft portion 12b may be made of Nylon 12 and may have an outer diameter of 0.028 inches, an inner diameter of 0.020 inches and length of 17mm. An aperture 28 as seen in Figures 1 B-1C is formed in the catheter shaft 12 to facilitate filling of the reservoir 14. A valve 26 allows the substance (or component(s) of the substance) to flow from the lumen 13 of the catheter shaft 12 into the reservoir 14 (see Figure 1 C) but does not allow substantial backflow from the reservoir 14 into the lumen 13 (see Figure 1 B). The valve 26 may comprise any suitable type of one way valve. In the particular embodiment shown, the valve 28 comprises an elastomeric sleeve valve made of a segment of C-f!ex® thermoplastic elastomer tubing (Consolidated Polymer Technologies, Inc., Clearwater, Florida).
[0069] Optionally, a distal radiopaque marker 24 and proximal radiopaque marker 22 may be provided to facilitate the desired positioning of the reservoir 14 within a subject's body. Each of these markers 22, 24 may be made of a ring of radiopaque material and may be mounted on the shaft 12 in alignment with each end of the reservoir's cylindrical sidewall 14a. In this particular example each marker 22, 24 comprises a band of Platinum-lridium alloy having outer diameter 0.034 inches and inner diameter 0.030 inches. These
markers are visible under various imaging techniques including fluoroscopy and CT scanning.
[0070] In the example shown, the proximal shaft portion 12a may be made of polyimide tubing of outer diameter 0.0618 inches and inner diameter 0.052 inches and length 20cm. A hub 16 comprising a female Luer connector made of dear polycarbonate (Part No. 41519, Qosina, Edgewood, NY) is attached to the proximal end of shaft 12. As seen in Figure 2C, this hub 16 has a proximal bore 100 that gradually narrows to a distal bore 102, thereby facilitating infusion of suspensions and viscous liquids. The distal bore 102 is approximately the same diameter as, and is continuous with, the shaft lumen 13.
[0071] Additionally, in the example shown, the device incorporates two types of position retaining apparatus, namely a suture loop 20 as well as a pair of projections in the nature of retention wings 18. The retention wings 18 are located at diametrically opposed locations on the shaft 12, proximal to the reservoir 14 to help retain the reservoir 14 at a desired position within the body, as will be explained in substantial detail below. In this example, each retention wing 18 comprises a preformed loop of nickel-titanium (nitinol) wire of diameter 0.0086 inches. Each retention wing 18 may be flexed or compressed to a collapsed position where it lies substantially flat against the outer surface of the shaft 12. However, these retention wings 18 are biased to a preformed configuration such that, when unconstrained, each retention wing 18 will resiliently spring outwardly to an extended position wherein it extends at an angle of from about 65 to 90 degrees relative to the longitudinal axis of the shaft 12. Such pre-forming of these wings 18 may be accomplished by heat treating the nitinol wire loop at 520°c for 20 minutes to produce an austenite finish temperature (Af) of 200C. Various alternatives to these retention wings 18 may be used. For example, Figure 3 shows an alternative retaining member 88 comprising proximal and distal resilient elastomeric flanges 90, 92 which are at spaced apart locations so as to rest against and engage opposite sides of an anatomical wall or structure. In Figure 3, the anatomical wall or structure comprises a bulla or sinus wall formed of bone B covered by mucosal tissue M. The distal flange 88 is
sufficiently resilient and flexible to collapse while passing through the small opening in the anatomical wall and to thereafter resume its expanded shape as seen in Figure 3.
[0072] The suture loop 20 (e.g., an eyelet or ring) may be formed of supple, flexible, resilient, elastic or superelastic material such as suture thread or nickel-titanium alloy (Nitinol) wire. In the particular embodiment shown, the suture loop is formed of black monofilament Nylon non-absorbable surgical suture material having a diameter of 0.0075 inches. The suture loop 20 may be collapsed against the outer surface of shaft 12. The suture loop 20 may be affixed to the outer surface of shaft 12 by winding the wire or other material around the shaft and securing the wire to the shaft using a suitable adhesive such as cyanoacrylate, epoxy or LJV curable adhesive and/or by mounting a polymeric sleeve or heat shrinkable member about the portions of wire that are wound around the shaft 12. In some embodiments, the suture loop may be colored so as to be visually distinguishable from blood and the red-pink color of the intra-nasal mucosa. For example, the suture loop 20 may be black, bright blue or green in color so as to be easily locatable by the surgeon. This suture loop 20 may be sutured to the adjacent tissue to anchor the distal portion of the device 10 in place.
[0073] As seen in Figures 2D and 2E, a tubular constraining sheath 30 may be positioned over the shaft 12. In the particular example shown, this constraining sheath 30 comprises a 10cm length of plastic tubing having an outer diameter of .084 inches and an inner diameter of .075 inches. This constraining sheath 30 is moveable back and forth between a retracted position (seen in Figure 2D) and an extended position (seen in Figure 2E). When in the extended position, the constraining sheath extends over the retention wings 18, suture loop 20 and the collapsed reservoir 14, thereby holding the retention wings 18 in their collapsed positions and forming a smooth protective covering over the retention wings 18, suture loop 20 and collapsed reservoir 14. Also, when in the extended position, the constraining sheath 30 will add column strength to the over all device and will deter kinking of the shaft 12 as it is pushed through relatively narrow and/or tortuous anatomical passages. After the device 10 has been inserted to the desired
position, the constraining sheath 12 may be withdrawn to its retracted position, thereby allowing the suture loop 20 to be accessible, the retention wings 18 to spring outwardly to their extended positions and the reservoir 14 to undergo expansion when it is subsequently loaded with the desired substance.
[0074] Although the particular examples of the spacer device 10 described above include a reservoir 14 formed of a single layer balloon, in some embodiments, the reservoir may comprise a balloon having multiple layers with different sized openings in each layer. The substance may then be selectively introduced between the particular layers that will facilitate the desired delivery of that particular substance at the desired rate. In this regard, by way of example, Figures 14 through 14D show another embodiment of a substance delivering spacer device 610 having a shaft 612 and a multi- layered reservoir balloon 614. The shaft 612 may be constructed and equipped in the same manner as the shaft 12 of the device 10 described above. However, in the embodiment three lumens 616, 618 and 620 extend through the shaft 612 and the reservoir 614 comprises a balloon having three layers 614a, 614b and 614c. The outermost layer 614a has openings 631a of a first size. The middle layer 614b has openings 631b of a second size that is smaller than the size of the openings 631a formed in the outer layer 614a. The inner-most layer 614c has openings 631c of a third size that is smaller than the size of the openings 631 b formed in the middle layer 614b. First lumen 616 opens into the space within the innermost layer 614c. Second lumen 618 opens into the space between the inner-most layer 614c and the middle layer 614b. Third lumen 620 opens into the space between the middle layer 614b and the outer-most layer 614a. In this manner, the operator may select the particular space into which a particular substance is to be infused so that the substance will be required to pass through either: a) only the openings 631a in the outer-most layer 614a; b) the openings 631b in the middle layer 614b as well as the openings 631a in the outer layer 614a; or c) all of the openings 631a, 631b, 631c in all three layers 614a, 614b and 614c. In this manner, the rate of elution of the substance may be optimized.
[0075] As will be described in more detail below, the substance delivering spacer device 10, 610 may be implanted in any suitable part or location of the body of a human or animal subject to perform a spacing function (e.g., to prevent tissue ingrowth, scarring, fibrosis, adhesion formation, etc.) and/or to deliver any desired therapeutic substance. For example, in ear, nose and throat applications the device 10, 610 may be implanted in a natural ostium or man-made opening formed in any paranasal sinus or air cell or in any other natural, surgically modified or surgically created opening or passageway, such as the outflow tract of a frontal sinus, the inferior, superior or medial meatus, etc.
[0076] Figures 4-5E show an example of an ethmoidotomy system that may be used separately or in conjunction with a substance delivering spacer device 10, 610 of the type described above. This ethmoidotomy system comprises a sheath 40 seen in Figure 5 and a sinus needle 60 seen in Figure 6. The sheath 40 and sinus needle 60 may be used separately or in combination. The combination of the sheath 40 and sinus needle 60 is shown in Figure 6.
[0077] The sheath 40 may be formed of a biocompatible polymer such as PEBAX and comprises a proximal sheath body 42 of a first diameter, a distal sheath body 44 of a second diameter (smaller than the first diameter) and a tapered step-down segment 54 between the proximal sheath body 42 and the distal sheath body 44. A flared region 46 is located at the proximal end PE of the sheath 40. A visual marker band 50 is optionally provided on the proximal sheath body 42 near its proximal end PE. A second visual marker band 48 is optionally located on the distal shaft portion 44 approximately 17 mm from the distal end DE. Also optionally, radiopaque markers 52, 56 may be provided at spaced apart locations on the distal sheath body 44. In the particular example shown, the distal radiopaque marker 56 is located approximately 1.5 mm from the distal end and the proximal radiopaque marker 52 is located approximately 17 mm from the distal end DE and beneath the distal edge of visual marker 48. Additionally, in some embodiments, optional wing members 53 may extend laterally from the distal sheath body 44 in the region of visual marker 48. These optional wing members 53 may be constructed in
substantially the same manner as the retention wings18 of the substance delivering spacer device 10 described above and, when extended, each wing member 53 may have a length of about 2 cm. These optional wing members 53 will abut against adjacent an adjacent anatomical structure to limit the distance through which the sheath 40 may be advanced through an opening or channel within the body. This sheath 40 may be used to facilitate insertion of the above-described substance delivering spacer device 10 or this sheath 40 may be used alone to facilitate suctioning of matter or for delivery of therapeutic or diagnostic substances.
[0078] In the embodiment shown in Figure 5, the sinus needle 60 comprises an elongate, curved needle body 62 having a sharp trocar tip 63. The proximal end of the needle body 62 is firmly, non-rotatebly anchored to handpiece 64. As seen in Figure 5A, this may be accomplished by forming a 90 degree bend in the proximal end of the needle body 62 and molding it in place within the handpeice 64 thereby providing a strong connection and preventing the needle body 62 from rotating relative to the handpiece 64. In the embodiment shown in the drawings, the needle body 48 is formed of solid stainless steel wire having an outer diameter of approximately 0.07 inches. A curve 65 is formed in the needle body 62. The needle body 62 is about 102 mm in length and the center of the curve 65 is located about 31 mm from the distal tip 63 of the needle body 62. The curve 65 forms an angle A2 of approximately 33 degrees. This particular embodiment of the sinus needle 60 is particularly suited for a needle ethmoidotomy as described below and the curve 52 allows the distal portion of the needle body 62 to be advanced through the ethmoid bulla and into the ethmoid air cells with decreased potential for inadvertent penetration through the adjacent skull base which protects the subject's brain. Also, as indicated in the enlarged views of Figures 5B and 5C, in this example the trocar tip 63 has three beveled edges arranged symmetrically around the central axis of needle shaft with each beveled edge being disposed at an angle B of about 20 degrees relative to the longitudinal axis of the needle body 62. This design enables sinus needle device 60 to be used for penetration through soft tissue (e.g., mucosa) as well as thin bone (e.g., the ethmoid bulla and other bones separating individual ethmoid air cells.
[0079] The handpiece 64 comprises a sighting member such as a fin 66, a top elongate member 70 and a bottom elongate member 68 that is attached to and substantially parallel to the top elongate member. The handpiece may also comprise a a distal grip portion 72,. All or part of the handpiece 64 may be coated with an elastomeric material and/or may be provided with grooves, ridges or surface configurations that facilitate firm grasping of the handpiece 64 by the operator.
[0080] The sighting fin 66 extends from the handpiece in a plane that is parallel to the plane of the needle curve 65, thereby providing to the operator a visual indication of the lateral direction in which the distal portion of the needle body 62 is advancing even when the distal end of the needle body 62 is within the subject's body and out of direct sight of the operator. Additionally, the top edge 67 of the vertical sighting fin 66 is parallel to and in substantial alignment with the distal portion of the needle body 62, thereby providing to the operator a visual indication of the vertical tilt or trajectory on which the needle tip 63 is advancing even when the distal end of the needle body 62 is within the subject's body and out of direct sight of the operator.
[0081] Figure 6 shows the needle sheath 40 positioned on the sinus needle body 62. As shown, the length of the needle sheath 40 is such that when the sheath 40 is fully advanced onto the needle body 62, the flared region 46 located at the proximal end PE of the sheath 40 will abut against the distal surface of the handpiece 64 and the distal tip 63 of the needle body 62 will protrude out of and beyond the distal end DE of the sheath 40. The sheath 40 is flexible enough to conform to the curve 65 of sinus needle body 62, as shown. Optionally, for some applications, an optical or electrical image guidance component 74 (e.g., sensors, reflectors, light sources, etc.) may be attached to the upper elongate member 70 of the handpiece 64, as seen in Figure 6, thereby allowing an optical or electromagnetic image guidance system to be used, in accordance with techniques well known in the art of ear, nose and throat surgery, to determine and/or guide the positioning of the needle tip 63 within the body of human or animal subject.
[0082] United States Patents Nos. 5,314,417 entitled "Safety Trocar" and 5,267,965 entitled "Safety Trocar", the entire disclosures of which are incorporated herein by reference, disclose safety mechanisms that may optionally be used in combination with the sinus needle device 60 and sheath 40.
[0083] As an alternative to a needle body 63 having a sharp tip such as a trocar tip 63, the sinus needle may comprise any other suitable tissue penetrating apparatus capable of forming the desired penetration through the intended tissue (e.g., for ethmoid applications, through mucosal tissue and bone). These other suitable tissue penetrating apparatus include but are not limited to rotating drills, burs, bipolar or monopolar radiofrequency or electrocautery probes, laser probes, etc. Figures 5D and 5E show one example of an alternative sinus penetrator 60a which is similar in construction to the sinus needle 60 described above except that the bottom elongate member 68 of the handpeice is replaced by a housing 68a having an electric motor (not shown) positioned therewithin and an on-off button. Also, in this device, the needle body 62 is replaced by a rotating bur assembly which comprises an elongate curved tube 62a having a flexible rotating drive shaft 84 extending therethrough and a rotating burr tip 82 attached to the distal end of the drive shaft 84, as shown in Figure 5E. Because the drive shaft 84 is flexible, it is capable of rotating even though it extends through the curve 65a of the tubular body 62a. The rotating burr tip may be a 0.6 mm, 0.7mm or 0.8mm diamond bur tip and the motor, drive shaft 84 and bur tip 82 may be substantially the same as used in the Ultrabur™ Fixed Tip Drill (Invotec International, Inc., Jacksonville, Florida).
[0084] In other alternative embodiments where the needle 62 is replaced by a laser probe, a fiber optic laser waveguide may extend through the probe and a suitable type of laser light may be delivered through the wave guide and out of the distal end of the probe to penetrate through the desired anatomical structure. For penetration through the ethmoid bulla or other soft tissue or bony paranasal structures one suitable type of laser is a holmiunτYAG laser. See, Metson, Ralph; HolmiumΥAG Laser Endoscopic Sinus Surgery: A
Randomized, Controlled Study; Laryngoscope; 106(1) Supplement 77:1-18 (January 1996).
Treatment of Ethmoid Sinusitus bv Needle Ethmoidotomv and Implantation of Substance Delivering Spacer Device With Sustained
Corticosteroid Delivery
[0085] Figures 7A-7K show one example of a method by which the above- described sinus needle device 60, sheath 40 and substance delivery device 10 may be used to perform a needle ethmoidotomy, to effectively "stent" the ethmoidotomy channel and to deliver a therapeutic substance (e.g., a corticosteroid) into the diseased ethmoid sinuses for a period of time postoperatively.
[0086] Initially, as seen in Figure 7A, the needle sheath 40 is placed on the needle body 62 as shown in Figure 6. In this embodiment, the inner diameter of the proximal sheath portion 42 is large enough to allow the constraining sheath 30 of the substance delivery device (shown in Figures 1D and 1E) to pass therethrough, whereas the internal diameter of the distal sheath portion 44 is the same or smaller than the outer diameter of the moveable sheath 30 but still sufficiently large in diameter to allow the collapsed reservoir 14 and non-deployed retention wings 18 to pass thereinto.
[0087] The subject is anesthetized or appropriate analgesia/sedation is administered. As shown in Figure 7A, the needle body 62 having the sheath 40 mounted thereon is inserted through the subject's nostril along with an endoscope 400 such as a Storz Hopkins™ II, 0 degree, autoclavable 4mm X 18mm telescope with a Storz Xenon 300™ or Xenon Nova™ light source (Karl Storz GmbH & Co., Tuttlingen, Germany). Also, in this example, a C-arm fluoroscope system may optionally be used to provide fluoroscopic images during portions of the procedure. One example of a commercially available C arm fluoroscope system that is suitable for this purpose is the OEC 9800 PlusTM Digital Mobile Imaging System (G. E. OEC Medical Systems, Inc., Salt Lake City, Utah). The operator may verify that the distal portion of the needle body 62 is in the proper vertical tilt and lateral direction by viewing the sighting fin 66 and its leading edge 67. Under endoscopic guidance, the needle tip 50 is pushed through the ethmoid bulla EB and into one or more ethmoid air cells
EAC. The approximately thirty-three degree angle 65 formed in this embodiment of the sinus needle body 62 allows the distal tip 63 to be advanced on a trajectory that is substantially parallel to (or in some cases even divergent from) the adjacent skull base SB. In this regard, when the procedure is performed on an adult human, the curve 65 of the ethmoidotomy needle body 62 may have a radius of about 0.75 inch and may form an angle A of about 33 degrees. The distal portion of the needle body 62 (i.e., the portion extending from the curve 62 to its distal tip 63) has a length of about 24 mm, thereby allowing for ease of maneuvering the needle/sheath assembly and allowing it to be inserted along side an endoscope 400 with the endoscope 400 being above or below the needle/sheath assembly. The ethmoidotomy needle body 62 is formed of a .073" diameter 304 stainless steel wire having a measured tensile strength (ASTM A313-03) in the range of about 253852 to 258665 psi. In cases where an image guidance component 74 is attached to the handpiece 64 of the sinus needle device 60, the operator may additionally use known techniques and apparatus for optical or electromagnetic image guidance of the advancement of the sinus needle body 62 relative to the skull base SB and other critical anatomical structures. Also, the depth of penetration must be carefully controlled so as not to penetrate all the way though the sphenoid wall and into the sphenoid sinus SS. To ensure that the sphenoid wall is not breached, the surgeon may choose a sheath 40 wherein the distance from the distal end DE of the sheath 40 to the proximal edge of visual marker 48 is less than the distance from the anterior surface of the ethmoid bulla EB to the wall of the sphenoid sinus SS. The distal visual marker 48 on the sheath 40 may then be visualized via the endoscope to gage the depth of penetration into the ethmoid air cells. The advancement may be stopped when the proximal end of visual marker 48 is seen to be flush with the ethmoid bulla EB, thereby ensuring that the sphenoid wall has not been breached. Also, if the sheath 40 incorporates the optional wing members 53, the device may be advanced until those wing members 53 abut against the anterior surface of the ethmoid bulla EB. Additionally, as seen in Figure 13, an optional external stop member 600 may be attached by any suitable means, such as a clip 602, grasper, adhesive, frictional engagement or any other means, to the sheath 40 at a location which will cause the stop
member 600 to abut against the subjects nose, thereby preventing the needle 62 and sheath 40 from being advanced beyond a safe distance into the ethmoids. The distance between the proximal and distal radiographic markers 52, 56 is substantially the same as the length of the reservoir 14 and such markers 44 may be viewed by fluoroscopy. The surgeon can use such fluoroscopic image to position the markers 52, 56 such that they demarcate the locations where the proximal and distal ends of the reservoir 14 are intended to reside.
[0088]As shown in Figure 7B, after the sheath 40 has been placed in the desired position, the needle 49 is withdrawn leaving the sheath 40 in place, with the proximal end of the sheath 40 extending out of the subject's nostril.
[0089] Prior to insertion of the substance delivering spacer device 10, the physician may optionally retract the constraining sheath 30 to expose suture loop 20, and a length of 2-0 or 3-0 suture material 17 having a straight or curved needle 19 may be passed through suture loop and doubled over. The constraining sheath 30 may then be moved to its advanced position, and the opposite ends of the doubled over suture 17 will be caused to protrude out of the proximal end of the constraining sheath 30 as shown in Figure 7C. The substance delivery device 10 with its reservoir in a collapsed state and the constraining sheath 30 in its advanced position (as shown in Figure 2E) is then inserted into the proximal end of the needle sheath 40 as seen in Figure 7C.
[0090] Thereafter, as seen in Figure 7D, the substance delivery device 10 with the constraining sheath 30 in its advanced position is advanced through the sheath 40 to a position where slight resistance to further advancement is felt due to abutment of the distal end of the constraining sheath 30 with the narrowed wall of the internal surface of the tapered segment 54.
[0091] Thereafter, as shown in Figure 7E, the surgeon will apply sufficient force to overcome the resistance to advancement, causing the constraining sheath 30 to move proximally to its retracted position (shown in Figure 2D) as the distal portion of the substance delivering spacer device 10, including the collapsed reservoir 14, advances into the distal sheath portion 42. The
positioning of the reservoir 14 within the distal sheath portion 42 may then be verified fluoroscopically by viewing the positions of the radiographic marker 24 on the device 10 relative to the positions of the radiographic markers 44 on the distal sheath portion 42. Also, using these markers, the actual positioning of the reservoir 14 relative to the surrounding anatomy may be checked.
[0092] Thereafter, as shown in Figure 7F, the sheath 40 with the constraining sheath 30 contained therein may be withdrawn proximally. This allows the retention wings 18 to spring outwardly and engage the adjacent septal walls between ethmoid air cells EAC or alternatively the internal wall surface of the ethmoid bulla EB. The deployment and engagement of the retention wings 18 may be verified fluoroscopically. This also allows the suture loop 20 to be exposed within the nasal cavity adjacent to the ethmoid bulla EB. Because the suture loop is colored differently from blood and the surrounding mucosa, the exposure of the suture loop may also be verified endoscopically.
[0093] Thereafter, as seen in Figure 7G, a syringe containing 0.31 cc to 0.35cc of Triamcinolone Acetonide injectable suspension (Kenalog® 40, Brystol-Myers Squibb Company, Princeton, New Jersey) is attached to the proximal Luer connector 16 of the substance delivering spacer device 10 and the Triamcinolone Acetonide injectable suspension is injected, thereby causing the reservoir 14 to expand. In some embodiments, the shaft 12 of the substance delivering spacer device 10 may be transparent so that the delivery of the substance through lumen 13 may be viewed through the endoscope 400.
[0094] Thereafter, as shown in Figure 7H, the shaft 12 adjacent to proximal Luer connector 16 is cut thereby removing the Luer hub 16. This allows the sinus needle sheath 42 with the constraining sheath 30 contained therein to be removed, thereby freeing the suture 17 and needle 19 for suturing to an anatomical structure adjacent to the suture loop 20. Alternatively, in some embodiments, the sheath 40 can be provided with a longitudinal perforation or weakened region which will allow the sheath to be peeled away and removed.
[0095] As seen in Figure 7I1 the sinus needle sheath 40 with the constraining sheath contained therein is removed and the suture 17 is used to attach
suture loop 20 to adjacent tissue, such as the mucosa M of the intranasal septum or that covering the nasal surface of the ethmoid bulla EB.
[0096] Thereafter, as seen in Figure 7J, the shaft 12 is cut at or distal to separation mark 15, and the proximal shaft 12a is removed.
[0097] As seen in Figure 7K, this procedure results in an ethmoidotomy channel or opening extending into one or more ethmoid air cell(s) EAC with the substance eluting reservoir 14 and distal shaft 12b remaining in place for a period of time (e.g., between 1 hour to 90 days, preferably between 7 to 29 days, most preferably about 14 days and in some cases about 7 days) following the performance of the needle ethmoidotomy procedure. Additionally, a small amount of the substance will remain in the distal shaft 12b distal to the location at which it is cut. This remaining substance may slowly leak out of the cut end of the distal shaft 12b thereby providing medication to adjacent turbinate or other nearby anatomical structures within the nasal antrum.
[0098] In this ethmoid example, the sinus needle sheath 40 has a distal shaft portion 44 made of Nylon having an outer diameter of .087 inches and inner diameter of .075 inches and length of 25mm. Intermediate tapered region 54 is about 5 mm in length and is tapered from an outer diameter of .104 inches and an inner diameter of .088 inches at its proximal end, to an outer diameter of .092 inches and an inner diameter of .075 inches at its distal end. Proximal shaft portion 42 is made of Nylon 12 and has an outer diameter of .102 inches and inner diameter of .088 inches and length of 3.5 inches. Distal and proximal sheath markers 44 are made of rings of a Pt-Ir alloy with an outer diameter of 0.087 inches and an inner diameter of 0.085 inches. The distal shaft marker 44 is located 1mm from the distal end DE of needle sheath 134. Proximal shaft marker 148 is located 18mm from the distal end of needle sheath 40. The total length of needle sheath 40 is 115mm.
[0099] Although the example of Figures 7A-7K is specific to treatment of ethmoid disease, the system of devices shown in the example of Figures 3A- 3L may also be used to form penetration tracts or openings (e.g., antrostomy openings, etc.) in various paranasal sinuses and other anatomical structures
and to position the substance delivering spacer device 10 within such penetration tracts or openings. Additionally, the substance delivering spacer device 10 may be used separately from the sinus needle device 60 in various ostia, openings, incisions and passageways of the body to act simply as a spacer and/or to deliver a desired diagnostic or therapeutic substance. In the treatment of sinus disease, steroids such as Kenalog®-40 (Triamcinolone Acetonide injectable Suspension, USP) are delivered to a paranasal region such as the ethmoid sinuses with device 10.
[0100]The implantable device 10 can be used to preferably deliver fluids or suspensions with a low surface tension. Fluids with low surface tension easily spread across a surface. This is especially useful to deliver substances over a large surface area, especially in anatomical regions such as ethmoid sinuses that have complicated 3-D geometries. In one embodiment, the low surface tension fluid comprises a surfactant. In one method embodiment, a low surface tension irrigating fluid containing one or more substances is delivered to the ethmoid sinuses. In some embodiments, a substantially inert fluid such as saline solution may be delivered to moisten the surrounding tissues and the device may perform a spacing and/or drainage/ventilation function. In other embodiments, an active substance such as a therapeutic or diagnostic substance may be delivered in addition to the spacing and/or drainage/ventilation function of the implanted device 10.
[0101] In some applications, the substance delivering spacer device 10 may be implanted within openings (e.g., natural ostia, surgically altered ostia, other man-made openings) of paranasal sinuses to facilitate the treatment of a disease or disorder affecting the paranasal sinus. In such applications, the opening of the paranasal sinus may be enlarged (e.g., dilated) before or after placement of a device 10, 104 of the present invention within such opening. One such procedure is balloon dilation of sinus cavity ostia. In such procedure, a guide catheter having a substantially fixed shape is inserted through the nose and advanced to a position where the distal end of the guide catheter is adjacent to the ostium of a paranasal sinus. A guidewire is then advanced through the guide catheter (e.g., Relieva™ Guide Catheter, Acclarent, Inc., Menlo Park, California) and into the paranasal sinus.
Thereafter, a balloon catheter {e.g., Relieva™ Balloon Catheter, Acclarent, Inc., Menlo Park, California) is advanced over the guidewire and is used to dilate the ostium of the paranasal sinus, thereby improving drainage from and/or ventilation of that paranasal sinus. Examples of such devices and procedures for balloon dilation of a paranasal sinus ostium are described in United States Patent Application Nos.: 10/829,917 entitled "Devices, Systems and Methods for Diagnosing and Treating Sinusitis and Other Disorders of the Ears, Nose and/or Throat;" 10/944,270 entitled "Apparatus and Methods for Dilating and Modifying Ostia of Paranasal Sinuses and Other Intranasal or Paranasal Structures;" 11/116,118 entitled "Methods and Devices for Performing Procedures Within the Ear, Nose, Throat and Paranasal Sinuses," 11/150,847 entitled "Devices, Systems And Methods Useable For Treating Sinusitus" and 11/234,395 entitled "Devices and Methods for Delivering Therapeutic Substances for the Treatment of Sinusitis and Other Disorders," the entire disclosure of each such patent application being expressly incorporated herein by reference.
Treatment of Frontal Sinusitis by Balloon Dilation of Frontal Outflow
Tract and Implantation of Spacer Device With
Sustained Corticosteroid Delivery
[0102] Figures 8A through 8G show an example of one method by which the substance delivering spacer device 10 may be placed in the frontal sinus outflow tract FSO to perform a stenting and substance delivery function following balloon dilation of the frontal sinus outflow tract FSO.
[0103] In this procedure, the endoscope 400 is inserted and, optionally, a C- arm fluoroscope (not shown) may also be positioned to provide fluoroscopic images of the procedure when desired. Although, for clarity and visual simplicity, the endoscope 400 is shown only in Figures 8A and 8B1 such endoscope 400 may remain in place throughout all or any part of this procedure and may be used for real time visualization of the movement and operation of the devices, as described in this example.
[0104] Under endoscopic visualization, a frontal sinus guide catheter 500 (e.g., the Relieva® 70 Degree Sinus Guide Catheter; Acclarent, Inc., Menlo Park, California) is inserted through the nostril and advanced to a position
where its distal end is within or aligned with the frontal sinus ostium FSO. Such positioning of the guide catheter 500 may be verified by endoscopic visualization and/or fluoroscopy.
[0105] Thereafter, a guidewire GW (Relieva® Sinus Guidewire; Acclarent, Inc., Menlo park, California) is advanced through the guide catheter 500 and into the frontal sinus FS, as shown in Figure 8A. The fluoroscope 404 may be used to verify that the guidewire GW has become coiled within the frontal sinus FS.
[0106] Thereafter, as shown in Figure 8B, a dilation catheter 502 (e.g., the Relieva® or Retieva XL Sinus Balloon Catheter, Acclarent, Inc., Menlo Park, California) is advanced over the guidewire GW and through the guide catheter 500 to a position where its dilator balloon 504 is positioned within the frontal sinus ostium FSO. The fluoroscope 400 may be used to verify that the guidewire GW has become coiled within the frontal sinus FS. With the dilator 504 so positioned, the dilator balloon 504 is expanded to cause dilation of the frontal sinus ostium FSO or other frontal sinus outflow tract. This procedure is described in detail in copending United States Patent Application Serial No. 11/355,512, the entire disclosure of which is expressly incorporated herein by reference. After the dilation has been completed, the dilator balloon 504 is again collapsed and the dilation catheter 502 is removed, leaving the guidewire 504 in place. Although this example includes this step of dilating the frontal sinus ostium FSO, this dilation step is optional. In some patients, the sinus ostium may have already been dilated or altered in a previous surgery or the physician may determine that dilation of the ostium is not needed prior to introduction of the spacer device 10.
[0107] Thereafter, the substance delivering spacer device 10 is prepared and advanced through the guide catheter 500 and into the frontal sinus FS. Prior to insertion of the device 10 into the guide catheter 500, the constraining tube 42 may be removed and the retention wings 18 may be manually folded forward (i.e., in the distal direction) using finger pressure as the spacer device 10 is inserted into the proximal end of the guide catheter 500. As the distal end of the spacer device emerges out of the distal end of the guide catheter
500, the retention wings 18 will spring outwardly and will engage the frontal sinus ostium FSO as shown in Figure 8C. Positioning of the reservoir 14 within the frontal sinus and successful deployment of the retention wings 18 may be verified fluoroscopically.
[0108] Thereafter, as shown in Figure 8D, a syringe containing 0.31 cc to 0.35cc of Triamcinolone Acetonide injectable suspension (Kenalog® 40, Brystol-Myers Squibb Company, Princeton, New Jersey) is attached to the proximal Luer connector of the sinus spacer device 10 and the Triamcinolone Acetonide injectable suspension is injected, thereby causing the reservoir 14 to expand. Successful expansion of the reservoir 14a may be verified by CT.
[0109] Thereafter, as shown in Figures 8E and 8F, the proximal end of the sinus spacer device 10 is cut off and the guide catheter is retracted proximally and removed. The operator may grasp the shaft 12 of the spacer device distal to the distal end of the guide catheter 500 as the guide catheter is removed to stabilize the spacer device 10 and to prevent it from being inadvertently dislodged from the frontal sinus FS during removal of the guide catheter 500.
[0110] Thereafter, a proximal portion of the shaft 12 of spacer device 10 may be cut away, leaving a short length of the shaft 12 hanging within the nose. The suture 17 with straight needle 19 is used to suture the suture tab 20 of the spacer device 10 to tissue within the nose, thereby helping to retain the implanted portion of the spacer device 10 in its desired position for a desired time period following the procedure. Some of the substance will remain in the remaining segment of shaft 12 distal to the cut and may leak into the nasal cavity subsequent to the procedure, thereby providing medication to other structures within the nasal cavity as well.
Treatment of Frontal Sinusitis by Implantation of Spacer Device With Sustained Corticosteroid Delivery
[0111] In this example, Figures 9A-9D show steps in another method in which frontal sinusitis is treated in an adult human subject. The frontal sinus ostium FSO may or may not have been previously surgically altered or dilated as described above. Under endoscopic visualization, a frontal sinus guide
catheter 500 (e.g., the Relieva® 70 Degree Sinus Guide Catheter; Acclarent, Inc., Menlo Park, California) is inserted through the nostril and advanced to a position where its distal end is within or aligned with the frontal sinus ostium FSO. Such positioning of the guide catheter 500 may be verified by endoscopic visualization and/or fluoroscopy.
[0112] Thereafter, a guidewire GW (Relieva® Sinus Guidewire; Acclarent, Inc., Menlo park, California) is advanced through the guide catheter 500 and into the frontal sinus FS, as shown in Figure 9A. The fluoroscope 404 may be used to verify that the guidewire GW has become coiled within the frontal sinus FS.
[0113] With reference to Figure 9B, after the guidewire GW has been inserted into the frontal sinus, the frontal sinus guide catheter 500 is removed, leaving the guidewire GW in place. A 5 French vascular dilator 420 (e.g., 5 F vessel dilator (inner diameter of 0.038 in.), Merritt Medical Systems, Inc., South Jordan, UT). The sheath/dilator combination is then advanced over the guidewire GW. The C-arm fluoroscope and/or the endoscope 400 may be used to observe the advancement of the sheath/dilator combination to a position where the proximal radiographic marker 52 of the sheath 40 is distal to the frontal recess (i.e., within the cavity of the frontal sinus). Once the sinus sheath 40 has been advanced to such location while within the lumen of the dilator, the 5F dilator 420 and the guidewire GW are removed leaving the sheath 40 in place, as shown in Figure 9C.
[0114] Thereafter, the substance spacer device 10 is prepared as described above and the constraining tube 30 is placed in its advanced position so as to constrain and cover the suture loop 20, retention wings 18 and reservoir 14 in their collapsed positions. The device 10 is advanced into the previously inserted sheath 40 in substantially the same manner as described above and shown in Figures 8C-8E.
[0115] Thereafter, the sheath 40 and constraining tube 30 are retracted and a syringe containing 0.31 cc to 0.35cc of Triamcinolone Acetonide injectable suspension (Kenalog® 40, Brystol-Myers Squibb Company, Princeton, New Jersey) is attached to the proximal Luer connector of the sinus spacer device
10 and the Triamcinolone Acetonide injectable suspension is injected, thereby causing the reservoir 14 to expand within the frontal sinus FS, as previously described above. Successful expansion of the reservoir 14a may be verified by CT scan if desired.
[0116] Thereafter, the proximal end of the sinus spacer device 10 is cut off, and the sheath 40 and constraining tube 30 are retracted proximally and removed in the same manner as described above and shown in Figures 8H- 8I.
[0117] Thereafter, a proximal portion of the shaft 12 of spacer device 10 may be cut away, leaving a short length of the shaft 12 hanging within the nose. The suture 17 with straight needle 19 is used to suture the suture tab 20 of the spacer device 10 to tissue within the nose, thereby helping to retain the implanted portion of the spacer device 10 in its desired position for a desired time period following the procedure as seen in Figure 9D. As described above, Triamcinolone Acetonide suspension that remains in the short segment of shaft 12 distal to the cut may subsequently leak into the nasal cavity NC, providing some additional therapeutic benefit to tissues in that area.
[0118] Although the accompanying drawings and above-described examples have specifically shown techniques for implanting the substance delivering spacer device 10 in the frontal sinus and ethmoid sinuses, the same techniques may be employed to implant the substance delivering spacer device 10 in maxillary or sphenoid sinuses. To facilitate placement of the device 10 in a maxillary sinus, the operator may use a technique that is essentially the same as that described above and shown in figures 9A-9D except that, instead of the frontal sinus guide 500, the operator will insert a maxillary sinus guide catheter 500 (e.g., the Relieva® 110 Degree Sinus Guide Catheter; Acclarent, Inc., Menlo park, California) through the nostril and will advance that guide catheter to a position where its distal end is within or aligned with the maxillary sinus ostium. Similarly, to facilitate placement of the device 10 in a sphenoid sinus, the operator may use a technique that is essentially the same as that described above and shown in figures 9A-9D
except that, instead of the frontal sinus guide 500, the operator will insert a sphenoid sinus guide catheter 500 (e.g., the Relieva® 30 Degree Sinus Guide Catheter; Acclarent, Inc., Menlo park, California) through the nostril and will advance that guide catheter to a position where its distal end is within or aligned with the sphenoid sinus ostium.
Stability of Triamcinolone Acetonide Within Spacer Device Following
Implantation
[0119] A study was performed to confirm that the Triamcinolone Acetonide injectable suspension (Kenalog® 40, Brystol-Myers Squibb Company, Princeton, New Jersey), when loaded into the reservoir 14 of the substance delivering spacer device 10, remains intact and capable of pharmacologic activity for at least 30 days following implantation of the device. In this study, the reservoir 14 of one device 10 was loaded by injecting 0.31cc of the Triamcinolone Acetonide injectable suspension as described above {hereinafter referred to as "Triamcinolone Acetonide loaded reservoir"). The reservoir 14 of a second device 10 was loaded with saline (hereinafter referred to as "placebo loaded reservoir") and the reservoir of a third device remained empty (hereinafter referred to as "blank reservoir") All three devices were maintained under ICH stability conditions (40°C + 2°C/ 75% RH ± 5% RH) in Caron Model 6030 Environmental Stability Chamber. High Performance Liquid Chromatography (HPLC) was performed on aliquots of the contents of each reservoir at day 0 and day 30. The results of this study are summarized in Table 1 below:
Table 1
RRT = RT of peak/RT of TA (RRT = Relative Retention Time, RT = Retention Time)
% Individual impurity = (Peak area of imp/Total peak area of K-40 sinus spacer) x 100
Total average peak area of K-40 sinus spacer at 0-day = 5869075
Total average peak area of K-40 sinus spacer at 30-day = 5233043
% Total impurities = (Total peak area of imp/Total peak area of K-40 sinus spacer) x
100
Only those impurity peaks > 0 02% are considered significant impurities.
[0120] The Triamcinolone Acetonide potency of samples obtained from the Triamcinolone Acetonide loaded reservoir at days 0 and day 30, respectively, was confirmed by HPLC. In this study, the levels of impurities rose within acceptable ranges and the potency of Triamcinolone Acetonide present in the Triamcinolone Acetonide reservoir remained sufficient to cause the intended local anti-inflammatory effect for at least 30 days.
Efficacy of Triamcinolone Acetonide Delivered Using Substance Delivering Spacer Device 10
[0121] Use of topical corticosteroid therapy to treat chronic sinus inflammatory conditions is based on the rationale that more effective drug concentrations can be achieved at local receptor sites in the nasal mucosa, with minimal risk of systemic adverse effects. Triamcinolone Acetonide (TA) is a second generation synthetic corticosteroid of which there are currently six compounds approved for intranasal use. All six corticosteroids appear to be relatively equal with regard to potency and effectiveness. TA was chosen for use in the
Ethmoid Sinus Spacer as the compound with the longest safety record and for its availability in a concentrated solution suitable for use in this device. Specifically, Kenalog-40 was used as it is one of the approved and marketed formulations of Triamcinolone Acetonide.
[0122] It has been established that intranasal and/or inhaled doses of Triamcinolone Acetonide do not cause hypothalamo-pituitary-adrenal (HPA) suppression even when drug is delivered for up to three years. See, Klossek JM et al., Local Safety Of Intranasal Triamcinolone Acetonide: Clinical And Histological Aspects Of Nasal Mucosa In The Long-Term Treatment Of Perennial Allergic Rhinitis, Rhinology, 39(1):17-22 (2001); Lund, VJ., Maximal Medical Therapy for Chronic Rhinosinusitis, Otolaryngol Clin N Am 38, 1301- 1310 (2005) and Laliberte F et al., Clinical And Pathologic Methods To Assess The Long-Term Safety Or Nasal Corticosteroids, Allergy 55(8): 718- 722 (2000).
[0123] Locally administered TA has been demonstrated to provide a reduction in the severity of both early and late phase reaction to allergens, reduced sensitivity of local nasal irritant receptors and reduced local inflammation and a decreased likelihood for secondary rhinovirus infections. Even long term local delivery of TA to the nasal sinus does not appear to damage nasal mucosa.
[0124] The volume of vehicle in the substance delivering spacer device 10 used in this study has a reservoir 14 that will hold 0.1 ml. when loaded to maximum capacity. If loaded to maximum capacity with the Kenalog-40, the reservoir will contain 4mg of TA. This amount of TA is roughly equivalent in potency to the 35-40 mg of Cortisol produced daily by normal human adrenal glands. Thus, a total 4 mg TA, even if released all at once, would not be expected to adversely affect adrenal corticoid activity.
[0125] As explained above, the openings 31 in the reservoir 14 of the substance delivering spacer device 10 may be designed to limit diffusion of TA from the reservoir so that only a small daily dose of drug is delivered over the course of two weeks. In this manner, the dose delivered locally into the ethmoids or other paranasal sinuses may be less than the recommended
dose of TA delivered with commercially available nasal inhalers (e.g., Nasacort® Inhaler, Sanofi-Aventis, Bridgewater, New Jersey).
[0126] Thirteen human subjects suffering from ethmoid sinusitis were treated by performance of a needle ethmoidotomy with post operative delivery of TA by implantation of a substance delivering spacer device 10 substantially as described above and shown in Figures 7A through 8J. Nine of these subjects were treated bilaterally and the remaining four unilaterally. Thus, twenty-two ethmoid sinuses were treated in total. A fourteenth patient suffering from frontal sinusitis was treated by a balloon dilation of the frontal outflow tract and with post operative delivery of TA by implantation of a substance delivering spacer device 10 substantially as described above and shown in Figures 8A through 8G.
Post-Operative Follow-up and Data Collection
Subjects Nos. 1-10:
[0127] Blood levels of TA were determined in subjects 1-10 prior to the administration of anesthesia and at 1 , 2 and 4 hours following implantation and loading of the substance delivering spacer device 10. If the particular subject stayed overnight at the treatment facility, a blood sample was taken at 23 hours or just prior to discharge. Additional blood samples were collected in subjects 1-10 at 3, 7, 10 and 14 days after the procedure and immediately prior to explant and removal of the substance delivering spacer device 10.
[0128] In addition to collection of blood samples as noted above, the patient was asked to fill out a Sino-Nasal Outcomes Test (SNOT-20) questionnaire. (SNOT-20 - Piccirillo, JF et al., Psychometric and clinimetric validity of the 20- ltem Sino-Nasal Outcome Test (SNOT-20), Copyright © 1996 by Jay F. Piccirillo M. D., Washington University, St. Louis, Missouri) at baseline and at 1 , 2 and 6 weeks following explant and removal of the substance delivering spacer device 10. Additionally, the patient was asked to fill out a questionnaire specific to the tolerability of the substance delivering spacer device 10. The device was removed during an office visit at day 14 following implantation. Quantification of residual drug in the device provided additional information
relevant to the elution of triamcinolone acetonide from the Ethmoid Sinus Spacer during the implantation of the device.
[0129] Investigators provided post-operative care as required except no steroid nasal sprays and nasal rinses were administered. Post-operative antibiotic treatment was administered at the discretion of the Investigator, as needed. This was to minimize the effects of concomitant medications on the study outcome.
[0130] A final CT scan of the ethmoid sinuses was taken at eight weeks to assess the condition of the ethmoid sinuses and when compared to baseline, the degree of improvement.
Subject Nos. 11-13:
[0131] Subjects Nos. 11 through 13 received the same post-operative care and blood sample collection as Subject Nos. 1-10, with the following exceptions:
[0132] Following the baseline blood sample taken prior to the administration of anesthesia, blood was drawn at 4 hours following device implantation on the day of the procedure and days 1 , (optional) 3, 7, 14, 21 and 28, prior to explant and removal of the substance delivering spacer device 10.
[0133] Six follow-up visits were scheduled throughout the study, at days 3, 7, 14, 21 and 28 and a final visit 10 weeks following the procedure. In addition to collection of blood samples as noted above, the patient was asked to fill out a SNOT-20 Quality of Life (QOL) questionnaire at baseline, and at 1 , 2, and 6 weeks following explant. Additionally, the patient was asked to fill out a questionnaire specific to the tolerability of the Ethmoid Sinus Spacer. The device was removed during an office visit at day 28 following implantation.
[0134] Investigators provided post-operative care as required except no steroid nasal sprays were administered. Post-operative antibiotic treatment was administered at the discretion of the Investigator, as needed. This was to minimize the effects of concomitant medications on the study outcome.
[0135] A final CT scan of the ethmoid sinuses was taken at ten weeks (six weeks post explant) to assess the condition of the ethmoid sinuses and when compared to baseline, the degree of improvement.
Subject No, 14;
[0136] Subject No. 14 was the one who was treated for frontal sinusitis rather than ethmoid disease. Subject No. 14 received post-operative follow-up and data collection (e.g., blood samples and SNOT-20 questionaires) in substantially the same manner as Subject Nos. 1-10.
CT Scan Results
[0137] The CT scans were read and improvement in the affected sinuses was scored by the Lund McKay scoring method. These Lund McKay Scores are shown graphically in Figure 10. At baseline (pre-operative) the average Lund McKay Score was 10.4. The average Lund McKay score at follow-up 3.9. Thus, the 14 subjects studied exhibited an average reduction of 65.1% in Lund McKay score.
SNOT-20 And Questionnaire Results
[0138] Figure 11 shows the average improvement from baseline in the SNOT- 20 scores as measured at 1 , 2, 4, and 6 weeks (Note: One patient deviated from protocol and completed the 6 week follow-up visit at four weeks.) A score of 1.07 or below was deemed to be indicative of a clinically significant reduction of sinusitis symptoms (i.e., a reduction of at least 0.8 from the baseline SNOT 20 score). These data indicate that clinically significant reductions in the average SNOT 20 scores were observed at 2, 4 and 6 weeks after the procedure.
[0139] Symptom improvement was also documented in the Patient Questionnaire administered at one, two and six weeks post procedure. All patients reported they were significantly improved or improved six weeks following the procedure, no patients reported feeling worse. At six weeks a majority of patients were satisfied with the results and stated that if given this treatment choice again, they would agree to have the surgery.
Statistical Analysis of Results
[0140] The SNOT-20 results were recorded during 5 post-procedural evaluation visits. The null and alternative hypotheses evaluated based on this endpoint are as follows:
H0. U {Day 42 minus baseline) = *J Ha' U (Day 42 minus baseline) r 0
[0141] Univariate analysis results from comparing the change in the SNOT-20 scores from baseline were analyzed using a paired-difference t-test. The results from this analysis revealed a significant reduction in the SNOT-20 scores within 7 days of the procedure. A consistent reduction was observed during all successive post-procedure evaluation visits. At the time enrollment was stopped, 13 of the 14 patients (92.9%) had completed the 42-day postprocedure evaluation visit. The reduction from baseline 42 days postprocedure was -22.08 points on the SNOT-20 scale, with a standard deviation of 14.69 and a probability value O.001. The effect size of this result is 1.50, which is reflective of a very strong treatment effect.
Lund-McKay Scores (CT Scan)
[0142] CT scans were performed at baseline and 42 days following the procedure to derive the LMK score. The null and alternative hypotheses evaluated based on this endpoint are as follows:
Ho- M (Day 42 minus baseline) = 0 Ha- M (Day 42 minus baseline) ^ 0
[0143] Univariate analysis results from comparing the change in the LMK scores from baseline were analyzed using a paired-difference t-test. The results from this analysis revealed a significant reduction in the LMK scores 42 days after the procedure. The reduction for baseline was 6.50 points on the LMK scale, with a standard deviation of 3.96, and a probability value <0.001. The effect size from this result is 1.64, which is reflective of a very
strong treatment effect.
[0144] A subset analysis was performed comparing the change in the LMK scores from the ethmoid sinuses. The results from this analysis also revealed a significant reduction in the LMK scores 42 days after the procedure. The reduction for baseline was 2.21 points on the LMK scale, with a standard deviation 1.53, and a probability value <0.001. The effect size of this result is 1.44, which is reflective of a very strong treatment effect.
[0145] The primary efficacy endpoint was examined using inferential statistics. Based on the performance success of the 14 patients enrolled (100%), the lower 95% exact binomial confidence interval was 76.84%.
Blood Plasma Analysis
[0146] To assess the secondary endpoint of the ability of TA to elute from the substance delivering spacer device 10 to over time, TA concentrations were determined in blood plasma from each of the collected blood samples. These data are summarized in Table 2 below.
Table 2
Summary of Plasma /levels of TA at Different Time Points (measured in picograms per mL)
[0147] Low (i.e., not systemically active) but detectable TA levels were determined in the subjects' blood plasma as far out as 28 days following implantation and loading of the substance delivering spacer device 10.
Conclusion
[0148] Locally effective doses of TA were delivered from the substance delivering spacer device 10 for up to 28 days post-procedure. The CT scans indicated significant reduction in sinus inflammation. The subjects also realized substantial improvement in sinusitis symptoms on the basis of the SNOT 20 and patient questionnaire results.
[0149] The term substance as used herein is to be broadly construed to include any feasible drugs, prodrugs, proteins, gene therapy preparations, cells, diagnostic agents, contrast or imaging agents, biologicals, etc. Such substances may be in bound or free form, liquid or solid, colloid or other suspension, solution or may be in the form of a gas or other fluid or non-fluid. For example, in some applications where it is desired to treat or prevent a microbial infection, the substance delivered may comprise a pharmaceutically acceptable salt or dosage form of an antimicrobial agent (e.g., antibiotic, antiviral, antiparasitic, antifungal, etc.), a corticosteroid or other antiinflammatory (e.g., an NSAID), a decongestant (e.g., vasoconstrictor), a mucous thinning agent (e.g., an expectorant or mucolytic), an agent that prevents of modifies an allergic response (e.g., an antihistamine, cytokine inhibitor, leucotriene inhibitor, IgE inhibitor, immunomodulator), an anesthetic agent with or without a vasoconstriction agents (e.g. Xylocaine with or without Epinephrine), an analgesic agent, an allergen or another substance that causes secretion of mucous by tissues, hemostatic agents to stop bleeding, antiproliferative agents, cytotoxic agents e.g. alcohol, biological agents such as protein molecules, stem cells, genes or gene therapy preparations, viral vectors carrying proteins or nucleic acids such as DNA or mRNA coding for important therapeutic functions or substances, cauterizing agents e.g. silver nitrate, etc.
[0150] Some non-limiting examples of antimicrobial agents that may be used in this invention include acyclovir, amantadine, rimantadine, oseltamivir, zanamivir, aminoglycosides (e.g., amikacin, gentamicin and tobramycin), amoxicillin, amoxicillin/clavulanate, amphotericin B, ampicillin, ampicillin/sulbactam, atovaquone, azithromycin, cefazolin, cefepime,
cefotaxime, cefotetan, cefpodoxime, ceftazidime, ceftizoxime, ceftriaxone, cefuroxime, cefuroxime axetil, cephalexin, chloramphenicol, clotrimazole, ciprofloxacin, clarithromycin, clindamycin, dapsone, dicloxacillin, doxycycline, erythromycin, fluconazole, foscamet, ganciclovir, atifloxacin, imipenem/cilastatin, isoniazid, itraconazole, ketoconazole, metronidazole, nafcillin, nafcillin, nystatin, penicillins including penicillin G, pentamidine, piperacillin/tazobactam, rifampin, quinupristin-dalfopristin, ticarcillin/clavulanate, trimethoprim/sulfamethoxazole, valacyclovir, vancomycin, mafenide, silver sulfadiazine, mupirocin, nystatin, triamcinolone/nystatin, clotrimazole/betamethasone, clotrimazole, ketoconazole, butoconazole, miconazole, tioconazole, detergent-like Chemicals that disrupt or disable microbes (e.g., nonoxynol-9, octoxynol-9, benzalkonium chloride, menfegol, and N-docasanol); chemicals that block microbial attachment to target cells and/or inhibits entry of infectious pathogens (e.g., sulphated and sulponated polymers such as PC-515 (carrageenan), Pro-2000, and Dextrin 2 Sulphate); antiretroviral agents (e.g., PMPA gel) that prevent retroviruses from replicating in the cells; genetically engineered or naturally occurring antibodies that combat pathogens such as anti-viral antibodies genetically engineered from plants known as "plantibodies;" agents which change the condition of the tissue to make it hostile to the pathogen (such as substances which alter mucosal pH (e.g., Buffer Gel and Acidform); non-pathogenic or "friendly" microbes that cause the production of hydrogen peroxide or other substances that kill or inhibit the growth of pathogenic microbes (e.g., lactobacillus); antimicrobial proteins or peptides such as those described in United States Patent No. 6,716,813 (Lin et al.) which is expressly incorporated herein by reference or antimicrobial metals (e.g., colloidal silver).
[0151] Additionally or alternatively, in some applications where it is desired to treat or prevent inflammation the substances delivered in this invention may include various steroids or other anti-inflammatory agents (e.g., nonsteroidal anti-inflammatory agents or NSAIDs), analgesic agents or antipyretic agents. For example, corticosteroids that have previously administered by intranasal administration may be used, such as beclomethasone (Vancenase® or Beconase®), flunisolide (Nasalide®), fluticasone proprionate (Flonase®),
triamcinolone acetonide (Nasacort®), budesonide (Rhinocort Aqua®), loterednol etabonate (Locort) and mometasone (Nasonex®). Other salt forms of the aforementioned corticosteroids may also be used. Also, other non- limiting examples of steroids that may be useable in the present invention include but are not limited to aclometasone, desonide, hydrocortisone, betamethasone, clocortolone, desoximetasone, fluocinolone, fiurandrenolide, mometasone, prednicarbate; amcinonide, desoximetasone, diflorasone, fluocinolone, fluocinonide, halcinonide, clobetasol, augmented betamethasone, diflorasone, haiobetasol, prednisone, dexamethasone and methylprednisolone. Other anti-inflammatory, analgesic or antipyretic agents that may be used include the nonselective COX inhibitors (e.g., salicylic acid derivatives, aspirin, sodium salicylate, choline magnesium thsalicylate, salsalate, diflunisal, sulfasalazine and olsalazine; para-aminophenol derivatives such as acetaminophen; indole and indene acetic acids such as indomethacin and sulindac; heteroaryl acetic acids such as tolmetin, dicofenac and ketorolac; arylpropionic acids such as ibuprofen, naproxen, flurbiprofen, ketoprofen, fenoprofen and oxaprozin; anthranilic acids (fenamates) such as mefenamic acid and meloxicam; enolic acids such as the oxicams (piroxicam, meloxicam) and alkanones such as nabumetone) and Selective COX-2 Inhibitors (e.g., diaryl-substituted furanones such as rofecoxib; diaryl-substituted pyrazoles such as celecoxib; indole acetic acids such as etodolac and sulfonanilides such as nimesulide).
[0152] Additionally or alternatively, in some applications, such as those where it is desired to treat or prevent an allergic or immune response and/or cellular proliferation, the substances delivered in this invention may include a) various cytokine inhibitors such as humanized anti-cytokine antibodies, anti-cytokine receptor antibodies, recombinant (new cell resulting from genetic recombination) antagonists, or soluble receptors; b) various leucothene modifiers such as zafirlukast, montelukast and zileuton; c) immunoglobulin E (IgE) inhibitors such as Omalizumab (an anti-lgE monoclonal antibody formerly called rhu Mab-E25) and secretory leukocyte protease inhibitor).
[0153] Additionally or alternatively, in some applications, such as those where it is desired to shrink mucosal tissue, cause decongestion or effect
hemostasis, the substances delivered in this invention may include various vasoconstrictors for decongestant and or hemostatic purposes including but not limited to pseudoephedrine, xylometazoline, oxymetazoline, phenylephrine, epinephrine, etc.
[0154] Additionally or alternatively, in some applications, such as those where it is desired to facilitate the flow of mucous, the substances delivered in this invention may include various mucolytics or other agents that modify the viscosity or consistency of mucous or mucoid secretions, including but not limited to acetylcysteine (Mucomyst™, Mucosil™) and guaifenesin.
[0155] Additionally or alternatively, in some applications such as those where it is desired to prevent or deter histamine release, the substances delivered in this invention may include various mast cell stabilizers or drugs which prevent the release of histamine such as cromolyn (e.g., Nasal Chrom®) and nedocromil.
[0156] Additionally or alternatively, in some applications such as those where it is desired to prevent or inhibit the effect of histamine, the substances delivered in this invention may include various antihistamines such as azelastine (e.g., Astylin®), diphenhydramine, loratidine, etc.
[0157] Additionally or alternatively, in some embodiments such as those where it is desired to dissolve, degrade, cut, break or remodel bone or cartilage, the substances delivered in this invention may include substances that weaken or modify bone and/or cartilage to facilitate other procedures of this invention wherein bone or cartilage is remodeled, reshaped, broken or removed. One example of such an agent would be a calcium chelator such as EDTA that could be injected or delivered in a substance delivery implant next to a region of bone that is to be remodeled or modified. Another example would be a preparation consisting of or containing bone degrading cells such as osteoclasts. Other examples would include various enzymes of material that may soften or break down components of bone or cartilage such as collagenase (CGN), trypsin, trypsin/EDTA, hyaluronidase, and tosyllysylchloromethane (TLCM).
[0158] Additionally or alternatively, in some applications, the substances delivered in this invention may include other classes of substances that are used to treat rhinitis, nasal polyps, nasal inflammation, and other disorders of the ear, nose and throat including but not limited to anti-cholinergic agents that tend to dry up nasal secretions such as ipratropium (Atrovent Nasal®), as well as other agents not listed here.
[0159] Additionally or alternatively, in some applications such as those where it is desired to draw fluid from polyps or edematous tissue, the substances delivered in this invention may include locally or topically acting diuretics such as furosemide and/or hyperosmolar agents such as sodium chloride gel or other salt preparations that draw water from tissue or substances that directly or indirectly change the osmolar content of the mucous to cause more water to exit the tissue to shrink the polyps directly at their site.
[0160] Additionally or alternatively, in some applications such as those wherein it is desired to treat a tumor or cancerous lesion, the substances delivered in this invention may include antitumor agents (e.g., cancer chemotherapeutic agents, biological response modifiers, vascularization inhibitors, hormone receptor blockers, cryotherapeutic agents or other agents that destroy or inhibit neoplasia or tumorigenesis) such as; alkylating agents or other agents which directly kill cancer cells by attacking their DNA (e.g., cyclophosphamide, isophosphamide), nitrosoureas or other agents which kill cancer cells by inhibiting changes necessary for cellular DNA repair (e.g., carmustine (BCNLJ) and lomustine (CCNU)), antimetabolites and other agents that block cancer cell growth by interfering with certain cell functions, usually DNA synthesis (e.g., 6 mercaptopurine and 5-fluorouracil (5FU), antitumor antibiotics and other compounds that act by binding or intercalating DNA and preventing RNA synthesis (e.g., doxorubicin, daunorubicin, epirubicin, idarubicin, mitomycin-C and bleomycin) plant (vinca) alkaloids and other antitumor agents derived from plants (e.g., vincristine and vinblastine), steroid hormones, hormone inhibitors, hormone receptor antagonists and other agents which affect the growth of hormone-responsive cancers (e.g., tamoxifen, herceptin, aromatase ingibitors such as aminoglutethamide and formestane, trriazole inhibitors such as letrozole and anastrazole, steroidal
inhibitors such as exemestane), anti-angiogenic proteins, small molecules, gene therapies and/or other agents that inhibit angiogenesis or vascularization of tumors (e.g., meth-1 , meth-2, thalidomide), bevacizumab (Avastin), squalamine, endostatin, angiostatin, Angiozyme, AE-941 (Neovastat), CC-5013 (Revimid), medi-522 (Vitaxin), 2-methoxyestradiol (2ME2, Panzem), carboxyamidotriazole (CAI), combretastatin A4 prodrug (CA4P), SU6668, SlM 1248, BMS-275291 , COL-3, EMD 121974, IMC-1C11 , IM862, TNP-470, celecoxib (Celebrex), rofecoxib (Vioxx), interferon alpha, interleukin-12 (IL-12) or any of the compounds identified in Science Vol. 289, Pages 1197-1201 (August 17, 2000) which is expressly incorporated herein by reference, biological response modifiers (e.g., interferon, bacillus calmette- guerin (BCG), monoclonal antibodies, interluken 2, granulocyte colony stimulating factor (GCSF), etc.), PGDF receptor antagonists, herceptin, asparaginase, busuiphan, carboplatin, cisplatin, carmustine, cchlorambucil, cytarabine, dacarbazine, etoposide, flucarbazine, flurouracil, gemcitabine, hydroxyurea, ifosphamide, irinotecan, lomustine, melphalan, mercaptopurine, methotrexate, thioguanine, thiotepa, tomudex, topotecan, treosulfan, vinblastine, vincristine, mitoazitrone, oxaliplatin, procarbazine, streptocin, taxol, taxotere, analogs/congeners and derivatives of such compounds as well as other antitumor agents not listed here.
[0161] Additionally or alternatively, in some applications such as those where it is desired to grow new cells or to modify existing cells, the substances delivered in this invention may include cells (mucosal cells, fibroblasts, stem cells or genetically engineered cells) as well as genes and gene delivery vehicles like plasmids, adenoviral vectors or naked DNA, mRNA, etc. injected with genes that code for anti-inflammatory substances, etc., and, as mentioned above, osteoclasts that modify or soften bone when so desired.
[0162] Any of the devices and methods described herein may also be used to deliver substances to the brain or alter the functioning of the olfactory system. Such examples include, the delivery of energy or the deposition of devices and/or substances and/or substance delivering implant(s) to occlude or alter olfactory perception, to suppress appetite or otherwise treat obesity, epilepsy (e.g., barbiturates such as phenobarbital or mephoobarbital; iminostilbenes
such as carbamazepine and oxcarbazepine; succinimides such as ethyisuximide; valproic acid; benzodiazepines such as clonazepam, clorazepate, diazepam and lorazepam, gabapentin, lamotrigine, acetazolamide, felbamate, levetiraceam, tiagabine, topiramate, zonisamide, etc.), personality or mental disorders (e.g., antidepressants, antianxiety agents, antipsychotics, etc.) , chronic pain, Parkinson's disease (e.g., dopamine receptor agonists such as bromocriptine, pergolide, ropinitrol and pramipexole; dopamine precursors such as levodopa; COMT inhibitors such as tolcapone and entacapone; selegiline; muscarinic receptor antagonists such as trihexyphenidyl, benztropine and diphenhydramine) and Alzheimer's disease, Huntington's disease or other dementias, disorders of cognition or chronic degenerative diseases (e.g. tacrine, donepezil, rivastigmine, galantamine, fluoxetine, carbamazepine, clozapine, clonazepam and proteins or genetic therapies that inhibit the formation of beta-amyloid plaques), etc.
[0163] The devices and methods disclosed herein may be used to deliver several combinations of two or more substances disclosed herein to a suitable target anatomical region. In one particular embodiment, the devices and methods disclosed herein are used to deliver a combination of an antiinflammatory agent (e.g. a steroid or an NSAID) and a mucolytic agent.
[0164] The devices and methods disclosed herein may be used to deliver gels or viscous liquids comprising one or more substances to anatomical regions such as paranasal sinuses. Such gels or viscous liquids may coat and adhere to a mucous membrane and thus provide sustained delivery of one or more substances to the mucous membrane. In one embodiment, a plasticized hydrocarbon gel comprising gelatin, pectin and sodium carboxymethylcellulose and a suitable substance may be delivered to a mucous membrane such as the mucous membrane of a paranasal sinus. Such gels can be used for sustained delivery of the suitable substance to the mucous membrane.
[0165] One or more of the substance reservoirs disclosed herein may comprise multiple compartments such that each compartment stores a particular substance formulation. The multiple compartments prevent mixing
of multiple substance formulations before substance formulations are delivered to the anatomy.
[0166] One or more of the substance reservoirs comprising holes or pores may be filled with a suitable substance at a sufficiently high pressure to cause a portion of the substance to squirt out of the holes or pores. This process may be used to deliver an initial bolus of the substance to the surrounding anatomy.
[0167] One or more of the substance reservoirs disclosed herein may be filled with a suitable substance after the substance reservoir is introduced in an anatomical region. Alternatively, one or more of the substance reservoirs disclosed herein may be filled with a suitable substance before the substance reservoir is introduced in an anatomical region. Alternatively, one or more of the substance reservoirs disclosed herein may be pre-filled with a solid, lyophilized or concentrated substance. The solid, lyophilized or concentrated substance is converted to an active form by introducing a solvent into the substance reservoir. This may be done just before or after the substance reservoir is introduced in an anatomical region. Alternatively, one or more of the substance reservoirs disclosed herein may be pre-filled with an inactive form of a substance. The inactive form of the substance is converted to an active form by introducing an activating agent into the substance reservoir. This may be done just before or after the substance reservoir is introduced in an anatomical region.
[0168] It is to be further appreciated that, as described herein, the implantable portion of a substance delivering spacer device 10 may include a through lumen that may function as a vent and/or drain when such implantable portion device is in a paranasal sinus, air cell, Eustachian tube, opening formed in the tympanum or any other location within the body.
[0169] The devices and methods disclosed herein may be used to mark an anatomical region with a suitable imageable marker. For example, the devices and methods disclosed herein may be used to deliver a radio opaque marker such as a radio opaque contrast agent to an ostium of a paranasal
sinus. This enables a user to image the ostium of the paranasal sinus using X-rays or fluoroscopy.
[0170]One or more of the substance delivery devices disclosed herein may comprise a curved, bent or angled region to enable the drug delivery devices to navigate through the anatomy.
[0171] The distal-most regions of one or more substance delivery devices disclosed herein may comprise an atraumatic tip. The atraumatic tip is used to prevent or reduce damage to the anatomy by the distal-most regions of the one or more substance delivery devices.
[0172] The outer surface of one of more substance delivery devices disclosed herein may comprise a coating that reduces or eliminates the risk of encrusting of the outer surface by a biological material. In one embodiment, the coating comprises a material that absorbs water to form a gel. Examples of such materials include, but are not limited to hyaluronic acid, etc.
[0173] One or more of the substance delivery devices disclosed herein may be designed to be easily removable from the anatomy after completion of a treatment.
[0174] One or more of the substance delivery devices disclosed herein may be refilled after a significant volume of substance filled in a substance reservoir has been delivered to the anatomy.
[0175] One or more of the substance delivery devices disclosed herein may comprise one or more markers to enable a user to locate and/or navigate the substance delivery devices through the anatomy. For example, the substance delivery devices may comprise visual markers to enable the user to determine the depth of insertion of the substance delivery devices into the anatomy. In another example, the substance delivery devices may comprise imaging markers to enable the user to locate and/or navigate the substance delivery devices using imaging modalities such as X-rays, MRI, etc.
[0176] As used herein, the term "opening of a paranasal sinus" shall include any opening in a paranasal sinus or air cell such as natural ostia, surgically
altered natural ostia, surgically created openings, antrostomy openings, ostiotomy openings, burr holes, drilled holes, ethmoidotomy openings, ethmoidectomy openings, natural or man made passageways, etc.
[0177] As used herein, the term "implantable" shall include any device that is maintained in the body of a human or animal for a period ranging from 30 minutes to 60 days.
[0178] In each of the above-described examples wherein an endoscope 400 is employed, the endoscope 400 is shown as being inserted separately form the other devices. However, in any applications or embodiments of the invention where feasible, an endoscope may be attached to or integrated with one or more of the other devices used during the procedure as described in parent application Serial No. .
[0179] It is to be appreciated that Examples 2 and 3 above describe techniques which may be used for introducing the spacer device 10 into frontal sinuses which may or may not have been previously altered by surgery or prior balloon dilations. In some cases, such as where the frontal outflow tract has been previously dilated or modified by surgery so that the fronal sinus FS is relatively easy to access, the operator may simply deliver the spacer device 10 through the constraining tube 42 (or sinus sheath 40, 40a) and into the frontal sinus, with or without the use of forceps or other operative instruments, thereby eliminating the need for the use of a guide catheter, guidewire, dilator or other devices for guiding or facilitating advancement of the spacer device 10 into the frontal sinus as described in Examples 2 and 3.
[0180] It is to be further appreciated that, although Examples 1 , 2 and 3 above describe Triamcinolone Acetonide injectable suspension (Kenalog® 40, Brystol-Myers Squibb Company, Princeton, New Jersey) as the therapeutic agent that is loaded into and elutes from the reservoir, various other therapeutic agents may be used in addition to, or as an alternative to, this Triamcinolone Acetonide injectable suspension. In some cases where it is desired to use the implanted spacer device 10a to deliver a steroid, the steroid may be prepared as a solution rather than a suspension. In such cases, the steroid will be dissolved in a suitable, biologically compatible
solvent. For example, Cyclodextrins have been described as suitable solvents for dissolution of at least some steroids. Khomutov, S. M., Dovbnya, D.V. and Donova, M. V., Dissolution of a Mixture of Steroids in Cyclodextrin Solutions: a Model Description; Pharmaceutical Chemistry Journal; Vol. 35, No. 1 i, pp.627-629 (November, 2001 ).
[0181] In some instances, the devices of the present invention may be used to deliver steroids or other substances in formulations that are commercially available as, or otherwise suitable for, intra-nasal delivery to the nasal mucosa as nasal drops or sprays (i.e., nasal solutions). In at least some cases, such nasal solutions are prepared so that they are similar to nasal secretions and, thus, do not interfere with normal ciliary action. Such nasal solutions usually are isotonic and slightly buffered to a pH of 5.5 to 6.5. In addition, antimicrobial preservatives, similar to those used in ophthalmic preparations, and appropriate drug stabilizers, if required, may be included in the formulation. Various commercial nasal preparations are known and include, for example, antibiotics, steroids, antihistamines, decongestants and ipitropium bromide.
[0182] Where possible and appropriate, any of the substances delivered by devices of the present invention may be in the form of liposomes or nanoparticles (e.g., nanocapsules). The formation and use of liposomes is generally known to those of skill in the art. Liposomes are formed from phospholipids dispersed in an aqueous medium such that they spontaneously form multilamellar concentric biiayer vesicles sometimes referred to as multilamellar vesicles (MLVs). MLVs are typically from 25 nm to 4 μm in diameter. When sonicated, MLVs form small unilamellar vesicles (SUVs) of about 200 to 500 angstroms in diameters having cores which contain the aqueous solution. In general, when dispersed in an aqueous medium, phospholipids can form various structures other than liposomes, depending on the molar ratio of lipid to water. At low molar lipd to water ratios, liposomes will form. The physical characteristics of liposomes depend on pH, tonicity and the presence or non-presence of divalent cations. Liposomes can interact with cells by different mechanisms, including 1) endocytosis (e.g., phagocytosis of the liposome by cells such as macrophages and neutrophils),
adsorption to the cell surface, 2) interaction with cell-surface components, 3) fusion with the plasma cell membrane by insertion of the lipid bilayer of the liposome into the plasma membrane or 4) transfer of liposomal lipids to cellular or subcellular membranes, or vice versa. Varying the liposome formulation can alter which mechanism(s) by which the lyposomes will interact with cells in the paranasal sinus, nasal mucosa, etc.
[0183] A nanocapsule is any nanoparticle that consists of a shell and a space, in which desired substances may be placed. Techniques for forming nanocapsules are known in the art. Polymeric nanocapsules can be made in specific sizes and shapes. They can be produced as monodisperse particles which have precisely defined physical and chemical properties and, thus, can be tailored to facilitate release of the therapeutic or diagnostic substance in response to particular bimolecular triggering mechanisms, such as pH, mucous flow or other conditions present within the paranasal sinus or other area in the ear, nose or throat where the device is implanted. Nanocapsules can be used in the present invention as "smart drugs" which have specific chemical receptors or binding sites that will bind to specific target cells (e.g., cancer cells associated with sinus or nasal tumors or cells associated with inflammatory conditions.
[0184] It is to be appreciated that the invention has been described hereabove with reference to certain examples or embodiments of the invention but that various additions, deletions, alterations and modifications may be made to those examples and embodiments without departing from the intended spirit and scope of the invention. For example, any element or attribute of one embodiment or example may be incorporated into or used with another embodiment or example, unless otherwise specified of if to do so would render the embodiment or example unsuitable for its intended use. Also, where the steps of a method or process have been described or listed in a particular order, the order of such steps may be changed unless otherwise specified or unless doing so would render the method or process unworkable for its intended purpose. All reasonable additions, deletions, modifications and alterations are to be considered equivalents of the described examples
and embodiments and are to be included within the scope of the following claims.
Claims
1. A method for treating ethmoid sinusitis in a patient using a penetrator that has a distal tip and a stopping mark or member located a spaced distance proximal to the distal tip, said spaced distance being less than the known distance between the ethmoid bulla and the ipsalateral sphenoid sinus, the method comprising:
forming an ethmoidotomy channel by advancing the penetrator through the ethmoid bulla in a direction that is non-perpendicular to the skull base and generally directed toward the ipsalateral sphenoid sinus;
stopping advancement of the penetrator when the stopping mark or member is approximately flush with the ethmoid bulla; and
removing the penetrator.
2. A method according to claim 1 , further comprising inserting a spacer device into the ethmoidotomy channel.
3. A method according to claim 2, wherein inserting the spacer device comprises advancing it through a sheath delivered at least partway through the ethmoidotomy channel by the penetrator.
4. A method according to claim 1 , wherein advancing the penetrator comprises advancing a needle.
5. A method according to claim 1 , wherein advancing the penetrator comprises advancing a drill.
6. A method according to claim 1 , wherein stopping advancement of the mark or member comprises viewing a mark of a color on the penetrator that is different from the color of blood or mucosal tissue.
7. A method according to claim 1 , wherein stopping advancement of the stopping mark or member comprises feeling tactile feedback from the penetrator as a stopping member contacts the ethmoid bulla.
8. A method according to claim 1, further comprising releasing a stopping member selected from the group consisting of a shoulder, a projection, a wire loop and a wing from within a sheath disposed over a portion of the penetrator.
9. A method according to claim 1 , wherein stopping advancement of the stopping mark or member comprises contacting a stopping member on the penetrator with the patient's nose.
10. A sinus penetrator device useable for forming an opening in one or more paranasal sinus or ethmoid air cell, the device comprising:
an elongate penetrator having a proximal end and a distal end; and
a stopping mark or member which substantially limits the depth to which the penetrator can penetrate into the sinus or air cell.
11. A device according to claim 10, wherein the penetrator comprises a needle.
12. A device according to claim 10, wherein the penetrator comprises a drill.
13. A device according to claim 10, wherein the stopping mark or member comprises a mark of a color that is different from the color of blood or mucosal tissue so as to be visually distinguishable.
14. A device according to claim 10, wherein the penetrator comprises an elongate member having a curve formed therein.
15. A device according to claim 14, wherein the curve is located about 20 mm to about 24 mm from a distal end of the penetrator.
16. A device according to claim 14, wherein the curve forms and angle of about 33 degrees.
17. A device according to claim 14, wherein the curve has a radius of curvature of about 0.75.
18. A device according to claim 10, wherein the penetrator comprises a needle in combination with a sheath that is positionable over the needle.
19. A device according to claim 18, wherein the stopping mark or member is located on the sheath at a location approximately 2 cm from a distal end of the sheath.
20. A device according to claim 10, wherein the device is to be used for penetration through the ethmoid bulla, and wherein the stopping mark or member comprises a stop member that abuts against the ethmoid bulla as the penetrator is advanced.
21. A device according to claim 20, wherein the stopping mark or member is located such that the distance to which the penetrator may be advanced through the ethmoid bulla is less than the distance between the ethmoid bulla and the ipsalateral sphenoid sinus, thereby substantially preventing the penetrator from entering the sphenoid sinus.
22. A device according to claim 10, wherein the stopping mark or member comprises a shoulder, projection, wire loop or wing that extends generally laterally from the penetrator.
23. A device according to claim 10, wherein the stopping mark or member comprises a stop member that abuts against the subject's nose thereby limiting the extent to which the penetrator can be inserted into the nose.
24. A device for forming an ethmoidotomy in an ethmoid sinus of a patient's head, the device comprising:
an elongate penetrator member having a proximal end and a sharp distal end; a handle coupled with the penetrator member at or near the proximal end; and
a sighting member disposed along the handle or the elongate member at a location to make it visible from an extracorporeal vantage point when the distal end of the elongate member is inserted into the patient, wherein the sighting member is useable by a user of the device to generally aim the distal end of the penetrator in a desired direction within the patient's head.
25. A device according to claim 24, wherein the handle comprises a top elongate member and a bottom elongate member that is attached to and substantially parallel to the top elongate member.
26. A device according to claim 25, further comprising a distal grip portion attached to distal ends of the top and bottom elongate members.
27. A device according to claim 24, which is fully or partially coated with an elastomeric material.
28. A device according to claim 24, wherein the sighting member comprises a fin.
29. A device according to claim 24, wherein the sighting member comprises a member that extends in a plane that is substantially parallel to a plane in which the elongate penetrator extends from the handle.
30. A device according to claim 29, wherein the sighting member further comprises a member that extends in a plane that is substantially normal to the plane in which the elongate penetrator extends from the handle.
31. A device according to claim 24, wherein the elongate working member has a curve, a proximal portion proximal to the curve and a distal portion distal to the curve, and wherein at least a portion of the sighting member is parallel to the distal portion of the elongate working member to thereby provide an indication of the direction or trajectory on which the distal portion of the elongate working member is being advanced.
32. A device according to claim 24, wherein the penetrator member comprises a needle.
33. A device according to claim 24, wherein the penetrator member comprises a drill.
34. A device according to claim 24, further comprising a stopping mark or member that limits the depth to which the penetrator can penetrate into the paranasal sinus or air cell.
35. A device according to claim 34, wherein the penetrator comprises a needle in combination with a sheath that is positionable over the needle.
36. A device according to claim 35 wherein the stopping mark or member is located on the sheath at a location approximately 2 cm from a distal end of the sheath.
37. A substance delivering spacer device that may be loaded with a therapeutic substance for delivery of the therapeutic substance, the device comprising:
an elongate tubular shaft;
an expandable reservoir on the shaft into which the therapeutic substance may be loaded, the reservoir having a substantially cylindrical side wall and tapered ends, openings being formed in the sidewall and tapered ends of the reservoir such that a therapeutic substance loaded into the reservoir will elute through the openings and out of the reservoir.
38. A device according to claim 37, wherein each opening has a diameter of about 20 microns to about 40 microns in diameter.
39. A device according to claim 38, wherein approximately 768 of the openings are formed in the reservoir.
40. A device according to claim 39, wherein approximately 672 openings are formed in the substantially cylindrical side wall and approximately 48 openings are formed in each tapered end of the reservoir.
41. A device according to claim 37, wherein the reservoir has an overall length of about 16 mm.
42. A device according to claim 41 , wherein the substantially cylindrical side wall of the reservoir has a length of about 13 mm and each tapered end portion has a length of about 1.5 mm.
43. A device according to claim 42, wherein the reservoir has a diameter of about 3.0 mm to about 3.5 mm when fully expanded.
44. A device according to claim 37, further comprising one or more retention members that frictionally engage adjacent tissue to hold the device in a desired location within a patient's body.
45. A device according to claim 37, further comprising one or more suture receiving members to facilitate suturing of the device in place within a patient's body.
46. A device according to claim 37, further comprising a constraining sheath that has a retracted position and an advanced position, said constraining sheath extending over said reservoir while the reservoir is in a collapsed state and the constraining sheath is in the advanced position.
47. A device according to claim 46 wherein at least a portion of the constraining sheath is transparent or sufficiently translucent to allow a user to see through the constraining sheath.
48. A system comprising a substance delivering spacer device according to claim 37 in combination with a sinus penetrator and a sheath, the sheath being disposed over the sinus penetrator, wherein the penetrator and sheath are configured to be advanced through a wall of a paranasal sinus or air cell, the penetrator being thereafter removable to leave the sheath in place, wherein the substance delivering spacer device is advanceable into the sheath, the sheath being thereafter removable, leaving the substance delivering spacer device in place within the sinus or air cell and a substance being thereafter injectable into the reservoir such that the substance will elute from the reservoir into the paranasal sinus or air cell.
49. A method for treating sinusitis, the method comprising:
placing an implantable device having a substance eluting reservoir within a paranasal sinus or within the ostium of a paranasal sinus;
introducing a steroid into the substance eluting reservoir so that the steroid elutes from the reservoir in an amount that is effective to treat the sinusitis.
50. A method according to claim 49, wherein introducing the steroid comprises introducing a Triamcinolone Acetontde suspension.
51. A method according to claim 49, wherein the steroid is in the form of a suspension and wherein the method further comprises adding additional liquid to the reservoir.
52. A method according to claim 49, wherein the method further comprises adding additional steroid to the reservoir.
53. A method according to claim 49, wherein introducing the steroid comprises introducing a steroid solution.
54. A method according to claim 53, wherein the steroid solution comprises at least one steroid dissolved in at least one cyclodextrin.
55. A method according to claim 49, wherein the reservoir is expandable and, when substantially fully expanded, has a working length of about 16mm and proximal and distal tapers of about 1.5mm each, a diameter of about 3.0mm and a total of about 768 openings through which the therapeutic substance may elute.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US92273007P | 2007-04-09 | 2007-04-09 | |
US60/922,730 | 2007-04-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008124787A2 true WO2008124787A2 (en) | 2008-10-16 |
WO2008124787A3 WO2008124787A3 (en) | 2008-12-11 |
Family
ID=39831574
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/059786 WO2008124787A2 (en) | 2007-04-09 | 2008-04-09 | Ethmoidotomy system and implantable spacer devices having therapeutic substance delivery capability for treatment of paranasal sinusitis |
Country Status (2)
Country | Link |
---|---|
US (1) | US8864787B2 (en) |
WO (1) | WO2008124787A2 (en) |
Families Citing this family (107)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10105592A1 (en) | 2001-02-06 | 2002-08-08 | Achim Goepferich | Placeholder for drug release in the frontal sinus |
US8317816B2 (en) | 2002-09-30 | 2012-11-27 | Acclarent, Inc. | Balloon catheters and methods for treating paranasal sinuses |
AU2004222340B2 (en) | 2003-03-14 | 2009-11-12 | Intersect Ent, Inc. | Sinus delivery of sustained release therapeutics |
US9089258B2 (en) | 2004-04-21 | 2015-07-28 | Acclarent, Inc. | Endoscopic methods and devices for transnasal procedures |
US8747389B2 (en) | 2004-04-21 | 2014-06-10 | Acclarent, Inc. | Systems for treating disorders of the ear, nose and throat |
US10188413B1 (en) | 2004-04-21 | 2019-01-29 | Acclarent, Inc. | Deflectable guide catheters and related methods |
US7654997B2 (en) | 2004-04-21 | 2010-02-02 | Acclarent, Inc. | Devices, systems and methods for diagnosing and treating sinusitus and other disorders of the ears, nose and/or throat |
US8702626B1 (en) | 2004-04-21 | 2014-04-22 | Acclarent, Inc. | Guidewires for performing image guided procedures |
US7419497B2 (en) | 2004-04-21 | 2008-09-02 | Acclarent, Inc. | Methods for treating ethmoid disease |
US7462175B2 (en) | 2004-04-21 | 2008-12-09 | Acclarent, Inc. | Devices, systems and methods for treating disorders of the ear, nose and throat |
US8932276B1 (en) | 2004-04-21 | 2015-01-13 | Acclarent, Inc. | Shapeable guide catheters and related methods |
US7361168B2 (en) * | 2004-04-21 | 2008-04-22 | Acclarent, Inc. | Implantable device and methods for delivering drugs and other substances to treat sinusitis and other disorders |
US9351750B2 (en) | 2004-04-21 | 2016-05-31 | Acclarent, Inc. | Devices and methods for treating maxillary sinus disease |
US20070167682A1 (en) | 2004-04-21 | 2007-07-19 | Acclarent, Inc. | Endoscopic methods and devices for transnasal procedures |
US8146400B2 (en) | 2004-04-21 | 2012-04-03 | Acclarent, Inc. | Endoscopic methods and devices for transnasal procedures |
US9399121B2 (en) | 2004-04-21 | 2016-07-26 | Acclarent, Inc. | Systems and methods for transnasal dilation of passageways in the ear, nose or throat |
US9554691B2 (en) | 2004-04-21 | 2017-01-31 | Acclarent, Inc. | Endoscopic methods and devices for transnasal procedures |
US20070208252A1 (en) | 2004-04-21 | 2007-09-06 | Acclarent, Inc. | Systems and methods for performing image guided procedures within the ear, nose, throat and paranasal sinuses |
US7410480B2 (en) | 2004-04-21 | 2008-08-12 | Acclarent, Inc. | Devices and methods for delivering therapeutic substances for the treatment of sinusitis and other disorders |
US20060063973A1 (en) | 2004-04-21 | 2006-03-23 | Acclarent, Inc. | Methods and apparatus for treating disorders of the ear, nose and throat |
US20060004323A1 (en) | 2004-04-21 | 2006-01-05 | Exploramed Nc1, Inc. | Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasal or paranasal structures |
US7559925B2 (en) | 2006-09-15 | 2009-07-14 | Acclarent Inc. | Methods and devices for facilitating visualization in a surgical environment |
US7803150B2 (en) | 2004-04-21 | 2010-09-28 | Acclarent, Inc. | Devices, systems and methods useable for treating sinusitis |
US9101384B2 (en) | 2004-04-21 | 2015-08-11 | Acclarent, Inc. | Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, Nose and/or throat |
US8894614B2 (en) | 2004-04-21 | 2014-11-25 | Acclarent, Inc. | Devices, systems and methods useable for treating frontal sinusitis |
US20190314620A1 (en) | 2004-04-21 | 2019-10-17 | Acclarent, Inc. | Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasal or paranasal structures |
US8764729B2 (en) | 2004-04-21 | 2014-07-01 | Acclarent, Inc. | Frontal sinus spacer |
EP2298318A1 (en) | 2005-04-04 | 2011-03-23 | Sinexus, Inc. | Device and methods for treating paranasal sinus conditions |
US8951225B2 (en) | 2005-06-10 | 2015-02-10 | Acclarent, Inc. | Catheters with non-removable guide members useable for treatment of sinusitis |
US8114113B2 (en) | 2005-09-23 | 2012-02-14 | Acclarent, Inc. | Multi-conduit balloon catheter |
US8190389B2 (en) | 2006-05-17 | 2012-05-29 | Acclarent, Inc. | Adapter for attaching electromagnetic image guidance components to a medical device |
US9987025B2 (en) * | 2006-05-26 | 2018-06-05 | Bruce B. Becker | Increased axial load carrying sheathed irrigating balloon catheter |
US20070276314A1 (en) * | 2006-05-26 | 2007-11-29 | Becker Bruce B | Nasolacrimal duct probing, intubating and irrigating device |
US8535707B2 (en) | 2006-07-10 | 2013-09-17 | Intersect Ent, Inc. | Devices and methods for delivering active agents to the osteomeatal complex |
US9820688B2 (en) | 2006-09-15 | 2017-11-21 | Acclarent, Inc. | Sinus illumination lightwire device |
US8439687B1 (en) | 2006-12-29 | 2013-05-14 | Acclarent, Inc. | Apparatus and method for simulated insertion and positioning of guidewares and other interventional devices |
WO2008124787A2 (en) | 2007-04-09 | 2008-10-16 | Acclarent, Inc. | Ethmoidotomy system and implantable spacer devices having therapeutic substance delivery capability for treatment of paranasal sinusitis |
US8118757B2 (en) | 2007-04-30 | 2012-02-21 | Acclarent, Inc. | Methods and devices for ostium measurement |
US8485199B2 (en) | 2007-05-08 | 2013-07-16 | Acclarent, Inc. | Methods and devices for protecting nasal turbinate during surgery |
CN101945621B (en) | 2007-12-18 | 2014-06-18 | 因特尔赛克特耳鼻喉公司 | Self-expanding devices and methods therefor |
US10206821B2 (en) | 2007-12-20 | 2019-02-19 | Acclarent, Inc. | Eustachian tube dilation balloon with ventilation path |
US8182432B2 (en) | 2008-03-10 | 2012-05-22 | Acclarent, Inc. | Corewire design and construction for medical devices |
MX2011001099A (en) | 2008-07-30 | 2011-03-15 | Acclarent Inc | Paranasal ostium finder devices and methods. |
CA2732355A1 (en) | 2008-08-01 | 2010-02-04 | Intersect Ent, Inc. | Methods and devices for crimping self-expanding devices |
IT1391274B1 (en) * | 2008-08-08 | 2011-12-01 | Medica S R L Ab | IRRIGATION AND SUCTION SYSTEM, IN PARTICULAR FOR LAPAROSCOPIC SURGERY |
WO2010022108A2 (en) * | 2008-08-18 | 2010-02-25 | Envisionier Medical Technologies, Inc. | Fluid delivery catheter apparatus |
US8945142B2 (en) | 2008-08-27 | 2015-02-03 | Cook Medical Technologies Llc | Delivery system for implanting nasal ventilation tube |
US20110201996A1 (en) * | 2008-08-27 | 2011-08-18 | Melder Patrick C | Nasal ventilation system and method of using same |
JP5584687B2 (en) | 2008-09-18 | 2014-09-03 | アクラレント インコーポレイテッド | Method and apparatus for treating ear, nose and throat disorders |
US20100241155A1 (en) | 2009-03-20 | 2010-09-23 | Acclarent, Inc. | Guide system with suction |
US8435290B2 (en) | 2009-03-31 | 2013-05-07 | Acclarent, Inc. | System and method for treatment of non-ventilating middle ear by providing a gas pathway through the nasopharynx |
US7978742B1 (en) | 2010-03-24 | 2011-07-12 | Corning Incorporated | Methods for operating diode lasers |
US10357640B2 (en) | 2009-05-15 | 2019-07-23 | Intersect Ent, Inc. | Expandable devices and methods for treating a nasal or sinus condition |
US8834513B2 (en) | 2009-06-05 | 2014-09-16 | Entellus Medical, Inc. | Method and articles for treating the sinus system |
US8282667B2 (en) * | 2009-06-05 | 2012-10-09 | Entellus Medical, Inc. | Sinus dilation catheter |
US8435261B2 (en) | 2009-07-15 | 2013-05-07 | Regents Of The University Of Minnesota | Treatment and placement device for sinusitis applications |
US20130018256A1 (en) * | 2009-11-25 | 2013-01-17 | Hanoch Kislev | Probing system for measuring the direction and speed of mucus flow in vivo |
EP2593165B1 (en) | 2010-07-12 | 2019-09-04 | Ramot at Tel-Aviv University Ltd. | Cannula with anchoring elements |
RU2538235C2 (en) * | 2010-09-22 | 2015-01-10 | Аккларент, Инк. | Methods and devices for treating sinus diseases |
US9155492B2 (en) | 2010-09-24 | 2015-10-13 | Acclarent, Inc. | Sinus illumination lightwire device |
US9022967B2 (en) | 2010-10-08 | 2015-05-05 | Sinopsys Surgical, Inc. | Implant device, tool, and methods relating to treatment of paranasal sinuses |
WO2013016275A1 (en) | 2011-07-22 | 2013-01-31 | Cook Medical Technologies Llc | Irrigation devices adapted to be used with a light source for the identification and treatment of bodily passages |
US9457173B2 (en) | 2011-09-10 | 2016-10-04 | Cook Medical Technologies Llc | Methods of providing access to a salivary duct |
US9283360B2 (en) | 2011-11-10 | 2016-03-15 | Entellus Medical, Inc. | Methods and devices for treating sinusitis |
US9375138B2 (en) | 2011-11-25 | 2016-06-28 | Cook Medical Technologies Llc | Steerable guide member and catheter |
EP2827785A1 (en) | 2012-03-19 | 2015-01-28 | Cook Medical Technologies LLC | Medical devices, methods and kits for delivering medication to a bodily passage |
EP2836170B1 (en) | 2012-04-11 | 2018-02-14 | Sinopsys Surgical, Inc. | Implantation tools, tool assemblies and kits |
WO2013162227A1 (en) * | 2012-04-25 | 2013-10-31 | 주식회사 고영테크놀러지 | Navigation system for surgery |
CN102789733A (en) * | 2012-08-24 | 2012-11-21 | 王学建 | Preoperative trainer of endoscopic sinus surgery |
WO2014071014A1 (en) | 2012-11-01 | 2014-05-08 | Muffin Incorporated | Implements for identifying sheath migration |
DK2903575T3 (en) | 2013-01-25 | 2018-01-22 | Dcs Surgical Inc | IMPLANT DEVICE AND NUTRITIONAL ACCESS KIT |
CA2903848C (en) | 2013-03-14 | 2022-03-29 | Intersect Ent, Inc. | Systems, devices, and method for treating a sinus condition |
US9956383B2 (en) | 2013-03-15 | 2018-05-01 | Cook Medical Technologies Llc | Medical devices and methods for providing access to a bodily passage during dilation |
US9433437B2 (en) | 2013-03-15 | 2016-09-06 | Acclarent, Inc. | Apparatus and method for treatment of ethmoid sinusitis |
US9629684B2 (en) | 2013-03-15 | 2017-04-25 | Acclarent, Inc. | Apparatus and method for treatment of ethmoid sinusitis |
US20150100042A1 (en) * | 2013-10-07 | 2015-04-09 | Impel Neuropharma Inc. | Muroid Family Nasal Device |
WO2015069433A1 (en) | 2013-10-16 | 2015-05-14 | Sinopsys Surgical, Inc. | Apparatuses, tools and kits relating to fluid manipulation treatments of paranasal sinuses |
CN104605900B (en) * | 2013-11-04 | 2017-04-12 | 上海交通大学医学院附属第九人民医院 | Skin expander capable of simultaneously providing biological additive effect |
US20140243872A1 (en) * | 2013-12-13 | 2014-08-28 | Scott Cordray | Reusable sinus dilation instrument and method of use |
US10016580B2 (en) | 2013-12-17 | 2018-07-10 | Biovision Technologies, Llc | Methods for treating sinus diseases |
US9516995B2 (en) | 2013-12-17 | 2016-12-13 | Biovision Technologies, Llc | Surgical device for performing a sphenopalatine ganglion block procedure |
US9510743B2 (en) | 2013-12-17 | 2016-12-06 | Biovision Technologies, Llc | Stabilized surgical device for performing a sphenopalatine ganglion block procedure |
US9694163B2 (en) | 2013-12-17 | 2017-07-04 | Biovision Technologies, Llc | Surgical device for performing a sphenopalatine ganglion block procedure |
WO2015098229A1 (en) * | 2013-12-26 | 2015-07-02 | オリンパス株式会社 | Insufflator |
WO2015106118A1 (en) | 2014-01-09 | 2015-07-16 | Sonitec Llc | Systems and methods using ultrasound for treatment |
EP2898920B1 (en) | 2014-01-24 | 2018-06-06 | Cook Medical Technologies LLC | Articulating balloon catheter |
US9937323B2 (en) | 2014-02-28 | 2018-04-10 | Cook Medical Technologies Llc | Deflectable catheters, systems, and methods for the visualization and treatment of bodily passages |
WO2016015002A1 (en) | 2014-07-24 | 2016-01-28 | Sinopsys Surgical, Inc. | Paranasal sinus access implant devices and related products and methods |
USD772406S1 (en) | 2014-12-16 | 2016-11-22 | Biovision Technologies, Llc | Surgical device |
CA2984207A1 (en) | 2015-05-12 | 2016-11-17 | National University Of Ireland Galway | Devices for therapeutic nasal neuromodulation and associated methods and systems |
JP7014610B2 (en) | 2015-06-29 | 2022-02-01 | ライラ・セラピューティクス・インコーポレーテッド | Implantable scaffolding for the treatment of sinusitis |
US10159586B2 (en) | 2015-06-29 | 2018-12-25 | 480 Biomedical Inc. | Scaffold loading and delivery systems |
US10232082B2 (en) | 2015-06-29 | 2019-03-19 | 480 Biomedical, Inc. | Implantable scaffolds for treatment of sinusitis |
US10828123B2 (en) * | 2015-07-02 | 2020-11-10 | Nico Corporation | Navigation stylet for a tissue access system |
US20170080182A1 (en) * | 2015-09-23 | 2017-03-23 | Brian William Rotenberg | Bilateral Frontal Sinus Device |
US10973664B2 (en) | 2015-12-30 | 2021-04-13 | Lyra Therapeutics, Inc. | Scaffold loading and delivery systems |
US10512764B2 (en) * | 2016-10-25 | 2019-12-24 | Acclarent, Inc. | Actuation features for dilation system |
US10195376B2 (en) * | 2017-01-03 | 2019-02-05 | Alex Nyirucz | Device and method for administration of compositions to the eustachian tube |
US10201639B2 (en) | 2017-05-01 | 2019-02-12 | 480 Biomedical, Inc. | Drug-eluting medical implants |
US11523942B2 (en) | 2017-08-10 | 2022-12-13 | Biosense Webster (Israel) Ltd. | Medical suction tool for a Eustachian tube |
CA3076375C (en) | 2017-09-20 | 2022-08-09 | Sinopsys Surgical, Inc. | Paranasal sinus fluid access implantation tools, assemblies, kits and methods |
US10525240B1 (en) | 2018-06-28 | 2020-01-07 | Sandler Scientific LLC | Sino-nasal rinse delivery device with agitation, flow-control and integrated medication management system |
US11419671B2 (en) | 2018-12-11 | 2022-08-23 | Neurent Medical Limited | Systems and methods for therapeutic nasal neuromodulation |
WO2020209961A1 (en) | 2019-04-08 | 2020-10-15 | Udayan Patel | Inflatable balloon over catheter with bypass passageway |
US11883091B2 (en) | 2020-04-09 | 2024-01-30 | Neurent Medical Limited | Systems and methods for improving sleep with therapeutic nasal treatment |
US11896818B2 (en) | 2020-04-09 | 2024-02-13 | Neurent Medical Limited | Systems and methods for therapeutic nasal treatment |
EP4304489A1 (en) * | 2021-03-08 | 2024-01-17 | Lyra Therapeutics, Inc. | Implantable corticosteroid matrix for sinus condition |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060063973A1 (en) * | 2004-04-21 | 2006-03-23 | Acclarent, Inc. | Methods and apparatus for treating disorders of the ear, nose and throat |
US20060085027A1 (en) * | 2001-05-22 | 2006-04-20 | Sanostec Corp. | Nasal congestion, obstruction relief, and drug delivery |
US20060106361A1 (en) * | 2004-04-21 | 2006-05-18 | Acclarent, Inc. | Devices and methods for delivering therapeutic substances for the treatment of sinusitis and other disorders |
US20060116749A1 (en) * | 2003-07-18 | 2006-06-01 | Broncus Technologies, Inc. | Devices for maintaining patency of surgically created channels in tissue |
US20060211752A1 (en) * | 2004-03-16 | 2006-09-21 | Kohn Leonard D | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression |
US20060271024A1 (en) * | 2005-01-25 | 2006-11-30 | Michael Gertner | Nasal Cavity Treatment Apparatus |
US20070020196A1 (en) * | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension |
US20070073269A1 (en) * | 2005-09-23 | 2007-03-29 | Becker Bruce B | Multi-conduit balloon catheter |
US20070135789A1 (en) * | 2004-04-21 | 2007-06-14 | Acclarent, Inc. | Use of mechanical dilator devices to enlarge ostia of paranasal sinuses and other passages in the ear, nose, throat and paranasal sinuses |
Family Cites Families (853)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US513667A (en) | 1894-01-30 | Sliding staple for hasps | ||
US2899227A (en) | 1959-08-11 | Charles-louis gschwend | ||
US504424A (en) | 1893-09-05 | Oscar de pezzer | ||
US446173A (en) | 1891-02-10 | Hasp and staple | ||
US705346A (en) | 1901-11-02 | 1902-07-22 | Jonathan R Hamilton | Dilator. |
US816792A (en) | 1904-09-06 | 1906-04-03 | Oliver H P Green | Lock. |
US798775A (en) | 1905-04-13 | 1905-09-05 | Valorus A Bradbury | Dispensing-bottle. |
US1024098A (en) * | 1908-02-28 | 1912-04-23 | Isaac T Price | Oscillating engine. |
US1080934A (en) | 1912-08-19 | 1913-12-09 | Walter L Shackleford | Rectal tube. |
US1200267A (en) | 1915-02-04 | 1916-10-03 | Motors Lock Company Of America | Lock for automobile-hoods. |
US1650959A (en) | 1926-04-08 | 1927-11-29 | Louis K Pitman | Surgical instrument |
US1735519A (en) | 1926-07-17 | 1929-11-12 | Arlyn T Vance | Physician's dilator |
US1878671A (en) | 1929-07-02 | 1932-09-20 | John Murray | Dilator |
US1828986A (en) | 1929-09-26 | 1931-10-27 | Golder E Stevens | Dilating irrigator |
US2201749A (en) | 1939-02-15 | 1940-05-21 | Vandegrift Middleton | Expanding vein tube |
US2525183A (en) | 1947-03-20 | 1950-10-10 | Jehu M Robison | Antral pressure device |
US2493326A (en) | 1949-03-01 | 1950-01-03 | John H Trinder | Tampon for control of intractable nasal hemorrhages |
US2847997A (en) | 1956-01-13 | 1958-08-19 | James J Tibone | Catheter |
US2906179A (en) | 1957-01-28 | 1959-09-29 | North American Aviation Inc | Vector gage |
US3037286A (en) | 1957-01-28 | 1962-06-05 | North American Aviation Inc | Vector gage |
US3009265A (en) | 1960-05-09 | 1961-11-21 | Superior Plastics Inc | Anatomical device |
US2995832A (en) | 1960-08-01 | 1961-08-15 | Alderson Res Lab Inc | Training aid for intravenous therapy |
US3173418A (en) | 1961-01-10 | 1965-03-16 | Ostap E Baran | Double-wall endotracheal cuff |
US3435826A (en) | 1964-05-27 | 1969-04-01 | Edwards Lab Inc | Embolectomy catheter |
US3347061A (en) | 1965-01-11 | 1967-10-17 | Eaton Yale & Towne | Flexible drive mechanism |
US3393073A (en) | 1965-04-16 | 1968-07-16 | Eastman Kodak Co | High contrast photographic emulsions |
US3376659A (en) * | 1965-06-09 | 1968-04-09 | Bard Inc C R | Demonstration device |
US3447061A (en) * | 1965-07-12 | 1969-05-27 | Basic Inc | Multi-phase rectifier with inherent phase balance |
US3384970A (en) | 1965-09-22 | 1968-05-28 | Boice Gages Inc | Precision coordinates measurement apparatus for gaging and layout operations |
US3486539A (en) | 1965-09-28 | 1969-12-30 | Jacuzzi Bros Inc | Liquid dispensing and metering assembly |
US3469578A (en) | 1965-10-12 | 1969-09-30 | Howard R Bierman | Infusion device for ambulatory patients with flow control means |
US3509638A (en) | 1966-08-04 | 1970-05-05 | Midland Ross Corp | Treating apparatus |
US3506005A (en) | 1967-02-23 | 1970-04-14 | Arthur S Gilio | Pressure infusion device for medical use |
US3552384A (en) | 1967-07-03 | 1971-01-05 | American Hospital Supply Corp | Controllable tip guide body and catheter |
US3515888A (en) | 1967-10-27 | 1970-06-02 | California Computer Products | Manual optical digitizer |
US3481043A (en) | 1967-12-12 | 1969-12-02 | Bendix Corp | Gaging machine |
US3531868A (en) | 1968-04-18 | 1970-10-06 | Ford Motor Co | Surface scanner for measuring the coordinates of points on a three-dimensional surface |
US3527220A (en) | 1968-06-28 | 1970-09-08 | Fairchild Hiller Corp | Implantable drug administrator |
US3504935A (en) * | 1969-02-03 | 1970-04-07 | Carl W Gullihur | Swivel coupling for fluid conduit |
US3993073A (en) | 1969-04-01 | 1976-11-23 | Alza Corporation | Novel drug delivery device |
US3967618A (en) | 1969-04-01 | 1976-07-06 | Alza Corporation | Drug delivery device |
US3948262A (en) | 1969-04-01 | 1976-04-06 | Alza Corporation | Novel drug delivery device |
US3624661A (en) | 1969-05-14 | 1971-11-30 | Honeywell Inc | Electrographic printing system with plural staggered electrode rows |
US3834394A (en) | 1969-11-21 | 1974-09-10 | R Sessions | Occlusion device and method and apparatus for inserting the same |
US3903893A (en) | 1970-05-04 | 1975-09-09 | Alexander L Scheer | Nasal hemostatic device |
US4069307A (en) | 1970-10-01 | 1978-01-17 | Alza Corporation | Drug-delivery device comprising certain polymeric materials for controlled release of drug |
GB1340788A (en) | 1971-02-04 | 1974-01-30 | Matburn Holdings Ltd | Nasal tampons |
US3731963A (en) | 1971-04-20 | 1973-05-08 | R Pond | Electrically actuated lock mechanism |
US3804081A (en) | 1971-07-29 | 1974-04-16 | Olympus Optical Co | Endoscope |
US3802096A (en) | 1971-08-09 | 1974-04-09 | H Matern | Composite model for medical study |
US3948254A (en) | 1971-11-08 | 1976-04-06 | Alza Corporation | Novel drug delivery device |
US3850176A (en) | 1972-02-07 | 1974-11-26 | G Gottschalk | Nasal tampon |
US3910617A (en) | 1972-02-20 | 1975-10-07 | Square D Co | Solenoid operated electric strike |
JPS4932484U (en) | 1972-06-19 | 1974-03-20 | ||
JPS4920979A (en) | 1972-06-19 | 1974-02-23 | ||
US3800788A (en) | 1972-07-12 | 1974-04-02 | N White | Antral catheter for reduction of fractures |
CH557178A (en) | 1972-08-10 | 1974-12-31 | Siemens Ag | DEVICE FOR DISPENSING DRUGS. |
US4016251A (en) | 1972-08-17 | 1977-04-05 | Alza Corporation | Vaginal drug dispensing device |
US3792391A (en) | 1972-12-18 | 1974-02-12 | L Ewing | Electrically operated two position electromechanical mechanism |
US3921636A (en) | 1973-01-15 | 1975-11-25 | Alza Corp | Novel drug delivery device |
US3993069A (en) | 1973-03-26 | 1976-11-23 | Alza Corporation | Liquid delivery device bladder |
US3847145A (en) | 1973-04-13 | 1974-11-12 | M Grossan | Nasal irrigation system |
US4450150A (en) | 1973-05-17 | 1984-05-22 | Arthur D. Little, Inc. | Biodegradable, implantable drug delivery depots, and method for preparing and using the same |
US3859993A (en) | 1973-08-27 | 1975-01-14 | Daniel G Bitner | Operating table accessory |
US3993072A (en) | 1974-08-28 | 1976-11-23 | Alza Corporation | Microporous drug delivery device |
US4052505A (en) | 1975-05-30 | 1977-10-04 | Alza Corporation | Ocular therapeutic system manufactured from copolymer |
DE2541084C3 (en) | 1975-09-15 | 1978-12-07 | Siemens Ag, 1000 Berlin Und 8000 Muenchen | Method for producing a self-supporting coil in the winding area |
US4102342A (en) | 1975-12-29 | 1978-07-25 | Taichiro Akiyama | Valved device |
US4138151A (en) | 1976-07-30 | 1979-02-06 | Olympus Optical Company Limited | Detent device for locking the lid of a cassette receiving compartment of a tape recorder |
US4471779A (en) | 1976-08-25 | 1984-09-18 | Becton, Dickinson And Company | Miniature balloon catheter |
US4207890A (en) | 1977-01-04 | 1980-06-17 | Mcneilab, Inc. | Drug-dispensing device and method |
JPS567971Y2 (en) | 1977-07-23 | 1981-02-21 | ||
US4184497A (en) | 1977-08-26 | 1980-01-22 | University Of Utah | Peritoneal dialysis catheter |
US4198766A (en) * | 1978-06-21 | 1980-04-22 | Baxter Travenol Laboratories, Inc. | Intravenous training/demonstration aid |
USRE31351E (en) | 1978-08-04 | 1983-08-16 | Bell Telephone Laboratories, Incorporated | Feedback nonlinear equalization of modulated data signals |
US4213095A (en) | 1978-08-04 | 1980-07-15 | Bell Telephone Laboratories, Incorporated | Feedforward nonlinear equalization of modulated data signals |
US4217898A (en) | 1978-10-23 | 1980-08-19 | Alza Corporation | System with microporous reservoir having surface for diffusional delivery of agent |
US4268115A (en) | 1979-06-01 | 1981-05-19 | Tetra-Tech, Inc. | Quick-release fiber-optic connector |
US4299226A (en) | 1979-08-08 | 1981-11-10 | Banka Vidya S | Coronary dilation method |
JPS5628334A (en) | 1979-08-14 | 1981-03-19 | Nissan Motor Co Ltd | Automatic change gear |
US4299227A (en) | 1979-10-19 | 1981-11-10 | Lincoff Harvey A | Ophthalmological appliance |
US4312353A (en) * | 1980-05-09 | 1982-01-26 | Mayfield Education And Research Fund | Method of creating and enlarging an opening in the brain |
US4338941A (en) | 1980-09-10 | 1982-07-13 | Payton Hugh W | Apparatus for arresting posterior nosebleeds |
DE3041873C2 (en) | 1980-11-06 | 1982-12-23 | Danfoss A/S, 6430 Nordborg | Device for generating a speed-dependent control pressure |
USD269204S (en) | 1981-02-05 | 1983-05-31 | Trepp Charles A | Dental hygiene device |
US4437856A (en) | 1981-02-09 | 1984-03-20 | Alberto Valli | Peritoneal catheter device for dialysis |
FR2502499B1 (en) | 1981-03-27 | 1987-01-23 | Farcot Jean Christian | APPARATUS FOR BLOOD RETROPERFUSION, IN PARTICULAR FOR THE TREATMENT OF INFARCTUS BY INJECTION OF ARTERIAL BLOOD INTO THE CORONARY SINUS |
CH653400A5 (en) | 1981-06-17 | 1985-12-31 | Bauer Kaba Ag | LOCK CYLINDER. |
US4435716A (en) | 1981-09-14 | 1984-03-06 | Adrian Zandbergen | Method of making a conical spiral antenna |
US4571239A (en) | 1982-03-01 | 1986-02-18 | Heyman Arnold M | Catheter-stylet assembly for slipover urethral instruments |
US5370675A (en) | 1992-08-12 | 1994-12-06 | Vidamed, Inc. | Medical probe device and method |
GB2125874B (en) | 1982-08-17 | 1985-08-14 | Michael David Dunn | Solenoid operated locks |
US4464175A (en) | 1982-08-25 | 1984-08-07 | Altman Alan R | Multipurpose tamponade and thrombosclerotherapy tube |
US4499899A (en) * | 1983-01-21 | 1985-02-19 | Brimfield Precision, Inc. | Fiber-optic illuminated microsurgical scissors |
US4581017B1 (en) | 1983-03-07 | 1994-05-17 | Bard Inc C R | Catheter systems |
US4639244A (en) | 1983-05-03 | 1987-01-27 | Nabil I. Rizk | Implantable electrophoretic pump for ionic drugs and associated methods |
US4564364A (en) | 1983-05-26 | 1986-01-14 | Alza Corporation | Active agent dispenser |
EP0129634B1 (en) | 1983-06-27 | 1988-05-04 | Börje Drettner | An instrument for the treatment of sinusitis |
USD283921S (en) | 1983-06-27 | 1986-05-20 | Difco Laboratories Incorporated | Blood collector |
US4554929A (en) | 1983-07-13 | 1985-11-26 | Advanced Cardiovascular Systems, Inc. | Catheter guide wire with short spring tip and method of using the same |
NL8302648A (en) * | 1983-07-26 | 1985-02-18 | Fundatech Sa | APPARATUS FOR SUPPLY AND EXTRACTION OF A LIQUID SUBSTANCE TO RESP. FROM THE JAWS. |
US4675613A (en) | 1983-08-11 | 1987-06-23 | Hewlett-Packard Company | Noise compensated synchronous detector system |
US4571240A (en) | 1983-08-12 | 1986-02-18 | Advanced Cardiovascular Systems, Inc. | Catheter having encapsulated tip marker |
CA1232814A (en) | 1983-09-16 | 1988-02-16 | Hidetoshi Sakamoto | Guide wire for catheter |
US4585000A (en) | 1983-09-28 | 1986-04-29 | Cordis Corporation | Expandable device for treating intravascular stenosis |
USD284892S (en) | 1983-09-29 | 1986-07-29 | Glassman Jacob A | Biliary exploratory balloon catheter with replaceable lead-tip |
SE442164B (en) | 1984-01-11 | 1985-12-09 | Olle Berg | DEVICE FOR NAVIGATION WALL OPERATIONS |
US4589868A (en) | 1984-03-12 | 1986-05-20 | Dretler Stephen P | Expandable dilator-catheter |
JPS60253428A (en) | 1984-05-30 | 1985-12-14 | 住友電気工業株式会社 | Fiberscope with bending mechanism |
US4851228A (en) | 1984-06-20 | 1989-07-25 | Merck & Co., Inc. | Multiparticulate controlled porosity osmotic |
US4596528A (en) | 1984-07-02 | 1986-06-24 | Lewis Leonard A | Simulated skin and method |
US5019075A (en) | 1984-10-24 | 1991-05-28 | The Beth Israel Hospital | Method and apparatus for angioplasty |
US4637389A (en) | 1985-04-08 | 1987-01-20 | Heyden Eugene L | Tubular device for intubation |
US4607622A (en) | 1985-04-11 | 1986-08-26 | Charles D. Fritch | Fiber optic ocular endoscope |
US4619274A (en) | 1985-04-18 | 1986-10-28 | Advanced Cardiovascular Systems, Inc. | Torsional guide wire with attenuated diameter |
US4645495A (en) | 1985-06-26 | 1987-02-24 | Vaillancourt Vincent L | Vascular access implant needle patch |
IT1182613B (en) | 1985-10-15 | 1987-10-05 | Olivetti & Co Spa | KEY WITH SELECTIVELY ACTIVATED DISPLAY AND KEYBOARD USING SUCH KEY |
US4748986A (en) | 1985-11-26 | 1988-06-07 | Advanced Cardiovascular Systems, Inc. | Floppy guide wire with opaque tip |
US4691948A (en) | 1985-11-27 | 1987-09-08 | A-Dec, Inc. | Fail-secure lock system |
US4669469A (en) | 1986-02-28 | 1987-06-02 | Devices For Vascular Intervention | Single lumen atherectomy catheter device |
US5350395A (en) | 1986-04-15 | 1994-09-27 | Yock Paul G | Angioplasty apparatus facilitating rapid exchanges |
US4708834A (en) | 1986-05-01 | 1987-11-24 | Pharmacaps, Inc. | Preparation of gelatin-encapsulated controlled release composition |
US4672961A (en) | 1986-05-19 | 1987-06-16 | Davies David H | Retrolasing catheter and method |
US4795439A (en) | 1986-06-06 | 1989-01-03 | Edward Weck Incorporated | Spiral multi-lumen catheter |
CH668188A5 (en) | 1986-06-09 | 1988-12-15 | Franz Rappai | Corticosteroid ointment compsns. - comprise e.g. dexamethasone in poly:alkylene glycol base, and are used esp. for treating rhinitis |
US5019372A (en) | 1986-06-27 | 1991-05-28 | The Children's Medical Center Corporation | Magnetically modulated polymeric drug release system |
US4854330A (en) | 1986-07-10 | 1989-08-08 | Medrad, Inc. | Formed core catheter guide wire assembly |
US4920967A (en) * | 1986-07-18 | 1990-05-01 | Pfizer Hospital Products Group, Inc. | Doppler tip wire guide |
US4847258A (en) | 1986-08-26 | 1989-07-11 | Ciba-Geigy Corporation | Substituted benzoylphenylureas compounds useful as pesticides |
US4803076A (en) | 1986-09-04 | 1989-02-07 | Pfizer Inc. | Controlled release device for an active substance |
US4726772A (en) * | 1986-12-01 | 1988-02-23 | Kurt Amplatz | Medical simulator |
US5312430A (en) * | 1986-12-09 | 1994-05-17 | Rosenbluth Robert F | Balloon dilation catheter |
US5030227A (en) | 1988-06-02 | 1991-07-09 | Advanced Surgical Intervention, Inc. | Balloon dilation catheter |
US4771776A (en) | 1987-01-06 | 1988-09-20 | Advanced Cardiovascular Systems, Inc. | Dilatation catheter with angled balloon and method |
US4819619A (en) | 1987-01-16 | 1989-04-11 | Augustine Scott D | Device for inserting a nasal tube |
US4815478A (en) | 1987-02-17 | 1989-03-28 | Medtronic Versaflex, Inc. | Steerable guidewire with deflectable tip |
US4736970A (en) | 1987-03-09 | 1988-04-12 | Mcgourty Thomas K | Electrically controlled door lock |
US4811743A (en) | 1987-04-21 | 1989-03-14 | Cordis Corporation | Catheter guidewire |
US4793359A (en) | 1987-04-24 | 1988-12-27 | Gv Medical, Inc. | Centering balloon structure for transluminal angioplasty catheter |
US4748969A (en) | 1987-05-07 | 1988-06-07 | Circon Corporation | Multi-lumen core deflecting endoscope |
US4867138A (en) | 1987-05-13 | 1989-09-19 | Olympus Optical Co., Ltd. | Rigid electronic endoscope |
US4755171A (en) | 1987-05-29 | 1988-07-05 | Tennant Jerald L | Tubular surgical device |
US4796629A (en) | 1987-06-03 | 1989-01-10 | Joseph Grayzel | Stiffened dilation balloon catheter device |
DE3719250A1 (en) | 1987-06-10 | 1988-12-22 | Kellner Hans Joerg Dr Med | ENDOSCOPE |
SE8704767L (en) | 1987-11-30 | 1989-05-31 | Sigmund Johannes Loefstedt | NEW METHOD FOR ADMINISTRATION OF MEDICINAL PRODUCTS |
US5041089A (en) | 1987-12-11 | 1991-08-20 | Devices For Vascular Intervention, Inc. | Vascular dilation catheter construction |
US4846186A (en) | 1988-01-12 | 1989-07-11 | Cordis Corporation | Flexible guidewire |
US4917667A (en) | 1988-02-11 | 1990-04-17 | Retroperfusion Systems, Inc. | Retroperfusion balloon catheter and method |
US5372138A (en) | 1988-03-21 | 1994-12-13 | Boston Scientific Corporation | Acousting imaging catheters and the like |
US4883465A (en) | 1988-05-24 | 1989-11-28 | Brennan H George | Nasal tampon and method for using |
US4998917A (en) * | 1988-05-26 | 1991-03-12 | Advanced Cardiovascular Systems, Inc. | High torque steerable dilatation catheter |
US4940062A (en) | 1988-05-26 | 1990-07-10 | Advanced Cardiovascular Systems, Inc. | Guiding member with deflectable tip |
AU618613B2 (en) | 1988-06-13 | 1992-01-02 | Yaroslavsky Mezhotraslevoi Nauchno-Tekhnichesky Tsentr | Device for diagnosing and treating nasal diseases |
DE68901817T2 (en) | 1988-06-29 | 1993-01-07 | Jaico Cv | PRESSURE CAPSULE FOR SPRAY CONTAINERS, AND SPRAY CONTAINERS USING SUCH A CAPSULE. |
US5267965A (en) | 1988-07-06 | 1993-12-07 | Ethicon, Inc. | Safety trocar |
EP0355996A3 (en) | 1988-07-21 | 1990-05-02 | Advanced Interventional Systems, Inc. | Guidance and delivery system for high-energy pulsed laser light and endoscope |
US5067489A (en) | 1988-08-16 | 1991-11-26 | Flexmedics Corporation | Flexible guide with safety tip |
US4917419A (en) | 1988-08-22 | 1990-04-17 | Mora Jr Saturnino F | Electromechanical door lock system |
US4898577A (en) | 1988-09-28 | 1990-02-06 | Advanced Cardiovascular Systems, Inc. | Guiding cathether with controllable distal tip |
JPH0296072A (en) | 1988-09-30 | 1990-04-06 | Aisin Seiki Co Ltd | Lid lock device |
US4943275A (en) | 1988-10-14 | 1990-07-24 | Abiomed Limited Partnership | Insertable balloon with curved support |
US4984581A (en) | 1988-10-12 | 1991-01-15 | Flexmedics Corporation | Flexible guide having two-way shape memory alloy |
JPH066342B2 (en) | 1988-10-14 | 1994-01-26 | 三菱重工業株式会社 | Shape memory film and its use |
US5090910A (en) | 1988-10-14 | 1992-02-25 | Narlo Jeanie R | Multiple three dimensional facial display system |
US4961433A (en) | 1988-11-02 | 1990-10-09 | Cardiometrics, Inc. | Guide wire assembly with electrical functions and male and female connectors for use therewith |
US5001825A (en) | 1988-11-03 | 1991-03-26 | Cordis Corporation | Catheter guidewire fabrication method |
US5189110A (en) | 1988-12-23 | 1993-02-23 | Asahi Kasei Kogyo Kabushiki Kaisha | Shape memory polymer resin, composition and the shape memorizing molded product thereof |
US5087246A (en) | 1988-12-29 | 1992-02-11 | C. R. Bard, Inc. | Dilation catheter with fluted balloon |
US4998916A (en) | 1989-01-09 | 1991-03-12 | Hammerslag Julius G | Steerable medical device |
US5221260A (en) | 1989-01-13 | 1993-06-22 | Scimed Life Systems, Inc. | Innerless dilatation balloon catheter |
US5087244A (en) | 1989-01-31 | 1992-02-11 | C. R. Bard, Inc. | Catheter and method for locally applying medication to the wall of a blood vessel or other body lumen |
US5662674A (en) | 1989-02-03 | 1997-09-02 | Debbas; Elie | Apparatus for locating a breast mass |
US4966163A (en) | 1989-02-14 | 1990-10-30 | Advanced Cardiovascular Systems, Inc. | Extendable guidewire for vascular procedures |
US5024650A (en) | 1989-02-15 | 1991-06-18 | Matsushita Electric Works, Ltd. | Stress dissolving refreshment system |
SU1662571A1 (en) | 1989-03-01 | 1991-07-15 | Курский Государственный Медицинский Институт | Process for preparing x-ray contrast agent for investigating sinuses |
US4946466A (en) | 1989-03-03 | 1990-08-07 | Cordis Corporation | Transluminal angioplasty apparatus |
RU1768142C (en) | 1989-03-29 | 1992-10-15 | Ярославский Межотраслевой Научно-Технический Центр | Device for therapy of sinuitis |
US4919112B1 (en) | 1989-04-07 | 1993-12-28 | Low-cost semi-disposable endoscope | |
US5069226A (en) | 1989-04-28 | 1991-12-03 | Tokin Corporation | Catheter guidewire with pseudo elastic shape memory alloy |
US5009655A (en) * | 1989-05-24 | 1991-04-23 | C. R. Bard, Inc. | Hot tip device with optical diagnostic capability |
EP0427852B1 (en) | 1989-05-24 | 1994-07-20 | Tsukada Medical Research Co., Ltd. | Balloon-carrying instrument for use in continuously injecting medical fluid |
US4994033A (en) | 1989-05-25 | 1991-02-19 | Schneider (Usa) Inc. | Intravascular drug delivery dilatation catheter |
WO1990014865A1 (en) | 1989-06-07 | 1990-12-13 | Ultra-Klean Ltd | Exercise and toning apparatus |
US5207695A (en) | 1989-06-19 | 1993-05-04 | Trout Iii Hugh H | Aortic graft, implantation device, and method for repairing aortic aneurysm |
DE69023515T2 (en) | 1989-06-28 | 1996-04-04 | David S Zimmon | INFLATABLE TAMPONADE DEVICES. |
DE3923851C1 (en) | 1989-07-19 | 1990-08-16 | Richard Wolf Gmbh, 7134 Knittlingen, De | |
DE3927001A1 (en) | 1989-08-16 | 1991-02-21 | Lucien C Dr Med Olivier | CATHETER SYSTEM |
US5180368A (en) | 1989-09-08 | 1993-01-19 | Advanced Cardiovascular Systems, Inc. | Rapidly exchangeable and expandable cage catheter for repairing damaged blood vessels |
US5021043A (en) | 1989-09-11 | 1991-06-04 | C. R. Bard, Inc. | Method and catheter for dilatation of the lacrimal system |
US5169386A (en) | 1989-09-11 | 1992-12-08 | Bruce B. Becker | Method and catheter for dilatation of the lacrimal system |
DE69002295T2 (en) | 1989-09-25 | 1993-11-04 | Schneider Usa Inc | MULTILAYER EXTRUSION AS A METHOD FOR PRODUCING BALLOONS FOR VESSEL PLASTICS. |
US5256144A (en) | 1989-11-02 | 1993-10-26 | Danforth Biomedical, Inc. | Low profile, high performance interventional catheters |
US5335671A (en) | 1989-11-06 | 1994-08-09 | Mectra Labs, Inc. | Tissue removal assembly with provision for an electro-cautery device |
US5026384A (en) | 1989-11-07 | 1991-06-25 | Interventional Technologies, Inc. | Atherectomy systems and methods |
US5112228A (en) * | 1989-11-13 | 1992-05-12 | Advanced Cardiovascular Systems, Inc. | Vascular model |
US5215105A (en) | 1989-11-14 | 1993-06-01 | Custom Medical Concepts, Inc. | Method of treating epidural lesions |
US5137517A (en) | 1989-11-28 | 1992-08-11 | Scimed Life Systems, Inc. | Device and method for gripping medical shaft |
US5053007A (en) | 1989-12-14 | 1991-10-01 | Scimed Life Systems, Inc. | Compression balloon protector for a balloon dilatation catheter and method of use thereof |
US5439446A (en) | 1994-06-30 | 1995-08-08 | Boston Scientific Corporation | Stent and therapeutic delivery system |
US5843089A (en) | 1990-12-28 | 1998-12-01 | Boston Scientific Corporation | Stent lining |
US5209730A (en) * | 1989-12-19 | 1993-05-11 | Scimed Life Systems, Inc. | Method for placement of a balloon dilatation catheter across a stenosis and apparatus therefor |
US5156595A (en) | 1989-12-28 | 1992-10-20 | Scimed Life Systems, Inc. | Dilatation balloon catheter and method of manufacturing |
USD329496S (en) | 1990-02-20 | 1992-09-15 | Celia Clarke | Needle depth gauge |
US5060660A (en) | 1990-02-28 | 1991-10-29 | C. R. Bard, Inc. | Steerable extendable guidewire with adjustable tip |
US5125915A (en) | 1990-03-02 | 1992-06-30 | Cardiopulmonics, Inc. | Locking y-connector for selective attachment to exterior of medical tubing |
AU113882S (en) | 1990-03-07 | 1992-05-08 | Terumo Corp | Catheter |
US5478565A (en) | 1990-03-27 | 1995-12-26 | Warner-Lambert Company | Treatment of sinus headache |
US5147315A (en) | 1990-04-06 | 1992-09-15 | C. R. Bard, Inc. | Access catheter and system for use in the female reproductive system |
US5238004A (en) | 1990-04-10 | 1993-08-24 | Boston Scientific Corporation | High elongation linear elastic guidewire |
US5171233A (en) | 1990-04-25 | 1992-12-15 | Microvena Corporation | Snare-type probe |
EP0527969A1 (en) | 1990-05-11 | 1993-02-24 | SAAB, Mark, A. | High-strength, thin-walled single piece catheters |
SE502055C2 (en) | 1990-05-23 | 1995-07-31 | Atos Medical Ab | Device for applying a drainage duct |
CA2081896A1 (en) | 1990-06-15 | 1991-12-16 | James E. Shapland | Drug delivery apparatus and method |
US5044678A (en) | 1990-07-25 | 1991-09-03 | Lectron Products, Inc. | Solenoid operated latch device with movable pole piece |
US5055051A (en) | 1990-08-03 | 1991-10-08 | Dornier Medical Systems, Inc. | Semi-anthropomorphic biliary/renal training phantom for medical imaging and lithotripsy training |
US5167220A (en) | 1990-08-09 | 1992-12-01 | Brown Cathy K | Systems and methods for maintaining a clear visual field during endoscopic procedures |
US5163989A (en) | 1990-08-27 | 1992-11-17 | Advanced Cardiovascular Systems, Inc. | Method for forming a balloon mold and the use of such mold |
US5345945A (en) | 1990-08-29 | 1994-09-13 | Baxter International Inc. | Dual coil guidewire with radiopaque distal tip |
US5197457A (en) * | 1990-09-12 | 1993-03-30 | Adair Edwin Lloyd | Deformable and removable sheath for optical catheter |
JP2699641B2 (en) | 1990-10-11 | 1998-01-19 | 日本電気株式会社 | Phase jitter suppression circuit |
JPH0683726B2 (en) | 1990-10-12 | 1994-10-26 | 日本精線株式会社 | Guide wire for catheter |
US5169043A (en) | 1990-12-12 | 1992-12-08 | Catania Claude L | Versatile carrying bag |
EP0491349B1 (en) | 1990-12-18 | 1998-03-18 | Advanced Cardiovascular Systems, Inc. | Method of manufacturing a Superelastic guiding member |
US5341818A (en) | 1992-12-22 | 1994-08-30 | Advanced Cardiovascular Systems, Inc. | Guidewire with superelastic distal portion |
US5102402A (en) * | 1991-01-04 | 1992-04-07 | Medtronic, Inc. | Releasable coatings on balloon catheters |
US5368558A (en) | 1991-01-11 | 1994-11-29 | Baxter International Inc. | Ultrasonic ablation catheter device having endoscopic component and method of using same |
US6006126A (en) | 1991-01-28 | 1999-12-21 | Cosman; Eric R. | System and method for stereotactic registration of image scan data |
US5465717A (en) | 1991-02-15 | 1995-11-14 | Cardiac Pathways Corporation | Apparatus and Method for ventricular mapping and ablation |
US5139510A (en) | 1991-02-22 | 1992-08-18 | Xomed-Treace Inc. | Nasal packing device |
AU1579092A (en) | 1991-02-27 | 1992-10-06 | Nova Pharmaceutical Corporation | Anti-infective and anti-inflammatory releasing systems for medical devices |
US5183470A (en) | 1991-03-04 | 1993-02-02 | International Medical, Inc. | Laparoscopic cholangiogram catheter and method of using same |
US5195168A (en) | 1991-03-15 | 1993-03-16 | Codex Corporation | Speech coder and method having spectral interpolation and fast codebook search |
US6733473B1 (en) | 1991-04-05 | 2004-05-11 | Boston Scientific Corporation | Adjustably stiffenable convertible catheter assembly |
US5211952A (en) | 1991-04-12 | 1993-05-18 | University Of Southern California | Contraceptive methods and formulations for use therein |
US5226302A (en) | 1991-04-15 | 1993-07-13 | Loctec Corporation | Six-way self-adjusting lock for use on truck storage boxes and the like |
CA2069052A1 (en) | 1991-05-21 | 1992-11-22 | L. Venkata Raman | Superelastic formable guidewire |
US5127393A (en) | 1991-05-28 | 1992-07-07 | Medilase, Inc. | Flexible endoscope with rigid introducer |
US5386817A (en) | 1991-06-10 | 1995-02-07 | Endomedical Technologies, Inc. | Endoscope sheath and valve system |
US5429582A (en) | 1991-06-14 | 1995-07-04 | Williams; Jeffery A. | Tumor treatment |
CA2068584C (en) | 1991-06-18 | 1997-04-22 | Paul H. Burmeister | Intravascular guide wire and method for manufacture thereof |
US5264260A (en) | 1991-06-20 | 1993-11-23 | Saab Mark A | Dilatation balloon fabricated from low molecular weight polymers |
US5236422A (en) | 1991-06-24 | 1993-08-17 | Eplett Jr James D | Antiseptic urinary catheter cuff |
US5766151A (en) | 1991-07-16 | 1998-06-16 | Heartport, Inc. | Endovascular system for arresting the heart |
US5269752A (en) | 1991-09-12 | 1993-12-14 | Bennett Laurence M | Method of extracorporeal treatment using a kink resistant catheter |
US5252183A (en) | 1991-09-13 | 1993-10-12 | Abb Lummus Crest Inc. | Process of pulping and bleaching fibrous plant material with tert-butyl alcohol and tert-butyl peroxide |
US5168864A (en) | 1991-09-26 | 1992-12-08 | Clarus Medical Systems, Inc. | Deflectable endoscope |
US5211985A (en) * | 1991-10-09 | 1993-05-18 | Ici Canada, Inc. | Multi-stage process for continuous coating of fertilizer particles |
US5304123A (en) | 1991-10-24 | 1994-04-19 | Children's Medical Center Corporation | Detachable balloon catheter for endoscopic treatment of vesicoureteral reflux |
US5333620A (en) | 1991-10-30 | 1994-08-02 | C. R. Bard, Inc. | High performance plastic coated medical guidewire |
US5290310A (en) * | 1991-10-30 | 1994-03-01 | Howmedica, Inc. | Hemostatic implant introducer |
US5246016A (en) | 1991-11-08 | 1993-09-21 | Baxter International Inc. | Transport catheter and multiple probe analysis method |
US5251092A (en) | 1991-11-27 | 1993-10-05 | Protek Devices, Lp | Receptacle assembly with both insulation displacement connector bussing and friction connector coupling of power conductors to surge suppressor circuit |
US5243996A (en) | 1992-01-03 | 1993-09-14 | Cook, Incorporated | Small-diameter superelastic wire guide |
US6190381B1 (en) | 1995-06-07 | 2001-02-20 | Arthrocare Corporation | Methods for tissue resection, ablation and aspiration |
US6109268A (en) | 1995-06-07 | 2000-08-29 | Arthrocare Corporation | Systems and methods for electrosurgical endoscopic sinus surgery |
US6063079A (en) | 1995-06-07 | 2000-05-16 | Arthrocare Corporation | Methods for electrosurgical treatment of turbinates |
US6086585A (en) | 1995-06-07 | 2000-07-11 | Arthrocare Corporation | System and methods for electrosurgical treatment of sleep obstructive disorders |
US6053172A (en) | 1995-06-07 | 2000-04-25 | Arthrocare Corporation | Systems and methods for electrosurgical sinus surgery |
US5273052A (en) | 1992-01-08 | 1993-12-28 | Danforth Biomedical, Incorporated | Guidewire with reversible contact seal for releasable securement to catheter |
DE69330119T2 (en) | 1992-01-09 | 2001-08-02 | Advanced Cardiovascular System | DEVICE FOR REPLACING A GUIDE WIRE |
US5250059A (en) | 1992-01-22 | 1993-10-05 | Devices For Vascular Intervention, Inc. | Atherectomy catheter having flexible nose cone |
US5699796A (en) | 1993-01-29 | 1997-12-23 | Cardima, Inc. | High resolution intravascular signal detection |
US5341240A (en) | 1992-02-06 | 1994-08-23 | Linvatec Corporation | Disposable endoscope |
JPH05211985A (en) | 1992-02-07 | 1993-08-24 | Olympus Optical Co Ltd | Endoscope guide apparatus for cerebral ventricle |
US5263926A (en) | 1992-02-18 | 1993-11-23 | Wilk Peter J | Device and related method for reducing swelling of hemorrhoidal tissues |
US5409444A (en) | 1992-03-04 | 1995-04-25 | Kensey Nash Corporation | Method and apparatus to reduce injury to the vascular system |
DE69326631T2 (en) | 1992-03-19 | 2000-06-08 | Medtronic Inc | Intraluminal expansion device |
US5346075A (en) | 1992-04-17 | 1994-09-13 | Johnson & Johnson Medical, Inc. | Apparatus and method for holding a medical instrument |
USD355031S (en) | 1992-04-20 | 1995-01-31 | Terumo Kabushiki Kaisha | Catheter |
US5368566A (en) | 1992-04-29 | 1994-11-29 | Cardiovascular Dynamics, Inc. | Delivery and temporary stent catheter having a reinforced perfusion lumen |
US5275593A (en) | 1992-04-30 | 1994-01-04 | Surgical Technologies, Inc. | Ophthalmic surgery probe assembly |
US5817102A (en) | 1992-05-08 | 1998-10-06 | Schneider (Usa) Inc. | Apparatus for delivering and deploying a stent |
US5584827A (en) | 1992-05-18 | 1996-12-17 | Ultracell Medical Technologies, Inc | Nasal-packing article |
US5713848A (en) | 1993-05-19 | 1998-02-03 | Dubrul; Will R. | Vibrating catheter |
US5772680A (en) | 1992-06-02 | 1998-06-30 | General Surgical Innovations, Inc. | Apparatus and method for developing an anatomic space for laparoscopic procedures with laparoscopic visualization |
US5255679A (en) | 1992-06-02 | 1993-10-26 | Cardiac Pathways Corporation | Endocardial catheter for mapping and/or ablation with an expandable basket structure having means for providing selective reinforcement and pressure sensing mechanism for use therewith, and method |
US5324284A (en) | 1992-06-05 | 1994-06-28 | Cardiac Pathways, Inc. | Endocardial mapping and ablation system utilizing a separately controlled ablation catheter and method |
US5348537A (en) | 1992-07-15 | 1994-09-20 | Advanced Cardiovascular Systems, Inc. | Catheter with intraluminal sealing element |
US5313967A (en) | 1992-07-24 | 1994-05-24 | Medtronic, Inc. | Helical guidewire |
US5707376A (en) * | 1992-08-06 | 1998-01-13 | William Cook Europe A/S | Stent introducer and method of use |
US5514131A (en) | 1992-08-12 | 1996-05-07 | Stuart D. Edwards | Method for the ablation treatment of the uvula |
ATE182273T1 (en) | 1992-08-18 | 1999-08-15 | Spectranetics Corp | GUIDE WIRE WITH FIBER OPTICS |
IT1258142B (en) | 1992-09-04 | 1996-02-20 | NASAL AND / OR RHINOPARINGEOUS SWAB | |
US5647361A (en) | 1992-09-28 | 1997-07-15 | Fonar Corporation | Magnetic resonance imaging method and apparatus for guiding invasive therapy |
SG49695A1 (en) | 1992-10-15 | 1998-06-15 | Gen Hospital Corp | An infusion pump with an electronically loadable drug library |
US5356418A (en) | 1992-10-28 | 1994-10-18 | Shturman Cardiology Systems, Inc. | Apparatus and method for rotational atherectomy |
US5295694A (en) * | 1992-10-27 | 1994-03-22 | Levin John M | Laparoscopic surgery simulating game |
US5336178A (en) | 1992-11-02 | 1994-08-09 | Localmed, Inc. | Intravascular catheter with infusion array |
US5314408A (en) * | 1992-11-13 | 1994-05-24 | Cardiovascular Imaging Systems, Inc. | Expandable member for a catheter system |
US5549542A (en) | 1992-11-17 | 1996-08-27 | Life Medical Technologies, Inc. | Deflectable endoscope |
ES2102187T3 (en) | 1992-11-18 | 1997-07-16 | Spectrascience Inc | DIAGNOSTIC DEVICE FOR IMAGE FORMATION. |
US5391147A (en) | 1992-12-01 | 1995-02-21 | Cardiac Pathways Corporation | Steerable catheter with adjustable bend location and/or radius and method |
US5314417A (en) | 1992-12-22 | 1994-05-24 | Ethicon, Inc. | Safety trocar |
US5368564A (en) | 1992-12-23 | 1994-11-29 | Angeion Corporation | Steerable catheter |
US5336163A (en) | 1993-01-06 | 1994-08-09 | Smith & Nephew Richards, Inc. | Expandable nasal stent |
CN2151720Y (en) | 1993-01-08 | 1994-01-05 | 陈吉峰 | Hemostat for nasal cavity and nasopharynx cavity |
WO1994015533A2 (en) | 1993-01-18 | 1994-07-21 | John Crowe | Endoscope forceps |
JP3345147B2 (en) | 1993-01-26 | 2002-11-18 | テルモ株式会社 | Vasodilators and catheters |
US5407433A (en) | 1993-02-10 | 1995-04-18 | Origin Medsystems, Inc. | Gas-tight seal accommodating surgical instruments with a wide range of diameters |
US5329927A (en) | 1993-02-25 | 1994-07-19 | Echo Cath, Inc. | Apparatus and method for locating an interventional medical device with a ultrasound color imaging system |
WO1994021320A1 (en) | 1993-03-15 | 1994-09-29 | Advanced Cardiovascular Systems, Inc. | Fluid delivery catheter |
US5318528A (en) * | 1993-04-13 | 1994-06-07 | Advanced Surgical Inc. | Steerable surgical devices |
EP0702535B1 (en) | 1993-04-13 | 2003-01-08 | Boston Scientific Corporation | Prosthesis delivery system with dilating tip |
US5985307A (en) | 1993-04-14 | 1999-11-16 | Emory University | Device and method for non-occlusive localized drug delivery |
US5350396A (en) | 1993-04-15 | 1994-09-27 | Hood Laboratories | Nasal splint |
US5824048A (en) | 1993-04-26 | 1998-10-20 | Medtronic, Inc. | Method for delivering a therapeutic substance to a body lumen |
US5464650A (en) | 1993-04-26 | 1995-11-07 | Medtronic, Inc. | Intravascular stent and method |
ATE161819T1 (en) | 1993-04-27 | 1998-01-15 | Solvay Fluor & Derivate | METHOD FOR PRODUCING CARBOXYLIC ACID ESTERS FROM CARBOXYLIC ACID HALIDES AND ALCOHOLS |
US5346508A (en) | 1993-04-29 | 1994-09-13 | Scimed Life Systems, Inc. | Apparatus and method for performing diagnostics and intravascular therapies |
US5450853A (en) | 1993-10-22 | 1995-09-19 | Scimed Life Systems, Inc. | Pressure sensor |
US5873835A (en) * | 1993-04-29 | 1999-02-23 | Scimed Life Systems, Inc. | Intravascular pressure and flow sensor |
US5617870A (en) * | 1993-04-29 | 1997-04-08 | Scimed Life Systems, Inc. | Intravascular flow measurement system |
US6832996B2 (en) | 1995-06-07 | 2004-12-21 | Arthrocare Corporation | Electrosurgical systems and methods for treating tissue |
DE4315821A1 (en) | 1993-05-12 | 1994-11-17 | Christian Dr Med Milewski | Device for tamponade and for keeping open bone-restricted body cavities and passages after surgical manipulation |
US5334187A (en) | 1993-05-21 | 1994-08-02 | Cathco, Inc. | Balloon catheter system with slit opening handle |
US5372584A (en) | 1993-06-24 | 1994-12-13 | Ovamed Corporation | Hysterosalpingography and selective salpingography |
JP3337272B2 (en) | 1993-06-29 | 2002-10-21 | 株式会社町田製作所 | Medical equipment |
US5402799A (en) | 1993-06-29 | 1995-04-04 | Cordis Corporation | Guidewire having flexible floppy tip |
EP0706353A1 (en) | 1993-07-02 | 1996-04-17 | Materials Evolution and Development USA, Inc. | Implantable system for cell growth control |
WO1995002430A1 (en) | 1993-07-15 | 1995-01-26 | Advanced Cardiovascular Systems, Inc. | Rapid exchange type intraluminal catheter with guiding element |
US5391199A (en) | 1993-07-20 | 1995-02-21 | Biosense, Inc. | Apparatus and method for treating cardiac arrhythmias |
US5472449A (en) | 1993-07-26 | 1995-12-05 | Chou; Kuei C. | Permanent pigment applicator having a detachable needle coupler |
US5415633A (en) | 1993-07-28 | 1995-05-16 | Active Control Experts, Inc. | Remotely steered catheterization device |
US5441494A (en) | 1993-07-29 | 1995-08-15 | Ethicon, Inc. | Manipulable hand for laparoscopy |
US6277107B1 (en) | 1993-08-13 | 2001-08-21 | Daig Corporation | Guiding introducer for introducing medical devices into the coronary sinus and process for using same |
US5562619A (en) | 1993-08-19 | 1996-10-08 | Boston Scientific Corporation | Deflectable catheter |
US5578048A (en) | 1993-09-15 | 1996-11-26 | United States Surgical Corporation | Manipulator apparatus |
WO1995008945A2 (en) | 1993-09-20 | 1995-04-06 | Boston Scientific Corporation | Multiple biopsy sampling device |
US5607386A (en) | 1993-09-21 | 1997-03-04 | Flam; Gary H. | Malleable fiberoptic intubating stylet and method |
US5558091A (en) | 1993-10-06 | 1996-09-24 | Biosense, Inc. | Magnetic determination of position and orientation |
US5400783A (en) | 1993-10-12 | 1995-03-28 | Cardiac Pathways Corporation | Endocardial mapping apparatus with rotatable arm and method |
US5465733A (en) | 1993-10-14 | 1995-11-14 | Hinohara; Tomoaki | Guide wire for catheters and method for its use |
US5445646A (en) | 1993-10-22 | 1995-08-29 | Scimed Lifesystems, Inc. | Single layer hydraulic sheath stent delivery apparatus and method |
US5437282A (en) | 1993-10-29 | 1995-08-01 | Boston Scientific Corporation | Drive shaft for acoustic imaging catheters and flexible catheters |
US5720300A (en) | 1993-11-10 | 1998-02-24 | C. R. Bard, Inc. | High performance wires for use in medical devices and alloys therefor |
US5334167A (en) | 1993-11-19 | 1994-08-02 | Cocanower David A | Modified nasogastric tube for use in enteral feeding |
US5507301A (en) | 1993-11-19 | 1996-04-16 | Advanced Cardiovascular Systems, Inc. | Catheter and guidewire system with flexible distal portions |
US5459700A (en) | 1993-11-22 | 1995-10-17 | Advanced Cardiovascular Systems, Inc. | Manual timer control for inflation device |
US6673025B1 (en) | 1993-12-01 | 2004-01-06 | Advanced Cardiovascular Systems, Inc. | Polymer coated guidewire |
US5451221A (en) | 1993-12-27 | 1995-09-19 | Cynosure, Inc. | Endoscopic light delivery system |
US6716216B1 (en) | 1998-08-14 | 2004-04-06 | Kyphon Inc. | Systems and methods for treating vertebral bodies |
US5538510A (en) | 1994-01-31 | 1996-07-23 | Cordis Corporation | Catheter having coextruded tubing |
SE9400364D0 (en) | 1994-02-02 | 1994-02-02 | Sven Eric Stangerup | Nasal catheter and procedure for the treatment of nasal bleeding |
US5904701A (en) | 1994-02-14 | 1999-05-18 | Daneshvar; Yousef | Device for aiding procedural and therapeutic interventions of the gastrointestinal tract |
US5591194A (en) | 1994-02-18 | 1997-01-07 | C. R. Bard, Inc. | Telescoping balloon catheter and method of use |
US5411016A (en) | 1994-02-22 | 1995-05-02 | Scimed Life Systems, Inc. | Intravascular balloon catheter for use in combination with an angioscope |
DE4405720C1 (en) | 1994-02-23 | 1995-10-19 | Wolf Gmbh Richard | Instrument for endoscopic therapy of carpal tunnel syndrome |
AUPM409094A0 (en) | 1994-02-25 | 1994-03-24 | Trimec Securities Pty. Limited | Improvements in electromagnetic locks |
US5582167A (en) | 1994-03-02 | 1996-12-10 | Thomas Jefferson University | Methods and apparatus for reducing tracheal infection using subglottic irrigation, drainage and servoregulation of endotracheal tube cuff pressure |
US5425370A (en) | 1994-03-23 | 1995-06-20 | Echocath, Inc. | Method and apparatus for locating vibrating devices |
US5887467A (en) | 1994-03-30 | 1999-03-30 | U-Code, Inc. | Pawl & solenoid locking mechanism |
US5454817A (en) | 1994-04-11 | 1995-10-03 | Katz; David L. | Oto-nasal foreign body extractor |
US5533985A (en) | 1994-04-20 | 1996-07-09 | Wang; James C. | Tubing |
US5507795A (en) * | 1994-04-29 | 1996-04-16 | Devices For Vascular Intervention, Inc. | Catheter with perfusion system |
US5599304A (en) | 1994-05-10 | 1997-02-04 | Mount Sinai School Of Medicine Of The City University Of New York | Sinonasal suction apparatus |
US6139510A (en) | 1994-05-11 | 2000-10-31 | Target Therapeutics Inc. | Super elastic alloy guidewire |
US5824044A (en) | 1994-05-12 | 1998-10-20 | Endovascular Technologies, Inc. | Bifurcated multicapsule intraluminal grafting system |
US5551946A (en) | 1994-05-17 | 1996-09-03 | Bullard; James R. | Multifunctional intubating guide stylet and laryngoscope |
US5497783A (en) | 1994-05-18 | 1996-03-12 | Scimed Life Systems, Inc. | Guidewire having radioscopic tip |
US5569183A (en) | 1994-06-01 | 1996-10-29 | Archimedes Surgical, Inc. | Method for performing surgery around a viewing space in the interior of the body |
JPH07327916A (en) | 1994-06-02 | 1995-12-19 | Olympus Optical Co Ltd | Visual field direction varying type endoscope |
ATE258452T1 (en) | 1994-06-17 | 2004-02-15 | Hisamitsu Pharmaceutical Co | ELECTRODE FOR IONTOPHORESIS AND DEVICE THEREFOR |
US5633000A (en) | 1994-06-23 | 1997-05-27 | Axxia Technologies | Subcutaneous implant |
US5857998A (en) | 1994-06-30 | 1999-01-12 | Boston Scientific Corporation | Stent and therapeutic delivery system |
US5458572A (en) | 1994-07-01 | 1995-10-17 | Boston Scientific Corp. | Catheter with balloon folding into predetermined configurations and method of manufacture |
US5441497A (en) | 1994-07-14 | 1995-08-15 | Pdt Cardiovascular, Inc. | Light diffusing guidewire |
US5486181A (en) | 1994-08-04 | 1996-01-23 | Implex Corporation | Acetabular cup, method and tool and installing the same |
US6579285B2 (en) | 1994-09-09 | 2003-06-17 | Cardiofocus, Inc. | Photoablation with infrared radiation |
US5803089A (en) | 1994-09-15 | 1998-09-08 | Visualization Technology, Inc. | Position tracking and imaging system for use in medical applications |
US5673707A (en) | 1994-09-23 | 1997-10-07 | Boston Scientific Corporation | Enhanced performance guidewire |
US5558652A (en) | 1994-10-06 | 1996-09-24 | B. Braun Medical, Inc. | Introducer with radiopaque marked tip and method of manufacture therefor |
US5722401A (en) | 1994-10-19 | 1998-03-03 | Cardiac Pathways Corporation | Endocardial mapping and/or ablation catheter probe |
US6458070B1 (en) | 1994-10-27 | 2002-10-01 | Novoste Corporation | Method and apparatus for treating a desired area in the vascular system of a patient |
US5814029A (en) | 1994-11-03 | 1998-09-29 | Daig Corporation | Guiding introducer system for use in ablation and mapping procedures in the left ventricle |
AU708529B2 (en) | 1994-11-10 | 1999-08-05 | University Of Kentucky Research Foundation, The | Implantable refillable controlled release device to deliver drugs directly to an internal portion of the body |
US6059752A (en) | 1994-12-09 | 2000-05-09 | Segal; Jerome | Mechanical apparatus and method for dilating and irradiating a site of treatment |
US5637113A (en) | 1994-12-13 | 1997-06-10 | Advanced Cardiovascular Systems, Inc. | Polymer film for wrapping a stent structure |
US5664580A (en) | 1995-01-31 | 1997-09-09 | Microvena Corporation | Guidewire having bimetallic coil |
US5599576A (en) | 1995-02-06 | 1997-02-04 | Surface Solutions Laboratories, Inc. | Medical apparatus with scratch-resistant coating and method of making same |
US5599284A (en) | 1995-02-08 | 1997-02-04 | Shea; John P. | Pre-operative nasal splint for endoscopic sinus surgery and method |
US6830785B1 (en) | 1995-03-20 | 2004-12-14 | Toto Ltd. | Method for photocatalytically rendering a surface of a substrate superhydrophilic, a substrate with a superhydrophilic photocatalytic surface, and method of making thereof |
AU5426096A (en) | 1995-03-21 | 1996-10-08 | Dippert, William H. | Uses of antibacterial compounds |
EP0820258B1 (en) | 1995-03-23 | 2002-10-09 | Advanced Animal Technology Limited | Substance delivery device |
WO1996030073A1 (en) | 1995-03-30 | 1996-10-03 | Heartport, Inc. | Endovascular cardiac venting catheter and method |
KR960032597U (en) | 1995-03-31 | 1996-10-24 | Tape recorder reservation recording switch | |
US5685838A (en) | 1995-04-17 | 1997-11-11 | Xomed-Treace, Inc. | Sinus debrider apparatus |
US5837313A (en) | 1995-04-19 | 1998-11-17 | Schneider (Usa) Inc | Drug release stent coating process |
US6638291B1 (en) | 1995-04-20 | 2003-10-28 | Micrus Corporation | Three dimensional, low friction vasoocclusive coil, and method of manufacture |
US5752522A (en) | 1995-05-04 | 1998-05-19 | Cardiovascular Concepts, Inc. | Lesion diameter measurement catheter and method |
US6122541A (en) | 1995-05-04 | 2000-09-19 | Radionics, Inc. | Head band for frameless stereotactic registration |
US5735817A (en) | 1995-05-19 | 1998-04-07 | Shantha; T. R. | Apparatus for transsphenoidal stimulation of the pituitary gland and adjoining brain structures |
US5656030A (en) | 1995-05-22 | 1997-08-12 | Boston Scientific Corporation | Bidirectional steerable catheter with deflectable distal tip |
JPH08317989A (en) | 1995-05-24 | 1996-12-03 | Piolax Inc | Guide wire for medical care |
DE69638035D1 (en) | 1995-05-26 | 2009-11-05 | Ishihara Sangyo Kaisha | Process for the preparation of substituted 1,1,1-trifluoro-3-buten-2-ones |
US5833650A (en) | 1995-06-05 | 1998-11-10 | Percusurge, Inc. | Catheter apparatus and method for treating occluded vessels |
US6238391B1 (en) | 1995-06-07 | 2001-05-29 | Arthrocare Corporation | Systems for tissue resection, ablation and aspiration |
US5752513A (en) | 1995-06-07 | 1998-05-19 | Biosense, Inc. | Method and apparatus for determining position of object |
CA2223990C (en) | 1995-06-07 | 2007-01-30 | Cardima, Inc. | Guiding catheter for coronary sinus |
US5729129A (en) | 1995-06-07 | 1998-03-17 | Biosense, Inc. | Magnetic location system with feedback adjustment of magnetic field generator |
US5707389A (en) | 1995-06-07 | 1998-01-13 | Baxter International Inc. | Side branch occlusion catheter device having integrated endoscope for performing endoscopically visualized occlusion of the side branches of an anatomical passageway |
US5782795A (en) * | 1995-06-30 | 1998-07-21 | Xomed Surgical Products, Inc. | Surgical suction cutting instrument with internal irrigation |
US6258046B1 (en) | 1995-07-06 | 2001-07-10 | Institute Of Critical Care Medicine | Method and device for assessing perfusion failure in a patient by measurement of blood flow |
US5645789A (en) | 1995-07-20 | 1997-07-08 | Navius Corporation | Distensible pet balloon and method of manufacture |
US5638819A (en) | 1995-08-29 | 1997-06-17 | Manwaring; Kim H. | Method and apparatus for guiding an instrument to a target |
US5669388A (en) | 1995-09-06 | 1997-09-23 | Echocath, Inc. | Apparatus and method for automatic placement of transducer |
US5601594A (en) | 1995-09-14 | 1997-02-11 | Best; Barry D. | Nasal stent |
GB2305174A (en) | 1995-09-15 | 1997-04-02 | Zeneca Ltd | Chemical process |
US6027461A (en) * | 1995-10-11 | 2000-02-22 | Micro Therapeutics, Inc. | Infusion guidewire having fixed core wire and flexible radiopaque marker |
US6283951B1 (en) | 1996-10-11 | 2001-09-04 | Transvascular, Inc. | Systems and methods for delivering drugs to selected locations within the body |
US6375615B1 (en) | 1995-10-13 | 2002-04-23 | Transvascular, Inc. | Tissue penetrating catheters having integral imaging transducers and their methods of use |
US6302875B1 (en) | 1996-10-11 | 2001-10-16 | Transvascular, Inc. | Catheters and related devices for forming passageways between blood vessels or other anatomical structures |
US6190353B1 (en) | 1995-10-13 | 2001-02-20 | Transvascular, Inc. | Methods and apparatus for bypassing arterial obstructions and/or performing other transvascular procedures |
US5916149A (en) | 1995-10-25 | 1999-06-29 | Ryan, Jr.; Edwin H. | Shielded illumination device for ophthalmic surgery and the like |
US6113567A (en) | 1995-10-25 | 2000-09-05 | Becker; Bruce B. | Lacrimal silicone tube with reduced friction |
US6287315B1 (en) | 1995-10-30 | 2001-09-11 | World Medical Manufacturing Corporation | Apparatus for delivering an endoluminal prosthesis |
US6019736A (en) | 1995-11-06 | 2000-02-01 | Francisco J. Avellanet | Guidewire for catheter |
US5843050A (en) | 1995-11-13 | 1998-12-01 | Micro Therapeutics, Inc. | Microcatheter |
US5749848A (en) * | 1995-11-13 | 1998-05-12 | Cardiovascular Imaging Systems, Inc. | Catheter system having imaging, balloon angioplasty, and stent deployment capabilities, and method of use for guided stent deployment |
US5827224A (en) | 1995-11-22 | 1998-10-27 | Shippert; Ronald D. | Pressure applying fluid transfer medical device |
FI100318B (en) | 1995-11-23 | 1997-11-14 | Fiskars Consumer Oy Ab | Articulated hand tools |
US5733248A (en) | 1995-11-29 | 1998-03-31 | Scimed Life Systems, Inc. | Universal guide catheter |
JPH09182809A (en) | 1995-12-28 | 1997-07-15 | Kondo Kosan:Kk | High-pressure gas injector |
AU712539B2 (en) | 1996-01-08 | 1999-11-11 | Biosense, Inc. | Methods and apparatus for myocardial revascularization |
US5722984A (en) | 1996-01-16 | 1998-03-03 | Iso Stent, Inc. | Antithrombogenic radioactive coating for an intravascular stent |
US6039699A (en) | 1996-01-22 | 2000-03-21 | Cordis Corporation | Stiff catheter guidewire with flexible distal portion |
IL125757A (en) | 1996-02-15 | 2003-09-17 | Biosense Inc | Medical procedures and apparatus using intrabody probes |
US5711315A (en) | 1996-02-15 | 1998-01-27 | Jerusalmy; Israel | Sinus lift method |
US6860264B2 (en) | 1996-02-26 | 2005-03-01 | Evergreen Medical Incorporated | Method and apparatus for endotracheal intubation using a light wand and curved guide |
US5817013A (en) | 1996-03-19 | 1998-10-06 | Enable Medical Corporation | Method and apparatus for the minimally invasive harvesting of a saphenous vein and the like |
US5682199A (en) | 1996-03-28 | 1997-10-28 | Jedmed Instrument Company | Video endoscope with interchangeable endoscope heads |
US5779699A (en) | 1996-03-29 | 1998-07-14 | Medtronic, Inc. | Slip resistant field focusing ablation catheter electrode |
US5980503A (en) | 1996-04-08 | 1999-11-09 | Guidant Corporation | Endoscopic cardioplegia infusion cannula and method of use |
BR9708543A (en) | 1996-04-10 | 1999-08-03 | Curaden Ag | Process for determining proximal passability of an interdental space |
US6549800B1 (en) | 1996-04-25 | 2003-04-15 | Johns Hopkins Unversity School Of Medicine | Methods for in vivo magnetic resonance imaging |
US6171298B1 (en) | 1996-05-03 | 2001-01-09 | Situs Corporation | Intravesical infuser |
US7022105B1 (en) | 1996-05-06 | 2006-04-04 | Novasys Medical Inc. | Treatment of tissue in sphincters, sinuses and orifices |
US6503087B1 (en) | 1996-05-08 | 2003-01-07 | Gaumard Scientific, Inc. | Interactive education system for teaching patient care |
US6050972A (en) | 1996-05-20 | 2000-04-18 | Percusurge, Inc. | Guidewire inflation system |
US6652480B1 (en) | 1997-03-06 | 2003-11-25 | Medtronic Ave., Inc. | Methods for reducing distal embolization |
US6270477B1 (en) | 1996-05-20 | 2001-08-07 | Percusurge, Inc. | Catheter for emboli containment |
US5693065A (en) | 1996-06-25 | 1997-12-02 | Rains, Iii; B. Manrin | Frontal sinus stent |
US6167296A (en) | 1996-06-28 | 2000-12-26 | The Board Of Trustees Of The Leland Stanford Junior University | Method for volumetric image navigation |
US5789391A (en) | 1996-07-03 | 1998-08-04 | Inspire Pharmaceuticals, Inc. | Method of treating sinusitis with uridine triphosphates and related compounds |
US5865767A (en) | 1996-07-10 | 1999-02-02 | Cordis Corporation | Guidewire having compound taper |
JPH1024098A (en) | 1996-07-10 | 1998-01-27 | Terumo Corp | Balloon and balloon catheter |
US5664567A (en) | 1996-07-16 | 1997-09-09 | Linder; Gerald S. | Fenestrated nasopharyngeal airway for drainage |
US6569147B1 (en) | 1996-07-26 | 2003-05-27 | Kensey Nash Corporation | Systems and methods of use for delivering beneficial agents for revascularizing stenotic bypass grafts and other occluded blood vessels and for other purposes |
US6126682A (en) | 1996-08-13 | 2000-10-03 | Oratec Interventions, Inc. | Method for treating annular fissures in intervertebral discs |
US5797878A (en) | 1996-08-15 | 1998-08-25 | Guidant Corporation | Catheter having optimized balloon taper angle |
US5833682A (en) | 1996-08-26 | 1998-11-10 | Illumenex Corporation | Light delivery system with blood flushing capability |
US5843113A (en) | 1996-10-08 | 1998-12-01 | High; Kenneth | Endocystotomy tool |
US5971975A (en) | 1996-10-09 | 1999-10-26 | Target Therapeutics, Inc. | Guide catheter with enhanced guidewire tracking |
US6016439A (en) | 1996-10-15 | 2000-01-18 | Biosense, Inc. | Method and apparatus for synthetic viewpoint imaging |
US5820568A (en) | 1996-10-15 | 1998-10-13 | Cardiac Pathways Corporation | Apparatus and method for aiding in the positioning of a catheter |
US5779669A (en) | 1996-10-28 | 1998-07-14 | C. R. Bard, Inc. | Steerable catheter with fixed curve |
US6913763B2 (en) | 1996-11-19 | 2005-07-05 | Intrabrain International Nv | Method and device for enhanced delivery of a biologically active agent through the spinal spaces into the central nervous system of a mammal |
US5872879A (en) | 1996-11-25 | 1999-02-16 | Boston Scientific Corporation | Rotatable connecting optical fibers |
US5836638A (en) | 1996-12-09 | 1998-11-17 | Illinois Tool Works Inc. | Fuel door assembly |
US5830188A (en) | 1996-12-11 | 1998-11-03 | Board Of Regents, The University Of Texas System | Curved cannula for continuous spinal anesthesia |
US5766194A (en) | 1996-12-23 | 1998-06-16 | Georgia Skin And Cancer Clinic, Pc | Surgical apparatus for tissue removal |
US5935061A (en) | 1997-01-03 | 1999-08-10 | Biosense, Inc. | Obstetrical instrument system and method |
US6007516A (en) | 1997-01-21 | 1999-12-28 | Vasca, Inc. | Valve port and method for vascular access |
US5980551A (en) | 1997-02-07 | 1999-11-09 | Endovasc Ltd., Inc. | Composition and method for making a biodegradable drug delivery stent |
US6669689B2 (en) | 1997-02-27 | 2003-12-30 | Cryocath Technologies Inc. | Cryosurgical catheter |
US6190332B1 (en) | 1998-02-19 | 2001-02-20 | Percusurge, Inc. | Core wire with shapeable tip |
US5879324A (en) * | 1997-03-06 | 1999-03-09 | Von Hoffmann; Gerard | Low profile catheter shaft |
AU6688398A (en) | 1997-03-06 | 1998-09-22 | Percusurge, Inc. | Intravascular aspiration system |
US6159170A (en) | 1997-03-13 | 2000-12-12 | Borodulin; German | Universal mechanical dilator combined with massaging action |
US6007991A (en) | 1997-03-28 | 1999-12-28 | The Research Foundation Of Suny | Antisense oligonucleotides for mitogen-activated protein kinases as therapy for cancer |
US6524299B1 (en) | 1997-04-09 | 2003-02-25 | Target Therapeutics, Inc. | Flow-directed catheter |
US5941816A (en) | 1997-04-15 | 1999-08-24 | Clarus Medical Systems, Inc. | Viewing system with adapter handle for medical breathing tubes |
US6019777A (en) | 1997-04-21 | 2000-02-01 | Advanced Cardiovascular Systems, Inc. | Catheter and method for a stent delivery system |
US5862693A (en) | 1997-05-02 | 1999-01-26 | Fort Lock Corporation | Electronically controlled security lock |
US6016429A (en) | 1997-05-28 | 2000-01-18 | Northern Telecom Limited | Method and apparatus for minimizing cellular network costs when upgrading the electronics in an existing cellular system |
WO1998055173A1 (en) | 1997-06-04 | 1998-12-10 | Advanced Cardiovascular Systems, Inc. | Steerable guidewire with enhanced distal support |
US5997562A (en) | 1997-06-13 | 1999-12-07 | Percusurge, Inc. | Medical wire introducer and balloon protective sheath |
US5938660A (en) | 1997-06-27 | 1999-08-17 | Daig Corporation | Process and device for the treatment of atrial arrhythmia |
DE19728273C1 (en) | 1997-07-02 | 1998-12-10 | Fuss Fritz Gmbh & Co | Locking device for furniture |
US6514249B1 (en) | 1997-07-08 | 2003-02-04 | Atrionix, Inc. | Positioning system and method for orienting an ablation element within a pulmonary vein ostium |
US20010004644A1 (en) * | 1997-07-21 | 2001-06-21 | Levin Bruce H. | Compositions, kits, apparatus, and methods for inhibiting cephalic inflammation |
US7799337B2 (en) | 1997-07-21 | 2010-09-21 | Levin Bruce H | Method for directed intranasal administration of a composition |
US6432986B2 (en) | 1997-07-21 | 2002-08-13 | Bruce H. Levin | Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches |
US5928192A (en) | 1997-07-24 | 1999-07-27 | Embol-X, Inc. | Arterial aspiration |
DE19732031C1 (en) | 1997-07-25 | 1999-04-22 | Solvay Fluor & Derivate | 2-phase production of carboxylic acid esters |
US5908407A (en) | 1997-07-25 | 1999-06-01 | Neuroperfusion, Inc. | Retroperfusion catheter apparatus and method |
US6015414A (en) | 1997-08-29 | 2000-01-18 | Stereotaxis, Inc. | Method and apparatus for magnetically controlling motion direction of a mechanically pushed catheter |
US5902247A (en) | 1997-09-09 | 1999-05-11 | Bioenterics Corporation | Transilluminating catheter |
US6066149A (en) | 1997-09-30 | 2000-05-23 | Target Therapeutics, Inc. | Mechanical clot treatment device with distal filter |
AU739331B2 (en) | 1997-10-01 | 2001-10-11 | Boston Scientific Limited | Dilation systems and related methods |
US6027478A (en) | 1997-10-09 | 2000-02-22 | Medical Purchasing Group, Inc. | Nasal cavity drainage and stoppage system |
US6042561A (en) | 1997-10-22 | 2000-03-28 | Ash Medical Systems, Inc. | Non-intravascular infusion access device |
US6056702A (en) | 1998-10-02 | 2000-05-02 | Cordis Corporation | Guidewire with outer sheath |
JP4121615B2 (en) | 1997-10-31 | 2008-07-23 | オリンパス株式会社 | Endoscope |
FR2770409B1 (en) | 1997-10-31 | 2000-06-23 | Soprane Sa | UNIVERSAL CATHETER |
US6048299A (en) | 1997-11-07 | 2000-04-11 | Radiance Medical Systems, Inc. | Radiation delivery catheter |
US6179811B1 (en) | 1997-11-25 | 2001-01-30 | Medtronic, Inc. | Imbedded marker and flexible guide wire shaft |
EP0920882A3 (en) | 1997-12-04 | 2000-01-05 | Schneider Inc. | Balloon dilatation-drug delivery catheter and stent deployment-drug delivery catheter in rapid exchange configuration |
US6117105A (en) | 1997-12-08 | 2000-09-12 | Cardeon Corporation | Aortic catheter and methods for inducing cardioplegic arrest and for selective aortic perfusion |
AU1999099A (en) | 1997-12-15 | 1999-07-05 | Arthrocare Corporation | Systems and methods for electrosurgical treatment of the head and neck |
CA2315842A1 (en) | 1997-12-23 | 1999-07-01 | Somnus Medical Technologies, Inc. | Apparatus for reducing tissue volumes by the use of energy |
US6093150A (en) | 1997-12-31 | 2000-07-25 | Acuson Corporation | Ultrasound otoscope |
US7008412B2 (en) | 1998-01-06 | 2006-03-07 | Cathlogic, Inc. | Subcutaneous port catheter system and associated method |
US5989231A (en) | 1998-01-15 | 1999-11-23 | Scimed Life Systems, Inc. | Optical gastrostomy and jejunostomy |
US6159178A (en) | 1998-01-23 | 2000-12-12 | Heartport, Inc. | Methods and devices for occluding the ascending aorta and maintaining circulation of oxygenated blood in the patient when the patient's heart is arrested |
US6295990B1 (en) | 1998-02-03 | 2001-10-02 | Salient Interventional Systems, Inc. | Methods and systems for treating ischemia |
US6083188A (en) | 1998-02-04 | 2000-07-04 | Becker; Bruce B. | Lacrimal silicone stent with very large diameter segment insertable transnasally |
US7169141B2 (en) | 1998-02-24 | 2007-01-30 | Hansen Medical, Inc. | Surgical instrument |
US6176829B1 (en) | 1998-02-26 | 2001-01-23 | Echocath, Inc. | Multi-beam diffraction grating imager apparatus and method |
US6183461B1 (en) | 1998-03-11 | 2001-02-06 | Situs Corporation | Method for delivering a medication |
JPH11265567A (en) | 1998-03-17 | 1999-09-28 | Mitsumi Electric Co Ltd | Disk drive |
DE19813383A1 (en) | 1998-03-26 | 1999-10-07 | Storz Karl Gmbh & Co | Device with a transmitter unit, via which the position of a medical instrument can be detected in the context of a CAS system |
ES2304807T3 (en) | 1998-03-31 | 2008-10-16 | Medtronic Vascular, Inc. | CATHETERS AND PERCUTANEOUS SYSTEMS OF ARTERIOVENOUS DEVIATION IN SITU. |
US6013019A (en) | 1998-04-06 | 2000-01-11 | Isostent, Inc. | Temporary radioisotope stent |
US6364856B1 (en) * | 1998-04-14 | 2002-04-02 | Boston Scientific Corporation | Medical device with sponge coating for controlled drug release |
US5968085A (en) | 1998-04-20 | 1999-10-19 | Medtronic, Inc. | Pacing lead with integral guidance using ultrasound |
EP1071772A2 (en) | 1998-04-24 | 2001-01-31 | Genentech, Inc. | Fizz proteins |
US6450989B2 (en) | 1998-04-27 | 2002-09-17 | Artemis Medical, Inc. | Dilating and support apparatus with disease inhibitors and methods for use |
US6175752B1 (en) | 1998-04-30 | 2001-01-16 | Therasense, Inc. | Analyte monitoring device and methods of use |
US6306105B1 (en) | 1998-05-14 | 2001-10-23 | Scimed Life Systems, Inc. | High performance coil wire |
US6280411B1 (en) | 1998-05-18 | 2001-08-28 | Scimed Life Systems, Inc. | Localized delivery of drug agents |
US6183464B1 (en) | 1998-06-01 | 2001-02-06 | Inviro Medical Devices Ltd. | Safety syringe with retractable needle and universal luer coupling |
US6048358A (en) | 1998-07-13 | 2000-04-11 | Barak; Shlomo | Method and apparatus for hemostasis following arterial catheterization |
US6290689B1 (en) | 1999-10-22 | 2001-09-18 | Corazón Technologies, Inc. | Catheter devices and methods for their use in the treatment of calcified vascular occlusions |
US6352503B1 (en) | 1998-07-17 | 2002-03-05 | Olympus Optical Co., Ltd. | Endoscopic surgery apparatus |
US5979290A (en) | 1998-07-20 | 1999-11-09 | Simeone; Salvatore | Mine clearing device |
NL1009738C2 (en) | 1998-07-24 | 2000-01-25 | Cordis Europ | Balloon catheter with filler for stent delivery. |
US20040064105A1 (en) | 2002-09-27 | 2004-04-01 | Capes David Francis | Single-use syringe |
US6168586B1 (en) | 1998-08-07 | 2001-01-02 | Embol-X, Inc. | Inflatable cannula and method of using same |
US5954694A (en) | 1998-08-07 | 1999-09-21 | Embol-X, Inc. | Nested tubing sections and methods for making same |
US6129713A (en) | 1998-08-11 | 2000-10-10 | Embol-X, Inc. | Slidable cannula and method of use |
CN2352818Y (en) | 1998-08-12 | 1999-12-08 | 李平 | Medical use light guide |
US6152943A (en) | 1998-08-14 | 2000-11-28 | Incept Llc | Methods and apparatus for intraluminal deposition of hydrogels |
WO2000009192A1 (en) | 1998-08-17 | 2000-02-24 | Kazuhiro Noda | Operation balloon |
JP3244660B2 (en) | 1998-08-17 | 2002-01-07 | 旭光学工業株式会社 | Endoscope treatment tool |
USD413629S (en) | 1998-08-18 | 1999-09-07 | HA-LO Industries, Inc. | Nasal tract model |
WO2000010636A1 (en) | 1998-08-19 | 2000-03-02 | Cook Incorporated | Preformed wire guide |
US6149213A (en) | 1998-10-01 | 2000-11-21 | Southco, Inc. | Blind latch keeper |
US6613066B1 (en) | 1998-10-05 | 2003-09-02 | Kaneka Corporation | Balloon catheter and production method therefor |
WO2000023009A1 (en) | 1998-10-21 | 2000-04-27 | Frauens John T | Apparatus for percutaneous interposition balloon arthroplasty |
AU3098400A (en) | 1998-11-09 | 2000-05-29 | Datascope Investment Corp. | Intra-aortic balloon catheter having an ultra-thin stretch blow molded balloon membrane |
US6174280B1 (en) | 1998-11-19 | 2001-01-16 | Vision Sciences, Inc. | Sheath for protecting and altering the bending characteristics of a flexible endoscope |
US6234958B1 (en) | 1998-11-30 | 2001-05-22 | Medical Access Systems, Llc | Medical device introduction system including medical introducer having a plurality of access ports and methods of performing medical procedures with same |
US20030018291A1 (en) * | 1999-12-08 | 2003-01-23 | Hill Frank C. | Ear tube and method of insertion |
US6464650B2 (en) | 1998-12-31 | 2002-10-15 | Advanced Cardiovascular Systems, Inc. | Guidewire with smoothly tapered segment |
US6206870B1 (en) | 1999-01-21 | 2001-03-27 | Quest Medical, Inc. | Catheter stylet handle |
AU2862200A (en) | 1999-01-27 | 2000-08-18 | Bruce H. Levin | Compositions, kits, apparatus, and methods for inhibiting cerebral neurovasculardisorders and muscular headaches |
DE19906191A1 (en) | 1999-02-15 | 2000-08-17 | Ingo F Herrmann | Mouldable endoscope for transmitting light and images with supplementary device has non-round cross section along longitudinal section for inserting in human or animal body opening |
US6398758B1 (en) | 1999-02-16 | 2002-06-04 | Stephen C. Jacobsen | Medicament delivery system |
US6332891B1 (en) | 1999-02-16 | 2001-12-25 | Stryker Corporation | System and method for performing image guided surgery |
US6468297B1 (en) | 1999-02-24 | 2002-10-22 | Cryovascular Systems, Inc. | Cryogenically enhanced intravascular interventions |
US10973397B2 (en) * | 1999-03-01 | 2021-04-13 | West View Research, Llc | Computerized information collection and processing apparatus |
JP4543553B2 (en) | 1999-03-03 | 2010-09-15 | オプティノーズ アズ | Nasal infeed device |
WO2000053252A1 (en) | 1999-03-08 | 2000-09-14 | University Of Virginia Patent Foundation | Device and method for delivering a material into the paranasal sinus cavities |
US6148823A (en) | 1999-03-17 | 2000-11-21 | Stereotaxis, Inc. | Method of and system for controlling magnetic elements in the body using a gapped toroid magnet |
US6200257B1 (en) | 1999-03-24 | 2001-03-13 | Proxima Therapeutics, Inc. | Catheter with permeable hydrogel membrane |
US6258065B1 (en) | 1999-03-26 | 2001-07-10 | Core Dynamics, Inc. | Surgical instrument seal assembly |
US6389313B1 (en) | 1999-03-26 | 2002-05-14 | Kevin S. Marchitto | Laser probes for drug permeation |
DE69917213T2 (en) | 1999-03-29 | 2005-07-28 | William Cook Europe Aps | A guidewire |
EP1040843B1 (en) | 1999-03-29 | 2005-09-28 | William Cook Europe A/S | A guidewire |
US6425877B1 (en) | 1999-04-02 | 2002-07-30 | Novasys Medical, Inc. | Treatment of tissue in the digestive circulatory respiratory urinary and reproductive systems |
US6328564B1 (en) | 1999-04-06 | 2001-12-11 | Raymond C. Thurow | Deep ear canal locating and head orienting device |
US6319275B1 (en) | 1999-04-07 | 2001-11-20 | Medtronic Ave, Inc. | Endolumenal prosthesis delivery assembly and method of use |
US6231543B1 (en) | 1999-04-15 | 2001-05-15 | Intella Interventional Systems, Inc. | Single lumen balloon catheter |
US6268574B1 (en) | 1999-04-29 | 2001-07-31 | Rudolph R. Edens | Electrical and pneumatic lock-out device |
US6689146B1 (en) | 1999-04-29 | 2004-02-10 | Stryker Corporation | Powered surgical handpiece with integrated irrigator and suction application |
EP1055397B1 (en) | 1999-04-29 | 2001-05-23 | Karl Storz GmbH & Co. KG | Medical instrument for preparing tissue |
WO2000065987A1 (en) | 1999-04-30 | 2000-11-09 | Applied Medical Resources Corporation | Guidewire |
JP2002543877A (en) | 1999-05-07 | 2002-12-24 | サルヴィアック・リミテッド | Embolism prevention device |
US6146415A (en) | 1999-05-07 | 2000-11-14 | Advanced Cardiovascular Systems, Inc. | Stent delivery system |
US6758830B1 (en) | 1999-05-11 | 2004-07-06 | Atrionix, Inc. | Catheter positioning system |
US6394093B1 (en) | 1999-05-13 | 2002-05-28 | Scott Lethi | Nasopharyngeal airway with inflatable cuff |
US20020006961A1 (en) | 1999-05-14 | 2002-01-17 | Katz Stanley E. | Method and composition for treating mammalian nasal and sinus diseases caused by inflammatory response |
DE19924440A1 (en) | 1999-05-28 | 2000-12-07 | Storz Karl Gmbh & Co Kg | Shaft for a flexible endoscope |
US6079755A (en) | 1999-06-07 | 2000-06-27 | Chang; Chih Chung | Electromagnetic lock device |
US6206900B1 (en) * | 1999-06-11 | 2001-03-27 | The General Hospital Corporation | Clot evacuation catheter |
US6585717B1 (en) | 1999-06-15 | 2003-07-01 | Cryocath Technologies Inc. | Deflection structure |
US6890329B2 (en) | 1999-06-15 | 2005-05-10 | Cryocath Technologies Inc. | Defined deflection structure |
DE29923582U1 (en) | 1999-07-08 | 2000-12-14 | Hintersdorf Steffen | Device for use within the area of the nose, in particular for insertion into the nasal cavities |
US6364900B1 (en) | 1999-07-14 | 2002-04-02 | Richard R. Heuser | Embolism prevention device |
JP3447984B2 (en) | 1999-07-21 | 2003-09-16 | 朝日インテック株式会社 | Medical guidewire |
US6596009B1 (en) | 1999-07-28 | 2003-07-22 | Jeffrey Jelic | Retrievable endoscopic orbital floor splint |
US6445939B1 (en) | 1999-08-09 | 2002-09-03 | Lightlab Imaging, Llc | Ultra-small optical probes, imaging optics, and methods for using same |
WO2001012255A1 (en) | 1999-08-12 | 2001-02-22 | Wilson-Cook Medical Inc. | Dilation balloon having multiple diameters |
US6638233B2 (en) | 1999-08-19 | 2003-10-28 | Fox Hollow Technologies, Inc. | Apparatus and methods for material capture and removal |
MXPA02001866A (en) | 1999-08-24 | 2003-09-25 | Neuron Therapeutics Inc | Methods useful in affecting apoptosis. |
US6249180B1 (en) | 1999-09-08 | 2001-06-19 | Atmel Corporation | Phase noise and additive noise estimation in a QAM demodulator |
US6221042B1 (en) | 1999-09-17 | 2001-04-24 | Scimed Life Systems, Inc. | Balloon with reversed cones |
US6939361B1 (en) | 1999-09-22 | 2005-09-06 | Nmt Medical, Inc. | Guidewire for a free standing intervascular device having an integral stop mechanism |
WO2001022897A1 (en) | 1999-09-28 | 2001-04-05 | Novasys Medical, Inc. | Treatment of tissue by application of energy and drugs |
JP2001095815A (en) | 1999-09-28 | 2001-04-10 | Olympus Optical Co Ltd | Microwave coagulation applicator |
US6398775B1 (en) * | 1999-10-21 | 2002-06-04 | Pulmonx | Apparatus and method for isolated lung access |
US7366562B2 (en) | 2003-10-17 | 2008-04-29 | Medtronic Navigation, Inc. | Method and apparatus for surgical navigation |
US6536437B1 (en) | 1999-10-29 | 2003-03-25 | Branislav M. Dragisic | Cuffed nasal airway and anesthetic wand system |
US6529756B1 (en) * | 1999-11-22 | 2003-03-04 | Scimed Life Systems, Inc. | Apparatus for mapping and coagulating soft tissue in or around body orifices |
US6533754B1 (en) | 1999-11-26 | 2003-03-18 | Terumo Kabushiki Kaisha | Catheter |
US6156294A (en) | 1999-11-28 | 2000-12-05 | Scientific Development And Research, Inc. | Composition and method for treatment of otitis media |
ATE357878T1 (en) | 1999-12-22 | 2007-04-15 | Boston Scient Ltd | ENDOLUMINAL OCCLUSION FLUSH CATHETER |
DE10042330A1 (en) * | 1999-12-22 | 2002-03-14 | Hans Sachse | Small intestine probe, wall-reinforced |
US6450975B1 (en) | 1999-12-30 | 2002-09-17 | Advanced Cardiovascular Systems, Inc. | Ultrasonic transmission guide wire |
DE10102433B4 (en) | 2000-01-21 | 2008-07-10 | Pentax Corp. | Flexible tube for an endoscope |
US7184827B1 (en) | 2000-01-24 | 2007-02-27 | Stuart D. Edwards | Shrinkage of dilatations in the body |
US6386197B1 (en) | 2000-01-27 | 2002-05-14 | Brook D. Miller | Nasal air passageway opening device |
US20010034530A1 (en) | 2000-01-27 | 2001-10-25 | Malackowski Donald W. | Surgery system |
US6312438B1 (en) | 2000-02-01 | 2001-11-06 | Medtronic Xomed, Inc. | Rotary bur instruments having bur tips with aspiration passages |
WO2001056641A1 (en) * | 2000-02-04 | 2001-08-09 | C. R. Bard, Inc. | Triple lumen stone balloon catheter and method |
US6589164B1 (en) | 2000-02-15 | 2003-07-08 | Transvascular, Inc. | Sterility barriers for insertion of non-sterile apparatus into catheters or other medical devices |
US6527753B2 (en) | 2000-02-29 | 2003-03-04 | Olympus Optical Co., Ltd. | Endoscopic treatment system |
US6485475B1 (en) | 2000-03-01 | 2002-11-26 | The Board Of Regents Of The University Texas System | Introducer needle for continuous perineural catheter placement |
US6443947B1 (en) | 2000-03-01 | 2002-09-03 | Alexei Marko | Device for thermal ablation of a cavity |
US6494894B2 (en) | 2000-03-16 | 2002-12-17 | Scimed Life Systems, Inc. | Coated wire |
AU143359S (en) | 2000-03-17 | 2001-03-28 | Astrazeneca Ab | Connector for a catheter |
US6485500B1 (en) | 2000-03-21 | 2002-11-26 | Advanced Cardiovascular Systems, Inc. | Emboli protection system |
US6440061B1 (en) | 2000-03-24 | 2002-08-27 | Donald E. Wenner | Laparoscopic instrument system for real-time biliary exploration and stone removal |
EP1267740A1 (en) | 2000-03-30 | 2003-01-02 | Cbyon, Inc. | Apparatus and method for calibrating an endoscope |
US6517478B2 (en) | 2000-03-30 | 2003-02-11 | Cbyon, Inc. | Apparatus and method for calibrating an endoscope |
US6984203B2 (en) | 2000-04-03 | 2006-01-10 | Neoguide Systems, Inc. | Endoscope with adjacently positioned guiding apparatus |
US6478776B1 (en) | 2000-04-05 | 2002-11-12 | Biocardia, Inc. | Implant delivery catheter system and methods for its use |
US6638268B2 (en) | 2000-04-07 | 2003-10-28 | Imran K. Niazi | Catheter to cannulate the coronary sinus |
US6860849B2 (en) | 2000-05-08 | 2005-03-01 | Pentax Corporation | Flexible tube for an endoscope |
GB0011053D0 (en) | 2000-05-09 | 2000-06-28 | Hudson John O | Medical device and use thereof |
EP1292214A4 (en) | 2000-05-19 | 2007-07-04 | Bard Inc C R | Guidewire with viewing capability |
DE60132452T2 (en) | 2000-05-31 | 2009-01-15 | Fox Hollow Technologies Inc., Redwood City | EMBOLIZING PROTECTION SYSTEM FOR VASCULAR TREATMENTS |
US6719749B1 (en) | 2000-06-01 | 2004-04-13 | Medical Components, Inc. | Multilumen catheter assembly and methods for making and inserting the same |
US6409863B1 (en) | 2000-06-12 | 2002-06-25 | Scimed Life Systems, Inc. | Methods of fabricating a catheter shaft having one or more guidewire ports |
FR2810458B1 (en) * | 2000-06-16 | 2004-04-09 | Entrelec Sa | ELECTRIC INTERCONNECTION COMB |
JP3345645B2 (en) | 2000-06-20 | 2002-11-18 | 東京大学長 | Body cavity observation device |
US6663589B1 (en) | 2000-06-20 | 2003-12-16 | Haim Halevy | Catheter system |
US6572590B1 (en) | 2000-07-13 | 2003-06-03 | Merit Medical Systems, Inc. | Adjustable quick-release valve with toggle capability |
JP2002028166A (en) | 2000-07-18 | 2002-01-29 | Olympus Optical Co Ltd | Treatment device for nasal cavity |
US6440389B1 (en) | 2000-07-19 | 2002-08-27 | The General Hospital Corporation | Fluorescent agents for real-time measurement of organ function |
US20050107738A1 (en) | 2000-07-21 | 2005-05-19 | Slater Charles R. | Occludable intravascular catheter for drug delivery and method of using the same |
WO2002007794A2 (en) | 2000-07-24 | 2002-01-31 | Stereotaxis, Inc. | Magnetically navigated pacing leads, and methods for delivering medical devices |
RU2213530C2 (en) | 2000-07-26 | 2003-10-10 | Сунцов Виктор Владимирович | Method and device for treating the cases of paranasal sinusitis |
JP4429495B2 (en) | 2000-07-28 | 2010-03-10 | オリンパス株式会社 | Endoscope |
DE10038376C2 (en) | 2000-08-07 | 2003-04-30 | Zangenstein Elektro | Door lock for the door of an electrical household appliance |
US6569146B1 (en) | 2000-08-18 | 2003-05-27 | Scimed Life Systems, Inc. | Method and apparatus for treating saphenous vein graft lesions |
US7625335B2 (en) | 2000-08-25 | 2009-12-01 | 3Shape Aps | Method and apparatus for three-dimensional optical scanning of interior surfaces |
US6607546B1 (en) | 2000-09-01 | 2003-08-19 | Roger E. Murken | Nasal catheter |
US6503263B2 (en) * | 2000-09-24 | 2003-01-07 | Medtronic, Inc. | Surgical micro-shaving instrument with elevator tip |
US6719763B2 (en) * | 2000-09-29 | 2004-04-13 | Olympus Optical Co., Ltd. | Endoscopic suturing device |
US7052474B2 (en) | 2000-10-02 | 2006-05-30 | Sandhill Scientific, Inc. | Pharyngoesophageal monitoring systems |
US6537294B1 (en) | 2000-10-17 | 2003-03-25 | Advanced Cardiovascular Systems, Inc. | Delivery systems for embolic filter devices |
US6702735B2 (en) | 2000-10-17 | 2004-03-09 | Charlotte Margaret Kelly | Device for movement along a passage |
US6585639B1 (en) | 2000-10-27 | 2003-07-01 | Pulmonx | Sheath and method for reconfiguring lung viewing scope |
US20020055746A1 (en) | 2000-11-03 | 2002-05-09 | Alan Burke | Method and apparatus for extracting foreign bodies from nasal passages and the like |
JP2002146659A (en) | 2000-11-07 | 2002-05-22 | Sumitomo Electric Ind Ltd | Metallic nonwoven fabric and method for producing the same |
US6571131B1 (en) | 2000-11-10 | 2003-05-27 | Biosense Webster, Inc. | Deflectable catheter with modifiable handle |
US6543452B1 (en) * | 2000-11-16 | 2003-04-08 | Medilyfe, Inc. | Nasal intubation device and system for intubation |
AU2002239278A1 (en) * | 2000-11-20 | 2002-05-27 | Surgi-Vision, Inc. | Connector and guidewire connectable thereto |
US6716813B2 (en) | 2000-11-28 | 2004-04-06 | House Ear Institute | Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis |
CA2436814A1 (en) | 2000-12-01 | 2002-07-18 | Nephros Therapeutics, Inc. | Intravascular drug delivery device and use therefor |
WO2002045598A2 (en) | 2000-12-05 | 2002-06-13 | Lumend, Inc. | Catheter system for vascular re-entry from a sub-intimal space |
US6500130B2 (en) | 2000-12-21 | 2002-12-31 | Scimed Life Systems, Inc. | Steerable guidewire |
US6672773B1 (en) * | 2000-12-29 | 2004-01-06 | Amkor Technology, Inc. | Optical fiber having tapered end and optical connector with reciprocal opening |
US6544223B1 (en) * | 2001-01-05 | 2003-04-08 | Advanced Cardiovascular Systems, Inc. | Balloon catheter for delivering therapeutic agents |
KR100731007B1 (en) | 2001-01-15 | 2007-06-22 | 앰코 테크놀로지 코리아 주식회사 | stack-type semiconductor package |
JP4153305B2 (en) * | 2001-01-30 | 2008-09-24 | ゼット − キャット、インコーポレイテッド | Instrument calibrator and tracking system |
US6997931B2 (en) | 2001-02-02 | 2006-02-14 | Lsi Solutions, Inc. | System for endoscopic suturing |
DE10104663A1 (en) | 2001-02-02 | 2002-08-08 | Solvay Fluor & Derivate | Production of fluorine compounds |
DE10105592A1 (en) * | 2001-02-06 | 2002-08-08 | Achim Goepferich | Placeholder for drug release in the frontal sinus |
JP3939158B2 (en) | 2001-02-06 | 2007-07-04 | オリンパス株式会社 | Endoscope device |
AU2002254157B2 (en) | 2001-03-09 | 2006-07-27 | Boston Scientific Limited | Medical slings |
US6585718B2 (en) | 2001-05-02 | 2003-07-01 | Cardiac Pacemakers, Inc. | Steerable catheter with shaft support system for resisting axial compressive loads |
US6796960B2 (en) | 2001-05-04 | 2004-09-28 | Wit Ip Corporation | Low thermal resistance elastic sleeves for medical device balloons |
US7041046B2 (en) | 2001-05-07 | 2006-05-09 | Xoft, Inc. | Combination ionizing radiation and immunomodulator delivery devices and methods for inhibiting hyperplasia |
US6712757B2 (en) * | 2001-05-16 | 2004-03-30 | Stephen Becker | Endoscope sleeve and irrigation device |
US7532920B1 (en) | 2001-05-31 | 2009-05-12 | Advanced Cardiovascular Systems, Inc. | Guidewire with optical fiber |
US7140480B2 (en) | 2001-06-07 | 2006-11-28 | Drussel Wilfley Design, Llc | Centrifugal clutch and cover mount assembly therefor |
US6966906B2 (en) | 2001-06-08 | 2005-11-22 | Joe Denton Brown | Deflection mechanism for a surgical instrument, such as a laser delivery device and/or endoscope, and method of use |
EP1404297B1 (en) | 2001-06-12 | 2011-04-27 | The Johns Hopkins University School Of Medicine | Reservoir device for intraocular drug delivery |
US20030013985A1 (en) | 2001-07-12 | 2003-01-16 | Vahid Saadat | Method for sensing temperature profile of a hollow body organ |
US7160255B2 (en) | 2001-07-12 | 2007-01-09 | Vahid Saadat | Method and device for sensing and mapping temperature profile of a hollow body organ |
JP4326942B2 (en) | 2001-07-17 | 2009-09-09 | フォックス・ホロー・テクノロジーズ・インコーポレーテッド | Liquid exchange system for local irrigation and aspiration with controlled liquid volume |
AUPR649601A0 (en) | 2001-07-20 | 2001-08-09 | Redfern Polymer Optics Pty Ltd | Casting preforms for optical fibres |
US7438701B2 (en) | 2001-07-26 | 2008-10-21 | Durect Corporation | Local concentration management system |
US6616659B1 (en) | 2001-07-27 | 2003-09-09 | Starion Instruments Corporation | Polypectomy device and method |
AU2002326661A1 (en) | 2001-08-17 | 2003-03-03 | Antares Pharma, Inc. | Administration of insulin by jet injection |
JP4761671B2 (en) | 2001-08-29 | 2011-08-31 | テルモ株式会社 | Shape memory balloon, manufacturing method thereof, and balloon catheter |
US20040127820A1 (en) | 2001-09-05 | 2004-07-01 | Clayman Ralph V. | Guidewire |
US20070112358A1 (en) * | 2001-09-06 | 2007-05-17 | Ryan Abbott | Systems and Methods for Treating Septal Defects |
AUPR785001A0 (en) | 2001-09-21 | 2001-10-18 | Kleiner, Daniel E. | Tamponade apparatus and method of using same |
US6918882B2 (en) | 2001-10-05 | 2005-07-19 | Scimed Life Systems, Inc. | Guidewire with stiffness blending connection |
US20030073900A1 (en) * | 2001-10-12 | 2003-04-17 | Pranitha Senarith | System and method for monitoring the movement of an interventional device within an anatomical site |
JP3772107B2 (en) | 2001-10-12 | 2006-05-10 | オリンパス株式会社 | Endoscope system |
FR2832516B1 (en) | 2001-11-19 | 2004-01-23 | Tokendo Sarl | ROTARY ENDOSCOPES WITH A DEVIED DISTAL VIEW |
US7488313B2 (en) | 2001-11-29 | 2009-02-10 | Boston Scientific Scimed, Inc. | Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment |
US6832715B2 (en) | 2001-12-03 | 2004-12-21 | Scimed Life Systems, Inc. | Guidewire distal tip soldering method |
US6612999B2 (en) | 2001-12-06 | 2003-09-02 | Cardiac Pacemakers, Inc. | Balloon actuated guide catheter |
US6755812B2 (en) | 2001-12-11 | 2004-06-29 | Cardiac Pacemakers, Inc. | Deflectable telescoping guide catheter |
US20030144683A1 (en) | 2001-12-13 | 2003-07-31 | Avantec Vascular Corporation | Inflatable members having concentrated force regions |
EP1319366A1 (en) | 2001-12-14 | 2003-06-18 | BrainLAB AG | Magnetic navigation for a catheter |
US7736301B1 (en) | 2001-12-18 | 2010-06-15 | Advanced Cardiovascular Systems, Inc. | Rotatable ferrules and interfaces for use with an optical guidewire |
US20030114732A1 (en) | 2001-12-18 | 2003-06-19 | Advanced Cardiovascular Systems, Inc. | Sheath for guiding imaging instruments |
US6939374B2 (en) | 2001-12-21 | 2005-09-06 | Scimed Life Systems, Inc. | Stents, stenting systems, and related methods for agent delivery |
US6955657B1 (en) | 2001-12-31 | 2005-10-18 | Advanced Cardiovascular Systems, Inc. | Intra-ventricular substance delivery catheter system |
US6740030B2 (en) | 2002-01-04 | 2004-05-25 | Vision Sciences, Inc. | Endoscope assemblies having working channels with reduced bending and stretching resistance |
US7493156B2 (en) | 2002-01-07 | 2009-02-17 | Cardiac Pacemakers, Inc. | Steerable guide catheter with pre-shaped rotatable shaft |
US20040158229A1 (en) | 2002-01-24 | 2004-08-12 | Quinn David G. | Catheter assembly and method of catheter insertion |
SE0200300D0 (en) | 2002-02-01 | 2002-02-01 | Aerocrine Ab | Diagnostic device and method |
AU2002226252A1 (en) | 2002-02-07 | 2003-09-02 | Carag Ag | Displacement device for a catheter |
US6610059B1 (en) | 2002-02-25 | 2003-08-26 | Hs West Investments Llc | Endoscopic instruments and methods for improved bubble aspiration at a surgical site |
JP2003320031A (en) | 2002-02-26 | 2003-11-11 | Buaayu:Kk | Balloon catheter |
US7128718B2 (en) | 2002-03-22 | 2006-10-31 | Cordis Corporation | Guidewire with deflectable tip |
US7074426B2 (en) | 2002-03-27 | 2006-07-11 | Frank Kochinke | Methods and drug delivery systems for the treatment of orofacial diseases |
US6855136B2 (en) * | 2002-04-03 | 2005-02-15 | Gore Enterprise Holdings, Inc. | Infusion catheter having an atraumatic tip |
US6942635B2 (en) | 2002-04-04 | 2005-09-13 | Angiodynamics, Inc. | Blood treatment catheter and method |
EP1499235B1 (en) | 2002-04-17 | 2016-08-17 | Covidien LP | Endoscope structures and techniques for navigating to a target in branched structure |
DE10217559B4 (en) | 2002-04-19 | 2004-02-19 | Universitätsklinikum Freiburg | Device for minimally invasive, intravascular aortic valve extraction |
US20040020492A1 (en) * | 2002-05-02 | 2004-02-05 | Dubrul William R. | Upper airway device and method |
US7610104B2 (en) | 2002-05-10 | 2009-10-27 | Cerebral Vascular Applications, Inc. | Methods and apparatus for lead placement on a surface of the heart |
PT1509256E (en) | 2002-05-24 | 2009-10-15 | Angiotech Int Ag | Compositions and methods for coating medical implants |
US6979290B2 (en) * | 2002-05-30 | 2005-12-27 | The Board Of Trustees Of The Leland Stanford Junior University | Apparatus and methods for coronary sinus access |
US7993353B2 (en) | 2002-06-04 | 2011-08-09 | Brainlab Ag | Medical tracking system with universal interface |
US20030229332A1 (en) | 2002-06-11 | 2003-12-11 | Scimed Life Systems, Inc. | Adjustable double balloon catheter with a through lumen for stone management |
IL150189A0 (en) | 2002-06-12 | 2002-12-01 | Acoustitech Ltd | Acoustic diagnosis of sinusitis |
GB0215270D0 (en) | 2002-07-02 | 2002-08-14 | Optinose As | Nasal devices |
JP2005532869A (en) | 2002-07-13 | 2005-11-04 | ストライカー・コーポレーション | Nose and throat cleaning system and cleaning method |
EP1552722A4 (en) | 2002-08-20 | 2006-06-21 | Univ California | Vibration detectors, sound detectors, hearing aids, cochlear implants and related methods |
US7174774B2 (en) | 2002-08-30 | 2007-02-13 | Kimberly-Clark Worldwide, Inc. | Method and apparatus of detecting pooling of fluid in disposable or non-disposable absorbent articles |
US6783522B2 (en) | 2002-09-09 | 2004-08-31 | Angel Medical Systems, Inc. | Implantable catheter having an improved check valve |
US6619085B1 (en) | 2002-09-12 | 2003-09-16 | Hui-Hua Hsieh | Remote-controlled lock |
AU2003227108B2 (en) | 2002-09-18 | 2008-12-04 | Asap Breathe Assist Pty Ltd | A nasal cavity dilator |
ITVR20020094A1 (en) | 2002-09-25 | 2002-12-24 | Vittorio Marinello | APPARATUS FOR THE PROCESSING OF THE NEW SYSTEM OF TREATMENT OF THE MAXILLARY SINUSITIES, OF THE FRONTAL AND OF THE TRIGE NEVRITES AND NEVRALGIES |
US7488337B2 (en) * | 2002-09-30 | 2009-02-10 | Saab Mark A | Apparatus and methods for bone, tissue and duct dilatation |
US7169163B2 (en) | 2002-09-30 | 2007-01-30 | Bruce Becker | Transnasal method and catheter for lacrimal system |
US8317816B2 (en) * | 2002-09-30 | 2012-11-27 | Acclarent, Inc. | Balloon catheters and methods for treating paranasal sinuses |
EP1413258B1 (en) | 2002-10-25 | 2005-03-23 | BrainLAB AG | Device and method for calibrating an element |
US20040220516A1 (en) | 2002-11-04 | 2004-11-04 | Stephen Solomon | Food extraction apparatus and method |
US6899672B2 (en) | 2002-11-08 | 2005-05-31 | Scimed Life Systems, Inc. | Endoscopic imaging system including removable deflection device |
US7881769B2 (en) * | 2002-11-18 | 2011-02-01 | Mediguide Ltd. | Method and system for mounting an MPS sensor on a catheter |
US7172562B2 (en) | 2002-11-22 | 2007-02-06 | Mckinley Laurence M | System, method and apparatus for locating, measuring and evaluating the enlargement of a foramen |
DE10254814A1 (en) | 2002-11-23 | 2004-06-03 | Fag Kugelfischer Ag | Load bearing |
US7184067B2 (en) | 2003-03-13 | 2007-02-27 | Eastman Kodak Company | Color OLED display system |
US7343920B2 (en) | 2002-12-20 | 2008-03-18 | Toby E Bruce | Connective tissue repair system |
TW589170B (en) | 2002-12-25 | 2004-06-01 | De-Yang Tian | Endoscopic device |
EP1435757A1 (en) | 2002-12-30 | 2004-07-07 | Andrzej Zarowski | Device implantable in a bony wall of the inner ear |
US20060047261A1 (en) * | 2004-06-28 | 2006-03-02 | Shailendra Joshi | Intra-arterial catheter for drug delivery |
EP1438942A1 (en) | 2003-01-17 | 2004-07-21 | Schering Oy | An otorhinological drug delivery device |
US8016752B2 (en) | 2003-01-17 | 2011-09-13 | Gore Enterprise Holdings, Inc. | Puncturable catheter |
US20040230156A1 (en) | 2003-02-13 | 2004-11-18 | Schreck Stefan Georg | Methods and devices for in-situ crosslinking of vascular tissue |
US6893393B2 (en) * | 2003-02-19 | 2005-05-17 | Boston Scientific Scimed., Inc. | Guidewire locking device and method |
JP4887138B2 (en) | 2003-02-21 | 2012-02-29 | エレクトロ−キャット リミテッド ライアビリティ カンパニー | System and method for measuring cross-sectional area and pressure gradient of an organ having a lumen |
US7182735B2 (en) | 2003-02-26 | 2007-02-27 | Scimed Life Systems, Inc. | Elongated intracorporal medical device |
US8167821B2 (en) | 2003-02-26 | 2012-05-01 | Boston Scientific Scimed, Inc. | Multiple diameter guidewire |
US10376711B2 (en) | 2003-03-14 | 2019-08-13 | Light Sciences Oncology Inc. | Light generating guide wire for intravascular use |
AU2004222340B2 (en) | 2003-03-14 | 2009-11-12 | Intersect Ent, Inc. | Sinus delivery of sustained release therapeutics |
CA2523777C (en) | 2003-03-14 | 2016-05-10 | Light Sciences Corporation | Light generating device to intravascular use |
US20040193073A1 (en) | 2003-03-31 | 2004-09-30 | Demello Richard M. | Composite guidewire with a linear elastic distal portion |
US7303533B2 (en) | 2003-04-10 | 2007-12-04 | Intraluminal Therapeutics, Inc. | Shapeable intraluminal device and method therefor |
US20040267347A1 (en) | 2003-05-01 | 2004-12-30 | Cervantes Marvin John | Protective elongated sleeve for stent systems |
US7431694B2 (en) | 2003-05-16 | 2008-10-07 | Ethicon Endo-Surgery, Inc. | Method of guiding medical devices |
US7641668B2 (en) * | 2003-05-16 | 2010-01-05 | Scimed Life Systems, Inc. | Fluid delivery system and related methods of use |
US20040236231A1 (en) | 2003-05-23 | 2004-11-25 | Embro Corporation | Light catheter for illuminating tissue structures |
US7108706B2 (en) | 2003-05-28 | 2006-09-19 | Rose Biomedical Development Corporation | Inflatable nasal packing device with two non-elastic, flexible bags oversized relative to nasal cavities |
JP4323221B2 (en) | 2003-05-30 | 2009-09-02 | テルモ株式会社 | Catheter assembly |
US7632291B2 (en) | 2003-06-13 | 2009-12-15 | Trivascular2, Inc. | Inflatable implant |
JP4398184B2 (en) | 2003-06-24 | 2010-01-13 | オリンパス株式会社 | Endoscope |
US7097612B2 (en) | 2003-07-29 | 2006-08-29 | Endoscopic Technologies, Inc. | Tissue positioner |
US7359755B2 (en) | 2003-08-08 | 2008-04-15 | Advanced Neuromodulation Systems, Inc. | Method and apparatus for implanting an electrical stimulation lead using a flexible introducer |
US6851290B1 (en) | 2003-08-11 | 2005-02-08 | Absolute Access & Security Products, Inc. | Door lock assembly and locking system for hinged double-acting impact-traffic doors |
US8740844B2 (en) | 2003-08-20 | 2014-06-03 | Boston Scientific Scimed, Inc. | Medical device with drug delivery member |
DE602004018342D1 (en) * | 2003-08-26 | 2009-01-22 | Zimmer Spine Inc | ACCESS SYSTEMS FOR MINIMALLY INVASIVE SURGERY |
US7313430B2 (en) | 2003-08-28 | 2007-12-25 | Medtronic Navigation, Inc. | Method and apparatus for performing stereotactic surgery |
US20050055077A1 (en) * | 2003-09-05 | 2005-03-10 | Doron Marco | Very low profile medical device system having an adjustable balloon |
JP2007505655A (en) | 2003-09-15 | 2007-03-15 | アトリウム メディカル コーポレーション | Application of therapeutic substances to tissue sites using porous medical devices |
US20050059931A1 (en) | 2003-09-16 | 2005-03-17 | Venomatrix | Methods and apparatus for localized and semi-localized drug delivery |
US20050059930A1 (en) * | 2003-09-16 | 2005-03-17 | Michi Garrison | Method and apparatus for localized drug delivery |
US20050113850A1 (en) | 2003-10-08 | 2005-05-26 | Tagge Bryan C. | Apparatus, system, and method for middle turbinate medializer |
US7004176B2 (en) * | 2003-10-17 | 2006-02-28 | Edwards Lifesciences Ag | Heart valve leaflet locator |
US8014849B2 (en) | 2003-11-21 | 2011-09-06 | Stryker Corporation | Rotational markers |
US7237313B2 (en) | 2003-12-05 | 2007-07-03 | Boston Scientific Scimed, Inc. | Elongated medical device for intracorporal use |
JP3864344B2 (en) | 2003-12-05 | 2006-12-27 | フジノン株式会社 | Endoscope insertion aid |
USD501677S1 (en) | 2003-12-11 | 2005-02-08 | Bruce B. Becker | Dilatation balloon catheter |
US20050131316A1 (en) | 2003-12-15 | 2005-06-16 | Cook Incorporated | Guidewire with flexible tip |
ATE534426T1 (en) | 2004-02-10 | 2011-12-15 | Synecor Llc | INTRAVASCULAR DELIVERY SYSTEM FOR THERAPEUTIC AGENTS |
EP1715788B1 (en) | 2004-02-17 | 2011-09-07 | Philips Electronics LTD | Method and apparatus for registration, verification, and referencing of internal organs |
US7988705B2 (en) | 2004-03-06 | 2011-08-02 | Lumen Biomedical, Inc. | Steerable device having a corewire within a tube and combination with a functional medical component |
WO2005089670A1 (en) | 2004-03-15 | 2005-09-29 | Durect Corporation | Pharmaceutical compositions for administration to a sinus |
US7282057B2 (en) | 2004-03-30 | 2007-10-16 | Wilson-Cook Medical, Inc. | Pediatric atresia magnets |
US20050234507A1 (en) | 2004-04-16 | 2005-10-20 | Jeff Geske | Medical tool for access to internal tissue |
US7452351B2 (en) | 2004-04-16 | 2008-11-18 | Kyphon Sarl | Spinal diagnostic methods and apparatus |
US7720521B2 (en) | 2004-04-21 | 2010-05-18 | Acclarent, Inc. | Methods and devices for performing procedures within the ear, nose, throat and paranasal sinuses |
US20060004323A1 (en) | 2004-04-21 | 2006-01-05 | Exploramed Nc1, Inc. | Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasal or paranasal structures |
US7654997B2 (en) * | 2004-04-21 | 2010-02-02 | Acclarent, Inc. | Devices, systems and methods for diagnosing and treating sinusitus and other disorders of the ears, nose and/or throat |
US8764729B2 (en) | 2004-04-21 | 2014-07-01 | Acclarent, Inc. | Frontal sinus spacer |
US20110004057A1 (en) * | 2004-04-21 | 2011-01-06 | Acclarent, Inc. | Systems and methods for transnasal dilation of passageways in the ear, nose or throat |
US8747389B2 (en) | 2004-04-21 | 2014-06-10 | Acclarent, Inc. | Systems for treating disorders of the ear, nose and throat |
US9399121B2 (en) | 2004-04-21 | 2016-07-26 | Acclarent, Inc. | Systems and methods for transnasal dilation of passageways in the ear, nose or throat |
US9089258B2 (en) | 2004-04-21 | 2015-07-28 | Acclarent, Inc. | Endoscopic methods and devices for transnasal procedures |
US9351750B2 (en) * | 2004-04-21 | 2016-05-31 | Acclarent, Inc. | Devices and methods for treating maxillary sinus disease |
US7419497B2 (en) | 2004-04-21 | 2008-09-02 | Acclarent, Inc. | Methods for treating ethmoid disease |
US7361168B2 (en) | 2004-04-21 | 2008-04-22 | Acclarent, Inc. | Implantable device and methods for delivering drugs and other substances to treat sinusitis and other disorders |
US9101384B2 (en) | 2004-04-21 | 2015-08-11 | Acclarent, Inc. | Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, Nose and/or throat |
US8146400B2 (en) * | 2004-04-21 | 2012-04-03 | Acclarent, Inc. | Endoscopic methods and devices for transnasal procedures |
US20070167682A1 (en) | 2004-04-21 | 2007-07-19 | Acclarent, Inc. | Endoscopic methods and devices for transnasal procedures |
US20070208252A1 (en) | 2004-04-21 | 2007-09-06 | Acclarent, Inc. | Systems and methods for performing image guided procedures within the ear, nose, throat and paranasal sinuses |
US7462175B2 (en) | 2004-04-21 | 2008-12-09 | Acclarent, Inc. | Devices, systems and methods for treating disorders of the ear, nose and throat |
US9554691B2 (en) | 2004-04-21 | 2017-01-31 | Acclarent, Inc. | Endoscopic methods and devices for transnasal procedures |
US20060284428A1 (en) | 2005-06-13 | 2006-12-21 | Darryl Beadle | High reliability gate lock for exterior use |
US7559925B2 (en) | 2006-09-15 | 2009-07-14 | Acclarent Inc. | Methods and devices for facilitating visualization in a surgical environment |
US8894614B2 (en) | 2004-04-21 | 2014-11-25 | Acclarent, Inc. | Devices, systems and methods useable for treating frontal sinusitis |
US20050244472A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Intraocular drug delivery systems containing excipients with reduced toxicity and related methods |
US7670282B2 (en) | 2004-06-14 | 2010-03-02 | Pneumrx, Inc. | Lung access device |
US9289576B2 (en) | 2004-06-17 | 2016-03-22 | W. L. Gore & Associates, Inc. | Catheter assembly |
US7207981B2 (en) * | 2004-06-28 | 2007-04-24 | Medtronic Vascular, Inc. | Multi-exchange catheter guide member with improved seal |
CA2574013A1 (en) | 2004-07-14 | 2006-01-19 | By-Pass, Inc. | Material delivery system |
US8277386B2 (en) * | 2004-09-27 | 2012-10-02 | Volcano Corporation | Combination sensor guidewire and methods of use |
FR2859377B1 (en) | 2004-10-22 | 2006-05-12 | Bertrand Lombard | THREE DIMENSIONAL LOCATION DEVICE |
US7347868B2 (en) * | 2004-10-26 | 2008-03-25 | Baronova, Inc. | Medical device delivery catheter |
US7235099B1 (en) | 2004-12-14 | 2007-06-26 | Micromedics, Inc. | Sphenoid sinus stent |
CA2587986A1 (en) | 2005-01-18 | 2006-07-27 | Traxtal Inc. | Electromagnetically tracked k-wire device |
US20060173382A1 (en) | 2005-01-31 | 2006-08-03 | John Schreiner | Guidewire with superelastic core |
US20080188803A1 (en) | 2005-02-03 | 2008-08-07 | Jang G David | Triple-profile balloon catheter |
US7195612B2 (en) | 2005-03-31 | 2007-03-27 | Gordis Corporation | Esophageal balloon catheter with visual marker |
EP2298318A1 (en) | 2005-04-04 | 2011-03-23 | Sinexus, Inc. | Device and methods for treating paranasal sinus conditions |
US7896891B2 (en) | 2005-05-20 | 2011-03-01 | Neotract, Inc. | Apparatus and method for manipulating or retracting tissue and anatomical structure |
US8951225B2 (en) | 2005-06-10 | 2015-02-10 | Acclarent, Inc. | Catheters with non-removable guide members useable for treatment of sinusitis |
EP1906894B1 (en) | 2005-06-20 | 2012-10-03 | Otomedics Advanced Medical Technologies Ltd. | Ear tubes |
CA2623516A1 (en) | 2005-09-20 | 2007-04-12 | Medsys S.A. | Device and method for controlling a remote appliance |
USD534216S1 (en) | 2005-09-23 | 2006-12-26 | Acclarent, Inc. | Anatomical model and demonstration/training device |
US7648367B1 (en) * | 2005-09-23 | 2010-01-19 | Acclarent, Inc. | Anatomical models and methods for training and demonstration of medical procedures |
AU2007221150B2 (en) | 2006-02-27 | 2012-09-20 | Ahm Technologies, Inc. | Eustachian tube device and method |
US8585753B2 (en) | 2006-03-04 | 2013-11-19 | John James Scanlon | Fibrillated biodegradable prosthesis |
US7520876B2 (en) | 2006-04-21 | 2009-04-21 | Entellus Medical, Inc. | Device and method for treatment of sinusitis |
US20070293946A1 (en) | 2006-05-12 | 2007-12-20 | Entrigue Surgical, Inc. | Middle Turbinate Medializer |
US20070269385A1 (en) | 2006-05-18 | 2007-11-22 | Mercator Medsystems, Inc | Devices, methods, and systems for delivering therapeutic agents for the treatment of sinusitis, rhinitis, and other disorders |
US8535707B2 (en) | 2006-07-10 | 2013-09-17 | Intersect Ent, Inc. | Devices and methods for delivering active agents to the osteomeatal complex |
US9820688B2 (en) | 2006-09-15 | 2017-11-21 | Acclarent, Inc. | Sinus illumination lightwire device |
EP2069000A2 (en) | 2006-09-20 | 2009-06-17 | University Of Virginia Patent Foundation | Tube, stent and collar insertion device |
US7496174B2 (en) | 2006-10-16 | 2009-02-24 | Oraya Therapeutics, Inc. | Portable orthovoltage radiotherapy |
WO2008051918A2 (en) | 2006-10-23 | 2008-05-02 | Allux Medical, Inc. | Methods, devices and kits for phototherapy and photodynamic therapy treatment of body cavities |
US7634233B2 (en) | 2006-11-27 | 2009-12-15 | Chung Shan Institute Of Science And Technology | Transmission system with interference avoidance capability and method thereof |
US8104483B2 (en) | 2006-12-26 | 2012-01-31 | The Spectranetics Corporation | Multi-port light delivery catheter and methods for the use thereof |
JP2008161491A (en) | 2006-12-28 | 2008-07-17 | Asahi Intecc Co Ltd | Medical guide wire |
US20080172033A1 (en) | 2007-01-16 | 2008-07-17 | Entellus Medical, Inc. | Apparatus and method for treatment of sinusitis |
WO2008124787A2 (en) | 2007-04-09 | 2008-10-16 | Acclarent, Inc. | Ethmoidotomy system and implantable spacer devices having therapeutic substance delivery capability for treatment of paranasal sinusitis |
US8425488B2 (en) | 2007-04-19 | 2013-04-23 | Acclarent, Inc. | System and method for the simultaneous bilateral treatment of target tissues within the ears using a guide block structure |
FR2916144A1 (en) | 2007-05-14 | 2008-11-21 | Olivier Pascal Bruno Rollet | Endotracheal catheter for use during surgery, has tube including distal end connected to collar and another end connected to circular pusher, where pusher is actuated outside buccal cavity by user after endotracheal intubation |
WO2009001358A2 (en) * | 2007-06-26 | 2008-12-31 | Galit Avior | Eustachian tube device |
EP2190520A4 (en) | 2007-09-20 | 2011-01-26 | Estimme Ltd | Electrical stimulation in the middle ear for treatment of hearing related disorders |
US20090088728A1 (en) * | 2007-09-28 | 2009-04-02 | Dollar Michael L | Malleable sleeve for balloon catheter and endoscopic surgical method |
USD590502S1 (en) * | 2007-11-13 | 2009-04-14 | Karl Storz Gmbh & Co. Kg | Grip for laparoscope |
US20090163890A1 (en) | 2007-12-20 | 2009-06-25 | Acclarent, Inc. | Method and System for Accessing, Diagnosing and Treating Target Tissue Regions Within the Middle Ear and the Eustachian Tube |
US20100198191A1 (en) | 2007-12-20 | 2010-08-05 | Acclarent, Inc. | Method and system for treating target tissue within the eustachian tube |
US20100274188A1 (en) | 2007-12-20 | 2010-10-28 | Acclarent, Inc. | Method and System for Treating Target Tissue Within the Eustachian Tube |
USD586916S1 (en) * | 2008-05-09 | 2009-02-17 | Lifescan Scotland, Ltd. | Handheld lancing device |
USD586465S1 (en) * | 2008-05-09 | 2009-02-10 | Lifescan Scotland Limited | Handheld lancing device |
NZ589742A (en) | 2008-05-27 | 2012-06-29 | Univ Melbourne | Methods of treating mammals with eustachian tube dysfunctions with betahistine |
JP5584687B2 (en) | 2008-09-18 | 2014-09-03 | アクラレント インコーポレイテッド | Method and apparatus for treating ear, nose and throat disorders |
US20100087811A1 (en) * | 2008-10-06 | 2010-04-08 | Coaptus Medical Corporation | Systems and Methods for Controlling Patient Catheters |
USD630321S1 (en) * | 2009-05-08 | 2011-01-04 | Angio Dynamics, Inc. | Probe handle |
US8608360B2 (en) | 2009-05-18 | 2013-12-17 | Günther Nath | Liquid light guide having position retaining function |
USD633207S1 (en) * | 2009-09-11 | 2011-02-22 | Stryker Trauma Ag | Multi-planar coupling |
-
2008
- 2008-04-09 WO PCT/US2008/059786 patent/WO2008124787A2/en active Application Filing
- 2008-04-09 US US12/100,361 patent/US8864787B2/en active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060085027A1 (en) * | 2001-05-22 | 2006-04-20 | Sanostec Corp. | Nasal congestion, obstruction relief, and drug delivery |
US20060116749A1 (en) * | 2003-07-18 | 2006-06-01 | Broncus Technologies, Inc. | Devices for maintaining patency of surgically created channels in tissue |
US20070020196A1 (en) * | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension |
US20060211752A1 (en) * | 2004-03-16 | 2006-09-21 | Kohn Leonard D | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression |
US20060063973A1 (en) * | 2004-04-21 | 2006-03-23 | Acclarent, Inc. | Methods and apparatus for treating disorders of the ear, nose and throat |
US20060106361A1 (en) * | 2004-04-21 | 2006-05-18 | Acclarent, Inc. | Devices and methods for delivering therapeutic substances for the treatment of sinusitis and other disorders |
US20070135789A1 (en) * | 2004-04-21 | 2007-06-14 | Acclarent, Inc. | Use of mechanical dilator devices to enlarge ostia of paranasal sinuses and other passages in the ear, nose, throat and paranasal sinuses |
US20060271024A1 (en) * | 2005-01-25 | 2006-11-30 | Michael Gertner | Nasal Cavity Treatment Apparatus |
US20070073269A1 (en) * | 2005-09-23 | 2007-03-29 | Becker Bruce B | Multi-conduit balloon catheter |
Also Published As
Publication number | Publication date |
---|---|
WO2008124787A3 (en) | 2008-12-11 |
US8864787B2 (en) | 2014-10-21 |
US20080287908A1 (en) | 2008-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10441758B2 (en) | Frontal sinus spacer | |
US8864787B2 (en) | Ethmoidotomy system and implantable spacer devices having therapeutic substance delivery capability for treatment of paranasal sinusitis | |
US9351750B2 (en) | Devices and methods for treating maxillary sinus disease | |
US8388642B2 (en) | Implantable devices and methods for treating sinusitis and other disorders | |
US9084876B2 (en) | Implantable devices and methods for delivering drugs and other substances to treat sinusitis and other disorders | |
AU2012201954B2 (en) | Implantable devices and methods for delivering drugs and other substances to treat sinusitis and other disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08745398 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08745398 Country of ref document: EP Kind code of ref document: A2 |